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c Neil James Kerr HendersonAbstract
In modern society people are concerned about their state of health and if they
do unfortunately become ill they want the best possible treatment to be made
available to them. In order to satisfy these demands new treatments have to be
developed. This can be a long and expensive process. Before any new treatment
can come to market it has to be proved to be both clinically eﬀective and eco-
nomically cost-eﬀective. With limited health care resources the cost-eﬀectiveness
of treatments is becoming ever more relevant.
In order to show whether a treatment is clinically eﬀective a clinical trial is
carried out and this is now usually accompanied by an economic evaluation, so
that the cost-eﬀectiveness of the treatment can be assessed. When a clinical trial
aimed at preventing clinical events is analysed, a time-to-ﬁrst event analysis is
often performed together with a cost-eﬀectiveness analysis. These analyses do not
always make the best use of the large amounts of patient information recorded
during the clinical trial. Using the randomised controlled trial (RCT) the Impact
Of Nicorandil in Angina (IONA) as an exemplar, ways in which the clinical and
economic evaluations of clinical trials can be expanded are explored.
There are three main parts of this thesis. Firstly, following a more detailed
introduction in Chapter 1, in Chapters 2 and 3 the IONA Study is introduced
iand the main clinical results of the study are given. Secondly, in Chapters 4,
5 and 6 the fact that patients could suﬀer more than one clinical endpoint is
considered. The models that can be used to incorporate the recurrent events are
introduced and then applied to the data from the IONA Study. Following on
from this, through the simulation of recurrent event data, the performance of the
models under diﬀerent known conditions is assessed. Thirdly, in Chapters 7 and 8
an introduction to health economics is given and following this the main results
of the economic evaluation of the IONA Study are presented. Areas in which
the results of the economic evaluation can be expanded are then investigated.
Finally, in Chapter 9 there is a discussion of the work as a whole and areas where
there would be the possibility of further work.
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xxiChapter 1
Introduction
Clinical trials play a critical role in the development of new types of treatments
and are important to many diﬀerent groups including the pharmaceutical indus-
try, who develop the new products, the National Health Service (NHS), who go
on to implement the use of such products in the UK, and patients, who are the
ones who will ultimately beneﬁt from the development of new treatments by using
them. During clinical trials large amounts of data are collected and recorded on
the patients who are taking part. In clinical trials where the time until a speciﬁc
event is important survival analysis is used to analyse the data. This is usually
based on a Cox proportional hazards model (Cox, 1972), with the only variable
included in the model being the treatment that is being investigated. As a result
a large amount of information which has been collected on patients is unused.
In recent times the importance of carrying out of an economic evaluation
alongside clinical trials has increased due to the budget constraints that health-
care providers like the NHS are under and the high cost of some of the new
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treatments which are coming to market, with the resulting high net cost of pre-
scribing them to patients. When an economic evaluation is undertaken commonly
only the beneﬁts a treatment gives and the costs both saved and accrued are con-
sidered and, as with a time-to-ﬁrst event analysis when the clinical outcome is
being investigated, any additional information that is available on patients is not
considered or used in the analysis.
As during the course of a clinical trial large amounts of information will be
collected this information could be included in the analysis of the trial, by looking
for variables that may be predictive of whether patients will suﬀer events and not
solely concentrating any analysis on the ﬁrst event that patients suﬀer and the
time to that ﬁrst event but including any further events that patients go onto
suﬀer. As well as making best use of all the information collected on patients
during the investigation of the clinical outcome the recorded patient data could
also be incorporated into an extended economic evaluation of the trial.
The basis of this work is the randomised controlled trial (RCT): the Impact
Of Nicorandil in Angina (IONA) Study and the resultant clinical and economic
evaluations that were undertaken on the data from the study and have been pub-
lished. (The IONA Study Group, 2002; Walker et al., 2006) Using the published
analyses as a base both the clinical and economic evaluations are expanded on
to incorporate all the data that was recorded on patients before and during the
study. Hence, the analysis is no longer concentrated solely on the standard time-
to-ﬁrst event analysis and the simple economic evaluation that have already been
undertaken.
In the paper by The IONA Study Group (2002) the main clinical results of the
study were presented in the form of a time-to-ﬁrst event analysis with the onlyCHAPTER 1. INTRODUCTION 3
explanatory variable ﬁtted in the model being whether patients were receiving
nicorandil, the study drug, or a placebo. The study design and implementation
as well as the main ﬁndings of the IONA Study are given in Chapter 2. The
additional demographic and clinical variables recorded on patients were not in-
cluded in the analysis nor were any further clinical endpoints that patients went
onto suﬀer after they had experienced their initial event.
In a follow up paper by The IONA Study Group (2005) the univariate sig-
niﬁcance of all the baseline variables recorded on patients who took part in the
IONA Study, including whether they were in the nicorandil or placebo group,
was explored and from these ﬁndings multivariable models predicting the risk of
patients suﬀering a primary as well as a secondary endpoint of the study were
built. In Chapter 3, following on from and expanding the results shown in Chap-
ter 2, the univariate signiﬁcance of the recorded baseline variables is considered
for both the primary endpoint of the IONA Study as well as the gastrointestinal
(GI) events that patients suﬀered, GI events are a potential side-eﬀect of being
treated with nicorandil. Multivariable predictive models for both the primary
endpoint as well as GI events patients suﬀered are derived. The set of baseline
variables used in Chapter 3 is marginally diﬀerent from the set used in the paper
by The IONA Study Group (2005) resulting in slightly diﬀerent models. The GI
events patients suﬀered were not considered in the paper by The IONA Study
Group (2005). Further models are built from sub-groups of the baseline variables
so that a full picture of the variables and diﬀerent combinations of variables that
are prognostic for both types of events can be seen.
Following on from expanding the clinical evaluation of the study the implica-
tions of incorporating into the analysis the fact that patients could suﬀer clinicalCHAPTER 1. INTRODUCTION 4
endpoints more than once will be investigated. As previously stated the main
results of the IONA Study were based on a time-to-ﬁrst event analysis. After
patients had experienced a ﬁrst primary endpoint they still continued to be mon-
itored and attended study visits until study closedown or they withdrew from
the study for any other reason, unless the endpoint had been death when, for
obvious reasons, the study period automatically ended for the patient.
During the period after patients suﬀered a ﬁrst event and the end of the study
they were at risk of suﬀering further events and many patients did go on to suﬀer
a second event and then further subsequent events. All the serious adverse events
that patients suﬀered during the study were documented and therefore all the
serious GI events that patients suﬀered were recorded. During the course of the
study some patients suﬀered multiple GI events. In the time-to-ﬁrst event analysis
none of the additional events that patients went on to suﬀer were considered.
Recurrent event models introduced in Chapter 4, can be ﬁtted to the data from
the IONA Study so that the multiple events that patients suﬀered can be included
in the analysis. The results are given in Chapter 5.
Having introduced and used the recurrent event models on real life data from
the IONA Study it was seen that the diﬀerent models have diﬀerent underlying
assumptions and can give diﬀerent results. Although in the case of the IONA
Study the results were broadly similar. In Chapter 6 through the simulation
of recurrent event data it is investigated how under known conditions recurrent
event models perform. If the results and generalisability of a clinical trial are to
be improved by the inclusion of any recurrent events that patients suﬀered in the
analysis it is important that the most appropriate model is used in each situation
to ensure the robustness of the ﬁndings.CHAPTER 1. INTRODUCTION 5
An introduction to health economics and some of the general terms and tech-
niques used in this area is given in Chapter 7. In Chapter 8 the main results
of the economic evaluation carried out on the IONA Study are presented. In
the paper by Walker et al. (2006) the economic evaluation of the IONA Study
was presented as a Cost-Eﬀectiveness Analysis (CEA) with the results being re-
ported in the form of an Incremental Cost-Eﬀectiveness Ratio (ICER). To take
into account the changing costs of procedures or equipment and hospital costs
univariate sensitivity analysis of the results were undertaken. In the economic
evaluation the baseline variables recorded on patients were not incorporated into
the analysis, similarly to the case of the main clinical results. In order to evaluate
the ICER the only information that was required were the numbers of primary
endpoints suﬀered in both the nicorandil and placebo groups as well as the costs
associated with each treatment group. The results of the cost-eﬀectiveness analy-
sis of the IONA Study showed that the cost per primary endpoint prevented was
low and in comparison to similarly evaluated treatments it was cost-eﬀective to
treat a population of patients similar to those included in the IONA Study with
nicorandil. (Walker et al., 2006). However, even within the IONA population
it is likely that for some sub-groups of patients treatment would be more cost-
eﬀective than for others. It might be possible to improve the cost-eﬀectiveness
of a treatment by targeting it to a sub-group of the potential patient population
where it would be most beneﬁcial in terms of resource use and hence maximise
the beneﬁts that can be gained from limited healthcare budgets. Importantly,
IONA recruited particularly high risk angina patients. Evaluation of the ICER
in the lowest risk sub-group of the high risk patients recruited in IONA might be
more representative of the type of results that might be achieved in the type ofCHAPTER 1. INTRODUCTION 6
patients excluded from the study. The cost-eﬀectiveness of a treatment, in this
case nicorandil, could possibly be improved by targeting it to those patients who
are at the highest risk of suﬀering an event so therefore more likely to beneﬁt
from treatment, assuming that treatment beneﬁt is proportional to risk and than
harmful eﬀects are not also increased.
All patients who were recruited in the IONA Study were at a high risk of
suﬀering CHD events but in order to identify those patients who were at the
highest risk of suﬀering events the baseline variables recorded on patients, which
related to coronary heart disease (CHD) in the case of the IONA Study, are used.
The risk of patients suﬀering events needs to be calculated and in the case of the
IONA Study this can be done by means of the multivariable predictive model
for the primary endpoint. This is investigated in Chapter 3. The already high
risk patients recruited in IONA can be split into sub-groups by their calculated
level of risk of suﬀering a CHD event and separate cost-eﬀectiveness analyses
then carried out. The same principle economic techniques are being used as
when the overall cost-eﬀectiveness of a treatment is being investigated but this
time the additional information recorded on patients is being incorporated into
the analysis. This enables those bodies that make recommendations about how
and to whom treatments should be prescribed to see the overall cost-eﬀectiveness
of the treatment as well as how the cost-eﬀectiveness changes when only those
patients who are at the highest risk of suﬀering events, and possibly being the
most likely to beneﬁt from treatment, are treated compared to the situation where
only those patients at a low risk of suﬀering an event are treated.
Treatments should beneﬁt patients that are being prescribed them but they
also have the potential to cause patients to experience side-eﬀects, for exampleCHAPTER 1. INTRODUCTION 7
the GI events that patients suﬀered during the IONA Study. These side-eﬀects
may have implications on the cost-eﬀectiveness of a treatment as well as health
implications. If there was a link between the beneﬁts, the reduction in the number
of CHD events suﬀered, and the side-eﬀects of nicorandil, the GI events suﬀered,
is investigated by looking at whether there was any relationship between the
risks of these events. This is done using the multivariable predictive model for the
primary endpoint found in Chapter 3 as well as the multivariable predictive model
for the GI events that patients suﬀered. The balance between harm, beneﬁts
and risk in a clinical trial is an important factor to consider when prescribing
recommendations are laid out for the treatment evaluated in a clinical trial.
Finally, in Chapter 9 a summary of the main results and ﬁndings is given. The
implications of these results and ﬁndings and the impact they could have on the
future analyses of clinical trials are discussed. In addition, a brief introduction
is given to areas where there would be the possibility of further work on the
evaluations of clinical trials.
Throughout this work it will be shown how both the clinical and economic
evaluations of clinical trials can be extended and expanded upon. This will be
achieved by making the best use of information recorded on patients during a
clinical trial by incorporating it into both the clinical and economic evaluations.
Thus, allowing more robust conclusions to be drawn from clinical trials.Chapter 2
The Impact Of Nicorandil in
Angina Study
In the UK 25% of all deaths are attributable to coronary heart disease and, of pa-
tients presenting with a ﬁrst myocardial infarction, 25% have a history of stable
angina. (Gandhi, 1997) If a treatment could be shown to have cardioprotec-
tive eﬀects in a large scale randomised controlled trial of patients suﬀering from
stable angina the beneﬁts could be potentially signiﬁcant. It was thought that
nicorandil, an existing antianginal drug, might have cardioprotective eﬀects in
patients suﬀering from stable angina and the IONA Study was carried out to test
this hypothesis. In this Chapter background information on nicorandil will be
given as well as the design and implementation of the study and details of adverse
events that patients suﬀered. Results for both the primary and secondary end-
points of the study will be described. Additionally, the side-eﬀects of nicorandil
will be investigated.
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2.1 Nicorandil
The drug nicorandil has been marketed in Japan since 1984 and in the UK it
was licensed for the long term symptomatic treatment of chronic angina pectoris.
Nicorandil is a nicotinamide ester that works in two diﬀerent ways, ﬁrstly it opens
ATP-sensitive potassium channels (KATP) and secondly it has similar properties
to a nitrate. Both these properties enable it to be used for the treatment of
angina. (The IONA Study Group, 2002) Nicorandil has been shown to have
similar antianginal eﬃcacy to oral nitrates, β-blockers and calcium antagonists.
(D¨ oring, 1992; Di Somma et al., 1993; The SWAN Study Group, 1999)
2.2 The IONA Study Design
The Impact Of Nicorandil in Angina (IONA) Study was a randomised double-
blind placebo controlled clinical trial in patients who were suﬀering from stable
angina of eﬀort. The aim of the study was to test the hypothesis that nicorandil
would reduce the incidents of coronary events in both men and women. The
IONA Study had a composite primary endpoint of coronary heart disease (CHD)
death, non-fatal myocardial infarction (MI) or unplanned hospital admission for
cardiac chest pain. There was also a secondary endpoint of coronary heart disease
death or non-fatal myocardial infarction. (The IONA Study Group, 2002) The
full deﬁnitions of the component parts of the primary and secondary endpoints
are given in Appendix A. Randomisation for the IONA Study started in May
1998 and ended in August 2000 with patients being recruited from 226 centres
in the UK. These were both primary care and hospital centres, with there beingCHAPTER 2. THE IMPACT OF NICORANDIL IN ANGINA STUDY 10
approximately equal numbers of patients recruited from both. The mean follow-
up of the study was 1.6 years (standard deviation (SD) 0.5 years), with the range
of follow-up being from 1 to 3 years and the last study visit took place in August
2001. In total 5,126 patients were randomised in the IONA Study, of these 2,565
were assigned to 20 mg of nicorandil twice daily and 2,561 to an identical placebo.
There were a number of inclusion and exclusion criteria before patients could
be randomised in the IONA Study. Both men and women were recruited for the
study, with men having to be aged ≥ 45 years old and women ≥ 55 years old.
Patients could be existing suﬀerers of chronic angina of eﬀort or could be newly
diagnosed. There were no standard antianginal therapies set out in the study
protocol and the medication that each individual patient received was judged to
be the optimum for them by the study investigator. As the patients were suﬀering
from angina they were all expected to be receiving at least one symptom relieving
oral antianginal drug: a long acting nitrate formulation, a β-blocker or a calcium
channel blocker. All patients who were randomised should also have experienced
one of the following:
1. previous myocardial infarction;
2. previous coronary artery bypass graft;
3. coronary heart disease proven by angiography or a documented positive
exercise test (≥ 1 mm ST depression) in the previous two years.
The last of the three inclusion criteria was required to be accompanied by at least
one of the following: left ventricular hypertrophy on ECG (tall R in aVL, SV1
+ RV6 > 35 mm, lateral T inversion); evidence of left ventricular dysfunctionCHAPTER 2. THE IMPACT OF NICORANDIL IN ANGINA STUDY 11
(ejection fraction ≤ 45% or end diastolic dimension > 5.5 cm); age ≥ 65 years;
diabetes (types I or II); hypertension (treated, and/or systolic blood pressure
> 160 mm Hg or diastolic blood pressure > 95 mm Hg); documented evidence
of other vascular disease (stroke, transient ischaemic attack requiring hospital
admission, peripheral arterial disease). (The IONA Study Group, 2001) The
rationale behind recruiting patients with additional risk factors was so that the
patients would be at high risk of suﬀering a primary endpoint during the period
of the study. Patients with any of the following were excluded from taking part
in the study:
1. uncontrolled cardiac failure or arrhythmias;
2. unstable angina;
3. coronary artery bypass graft or myocardial infarction in the previous three
months
4. percutaneous transluminal coronary angioplasty in the previous six months;
5. uncontrolled hypertension (systolic blood pressure > 180 mm Hg or diastolic
blood pressure > 110 mm Hg);
6. the presence of other diseases that in the investigator’s opinion would re-
duce life expectancy or inﬂuence signiﬁcantly the patient’s cardiovascular
condition;
7. current treatment with nicorandil;
8. current treatment with sulfonylureas (this group of antidiabetic drugs blocks
potassium channel opening);CHAPTER 2. THE IMPACT OF NICORANDIL IN ANGINA STUDY 12
9. pregnancy or lactation;
10. legal incapacity or limited legal capacity;
11. participation in another clinical study within the previous 30 days;
12. presence of contraindications to the study medication;
13. known drug or alcohol abuse.
All subjects provided written informed consent.
Before patients were randomised they had the following baseline characteris-
tics recorded: age, height, weight, body mass index (BMI), systolic blood pressure
(SBP), diastolic blood pressure (DBP), heart rate, recorded as beats per minute
(bpm), sex, whether they were diabetic, hypertensive, a current smoker, whether
they had suﬀered a previous myocardial infarction, coronary artery bypass graft
(CABG), percutaneous transluminal coronary angioplasty (PTCA), angiogram,
stroke, whether they had been admitted to hospital due to a transient ischemic
attack (TIA), whether they had a history of left ventricular hypertrophy (LVH),
of left ventricular dysfunction (LVD) or of peripheral vascular disease (PVD). In
addition patients had the severity of their angina assessed using the Canadian
Cardiovascular Society Functional classiﬁcation of angina (CCSF), this is a four
point scale with patients classiﬁed as level I having the mildest level of angina
and patients classiﬁed as level IV having the most severe level of angina. The
baseline characteristics for the patients who took part in the IONA Study can be
seen in Table 2.1.
When patients were randomised they were assigned to nicorandil, 10 mg twice
daily, or identical placebo in a double-blind manner for the ﬁrst two weeks ofCHAPTER 2. THE IMPACT OF NICORANDIL IN ANGINA STUDY 13
Table 2.1: Baseline characteristics for patients in the IONA Study shown
with mean (SD) for continuous variables and number of patients
(%) for categorical variables
Nicorandil (n = 2,565) Placebo (n = 2,561)
Continuous Risk Factors, Mean (SD)
Age (years) 67 (8) 67 (9)
Height (cm) 169 (9) 169 (9)
Weight (kg) 79 (15) 80 (15)
BMI (kg/m2) 28 (5) 28 (4)
SBP (mm Hg) 138 (19) 138 (19)
DBP (mm Hg) 79 (10) 79 (10)
Heart rate (bpm) 66 (12) 67 (12)
Categorical Risk Factors, n (%)
Male 1,962 (76.5%) 1,948 (76.1%)
Diabetic 197 (7.7%) 232 (9.1%)
Hypertensive 1,197 (46.7%) 1,178 (46.0%)
Current Smoker 417 (16.3%) 425 (16.6%)
History of Vascular Disease, n (%)
Previous MI 1,696 (66.1%) 1,682 (65.7%)
Previous CABG 572 (22.3%) 590 (23.0%)
Previous PTCA 360 (14.0%) 392 (15.3%)
Previous Angiogram 1,508 (58.8%) 1,525 (59.6%)
Previous Stroke 134 (5.2%) 116 (4.5%)
Hospital Admission for TIA 47 (1.8%) 55 (2.1%)
History of LVH 259 (10.1%) 260 (10.2%)
History of LVD 230 (9.0%) 206 (8.1%)
History of PVD 289 (11.3%) 335 (13.1%)
CCSF Classiﬁcation for Angina, n (%)
Level I 671 (26.2%) 692 (27.0%)
Level II 1,695 (62.6%) 1,583 (61.9%)
Level III 272 (10.6%) 275 (10.7%)
Level IV 15 (0.6%) 9 (0.4%)CHAPTER 2. THE IMPACT OF NICORANDIL IN ANGINA STUDY 14
the study. After two weeks a study visit was scheduled where the tolerance to
nicorandil or the placebo was assessed. For those patients who were tolerating
10 mg twice daily of nicorandil the dose of nicorandil was increased to 20 mg
twice daily or matching placebo. Eight weeks after randomisation there was a
second study visit where again tolerance to the drug as well as compliance to the
treatment regime were assessed. The compliance of patients to their treatment
regime was assessed by counting the number of pills, nicorandil or placebo, they
returned at study visits. If required, the dosage of nicorandil could be down
titrated at this visit. After the study visit at eight weeks further visits took
place every sixteen weeks until the study follow-up came to an end. Patients
were still followed until study closedown even if they had ceased to comply with
their study treatment and all patients were expected to have a study closedown
visit. At all study visits compliance was assessed as well as all serious adverse
events and adverse events leading to discontinuation of study drug. In addition
the angina status of patients was assessed at each visit by the CCSF classiﬁcation
of angina and also the concomitant drug treatments patients were being treated
with were recorded. Common types of cardiovascular medications that patients
who took part in IONA Study were being treated with were: ACE inhibitors,
antiplatelets (and aspirin), β-blockers, long acting nitrates, diuretics, statins and
calcium channel blockers (CCBs). The diuretics could be further divided into
ordinary and loop diuretics. In addition the three most prescribed CCBs were
amlodipine, diltiazem and nifedipine. The numbers of patients being treated with
the diﬀerent cardiovascular medications at baseline can be seen in Table 2.2.
The IONA Study had a target samples size of 5,000 and with this sample size
the study had 80% power, with a 5% signiﬁcance level, to detect a 20% reductionCHAPTER 2. THE IMPACT OF NICORANDIL IN ANGINA STUDY 15
Table 2.2: The numbers (%) of patients being prescribed the diﬀerent car-
diovascular medications at baseline
Cardiovascular Medication Nicorandil (n = 2,565) Placebo (n = 2,561)
ACE Inhibitors 739 (28.8%) 759 (29.6%)
Antiplatelets (and Aspirin) 2283 (89.0%) 2238 (87.4%)
β-Blockers 1469 (57.3%) 1433 (56.0%)
Long Acting Nitrates 1359 (53.0%) 1358 (53.0%)
Ordinary Diuretics 273 (10.6%) 271 (10.6%)
Loop Diuretics 542 (21.3%) 528 (20.6%)
Statins 1449 (56.5%) 1486 (58.0%)
Calcium Channel Blockers 1411 (55.0%) 1397 (54.6%)
Most commonly prescribed Calcium Channel Blockers
Amlodipine 501 (19.5%) 472 (18.4%)
Diltiazem 613 (23.9%) 638 (24.9%)
Nifedipine 204 (8.0%) 199 (7.8%)
in the rate of the primary endpoint, assuming the placebo event rate would be
13%. There was 80% power, again with 5% signiﬁcance level, to detect a 25%
reduction in the rate of the secondary endpoint assuming a placebo event rate of
8%. (The IONA Study Group, 2002) The assumption regarding the placebo event
rate for the secondary endpoint turned out to be incorrect. Instead of the assumed
8% event rate the actual event rate in the placebo group was substantially lower
at 5.2%. As a result the IONA Study was underpowered to show statistical
signiﬁcance when analysing the secondary endpoint.CHAPTER 2. THE IMPACT OF NICORANDIL IN ANGINA STUDY 16
2.3 Adverse Events and Reasons for Study Non-
Completion
As was stated in Section 2.2, at all study visits serious adverse events and ad-
verse events leading to discontinuation of study drug that patients suﬀered were
recorded. The serious adverse events were coded using a proprietary dictionary
provided by Merck KGaA, Merck KGaA were one of the sponsors of the IONA
Study along with Aventis Pharma and Chugai Pharmaceutical Company. There
were a number of diﬀerent types of adverse events recorded which led to pa-
tients discontinuing their study drug, the most common of which was headaches.
It is known that nicorandil when ﬁrst taken can cause patients to suﬀer from
headaches. In total 445 patients stopped their study drug due to suﬀering from
headaches, of which 364 were in the nicorandil group (14.2% of the group) and 81
in the placebo group (3.2% of the group). This reinforces the fact that headaches
are a side-eﬀect of nicorandil. The reasons for patient non-completion, excluding
death, are shown in Table 2.3. Also shown are the numbers of patients who were
lost to follow-up and who withdrew informed consent.
Table 2.3: Reasons and patient numbers (%) for non-completion in the IONA
Study
Reason for Non-Completion Nicorandil (n = 2,565) Placebo (n = 2,561)
Discontinued intervention 1,003 (39.1%) 809 (31.6%)
Reason for discontinuation
Headache 364 (14.2%) 81 (3.2%)
Other non-fatal adverse events 342 (13.3%) 375 (14.6%)
Non-adverse event reason 297 (11.6%) 353 (13.8%)
Lost to follow-up 2 (0.04%) 2 (0.04%)
Withdrew informed consent 44 (1.7%) 41 (1.6%)CHAPTER 2. THE IMPACT OF NICORANDIL IN ANGINA STUDY 17
Potentially more severe side-eﬀects were the GI events and resultant hospi-
talisations that nicorandil may cause. The events that were deﬁned as GI events
were serious adverse events that were coded as occurring within the gastroin-
testinal body system using the coding dictionary provided by Merck KGaA. The
lengths of any resultant hospitalisations due to serious adverse events were also
recorded. Therefore, even though GI events were not a predeﬁned study outcome
the numbers and types of all GI hospitalisations that patients suﬀered during
their participation in the IONA Study were recorded. The statistical power of
ﬁnding a diﬀerence in the rate of GI events that patients suﬀered between the
nicorandil and placebo groups was not considered before the start of the study.
The data that were collected will be used to investigate whether nicorandil does,
in this instance, increase the likelihood of suﬀering GI events. It should be noted
that all serious adverse events were recorded regardless of whether or not they
could deﬁnitely be attributed to the study drug that patients were taking.
2.4 Results of the IONA Study
To analyse the primary and secondary endpoints of the IONA Study as well as
the GI events a Cox proportional hazards model was used to estimate the hazard
ratio (HR) associated with random treatment allocation with accompanying 95%
conﬁdence intervals (CI). (Cox, 1972) In all three of these analyses the only co-
variate that was ﬁtted in the model was the randomised treatment patients were
receiving. When ﬁtting a Cox model there is an underlying assumption of pro-
portional hazards between the treatment groups. The assumption of proportional
hazards was checked for the three types of event analysed and found to be validCHAPTER 2. THE IMPACT OF NICORANDIL IN ANGINA STUDY 18
in each case. The analyses were carried out on an intention-to-treat basis. For
the patients who were lost to follow-up, withdrew informed consent for follow-up
or died from none CHD reasons their observation times were censored at the time
of their last study visit. For all other patients clinical outcomes were sought until
one of the following occurred: death or study closedown. The results shown in
Sections 2.4.1 and 2.4.2 can be found in the original results paper. In the paper
only the total number of GI events suﬀered by patients during the study was
given and no formal analysis was conducted.
The majority of patients suﬀered an unplanned hospital admission as their
ﬁrst primary endpoint but patients could go on to either die due to CHD or
suﬀer a non-fatal MI. When the secondary endpoint was being investigated the
Table 2.4: The breakdown and numbers (%) of the component parts for the
ﬁrst primary and secondary endpoints that patients suﬀered dur-
ing the IONA Study
Endpoint Component Part Nicorandil Placebo
(n = 2,565) (n = 2,561)
Primary Endpoint
CHD death 36 (1.4%) 54 (2.1%)
Non-fatal MI 47 (1.8%) 60 (2.3%)
Unplanned hospital admission
for cardiac chest pain
254 (9.9%) 284 (11.1%)
Secondary Endpoint
CHD death 51 (2.0%) 62 (2.4%)
Non-fatal MI 56 (2.2%) 72 (2.8%)
unplanned hospital admission that patients suﬀered were not considered. There-
fore, for the ﬁrst events that patients suﬀered, included in the analysis contained
in Sections 2.4.1 and 2.4.2, the numbers of patients who suﬀered the component
parts common to both the primary and secondary endpoints were greater for theCHAPTER 2. THE IMPACT OF NICORANDIL IN ANGINA STUDY 19
secondary endpoint. The breakdown of the component parts and the numbers
of patients who suﬀered them for the ﬁrst primary and secondary endpoints are
shown in Table 2.4.
2.4.1 Primary Endpoint
The Kaplan-Meier estimates for the primary endpoint split by treatment group
can be seen in Figure 2.1. As the time from randomisation increases there is
Figure 2.1: Kaplan-Meier estimates for the primary endpoint of the IONA
Study
an apparent separation in the curves for the nicorandil and placebo groups with
the percentage of patients in the nicorandil group who have suﬀered a primaryCHAPTER 2. THE IMPACT OF NICORANDIL IN ANGINA STUDY 20
endpoint being lower than in the placebo group. If nicorandil does have cardio-
protective properties then this is the pattern that would have been expected.
To see if the reduction in the number of primary endpoints suﬀered by patients
treated with nicorandil was statistically signiﬁcant a Cox proportional hazard
model was ﬁtted to the data, the results can be seen in Table 2.5 along with
the numbers of patients who suﬀered each endpoint. (The IONA Study Group,
Table 2.5: Results of the IONA Study. The table contains numbers of events
(%), estimated hazard ratios, 95% CIs and p-values
Endpoint Nicorandil Placebo Hazard 95% Conﬁdence P-Value
(n = 2,565) (n = 2,561) Ratio Interval
Primary 337 (13.1%) 398 (15.5%) 0.83 (0.72 – 0.97) 0.014
Secondary 107 (4.2%) 134 (5.2%) 0.79 (0.61 – 1.02) 0.068
2002) The HR for treatment with nicorandil relative to placebo for the primary
endpoint, the composite endpoint of CHD death, non-fatal MI or unplanned
hospital admission for cardiac chest pain, was 0.83 (95% CI: 0.72 - 0.97) and
the p-value = 0.014. This implies that nicorandil reduced the risk of a primary
endpoint, by 17% with this reduction likely to be in the range of 3% to 28%.
2.4.2 Secondary Endpoint
The Kaplan-Meier estimates split by treatment group for the secondary endpoint
can be seen in Figure 2.2. As was seen for the primary endpoint as the time
since randomisation increases there is an apparent separation in the curves for the
nicorandil and placebo groups. The percentage of patients in the nicorandil group
who suﬀered secondary endpoints was lower than the percentage in the placebo
group. Subjectively again the Kaplan-Meier estimates indicate that nicorandilCHAPTER 2. THE IMPACT OF NICORANDIL IN ANGINA STUDY 21
Figure 2.2: Kaplan-Meier estimates for the secondary endpoint of the IONA
Study
does have cardioprotective eﬀects.
Looking at the results for the secondary endpoint, of CHD death or non-fatal
MI, in Table 2.5, the HR was 0.79 (95% CI: 0.61 - 1.02) and the p-value = 0.068,
just failing to achieve statistical signiﬁcance. The point estimate for the reduction
in risk of suﬀering a secondary endpoint was 21% which is greater than the point
estimate of 17% for the reduction in risk of suﬀering a primary endpoint. Due to
the event rate for the secondary endpoint being lower than expected the results
fail to reach statistical signiﬁcance but they are consistent with the results for
the primary endpoint.CHAPTER 2. THE IMPACT OF NICORANDIL IN ANGINA STUDY 22
2.4.3 Gastrointestinal Events
As was mentioned in Section 2.3, the incidence of GI events was not a predeﬁned
outcome of the IONA Study, although an increase in the number of GI events
patients in the nicorandil group suﬀered was observed compared to patients in
Figure 2.3: Kaplan-Meier estimates for the GI events suﬀered by patients
during the IONA Study
the placebo group. Whether this increase in GI events was statistically signiﬁcant
will be explored. The Kaplan-Meier estimates split by treatment group for the
GI events that patients suﬀered can be seen in Figure 2.3.
As with both the primary and secondary endpoints as the time since patientsCHAPTER 2. THE IMPACT OF NICORANDIL IN ANGINA STUDY 23
were randomised increases the curves for the nicorandil and placebo groups sepa-
rate but on this occasion it was the nicorandil group that had the higher percent-
age of patients who suﬀered events. The Kaplan-Meier estimates suggest that
nicorandil does increase the risk of patients suﬀering GI events. The number of
patients in the nicorandil group of the study who suﬀered a ﬁrst GI event was
157 (6.1% of the group) and in the placebo group it was 108 (4.2% of the group).
The HR for suﬀering a GI event, nicorandil relative to placebo, was 1.46 (95%
CI: 1.14 - 1.86) and the p-value = 0.0027. Patients treated with nicorandil had
an increased risk of suﬀering a GI event of 46%, with this increase likely to be in
the range of 14% to 86%.Chapter 3
Further Modelling of the IONA
Study
In Section 2.4 the results of the time-to-ﬁrst event analysis for the primary end-
point of the IONA Study were reported as well as the ﬁndings for the GI events
that patients suﬀered. In both of these analyses the only baseline variable ﬁt-
ted was the randomised treatment patients were receiving. Other variables were
also recorded at baseline on all patients who took part in the IONA Study, see
Tables 2.1 and 2.2. In this Chapter, in addition to randomised treatment, the
other baseline variables will be used to build prognostic models for the primary
endpoint of the study and for the GI events patients suﬀered. These will be based
on Cox proportional hazards models. (Cox, 1972) These models will be then used
in Chapter 8, when the economic impact of the IONA Study is being assessed.
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3.1 The Model Fitting Process
When it came to the model ﬁtting there were two alterations to the baseline
variables that are shown in Table 2.1. Firstly due to the close clinical relationship
between suﬀering a stroke and a TIA and the relatively small numbers of patients
who had been admitted to hospital due to a TIA, 47 (1.8%) in the nicorandil group
and 55 (2.1%) in the placebo group, a stroke and hospitalisation due to a TIA
were combined. The numbers of patients with the composite outcome were 172
(6.7%) in the nicorandil group and 162 (6.3%) in the placebo group. Secondly
due to the small number of patients who had their angina classiﬁed as level IV by
the CCSF classiﬁcation, 15 (0.6%) patients in the nicorandil group and 9 (0.4%)
patients in the placebo group, levels III and IV of the CCSF classiﬁcation were
combined together to form a new level III/IV. The new combined level contained
287 (11.2%) patients from the nicorandil group and 284 (11.1%) patients from
the placebo group. All other variables were unaltered.
In order to select the variables that were to be included in the ﬁnal models as
explanatory variables a stepwise variable selection procedure was implemented.
The signiﬁcance level to enter the model was set at 0.05 and the signiﬁcance
level to leave the model was also set at 0.05. The rationale behind using a vari-
able selection procedure to build the models was the large number of potential
explanatory variables that were available for inclusion. In addition to using a
stepwise variable selection procedure both forward and backward variable selec-
tion procedures were also used throughout to see if any diﬀerences in the variables
selected in the ﬁnal models by the diﬀerent selection methods were apparent and
if any of these diﬀerences would have implications for the interpretation of theCHAPTER 3. FURTHER MODELLING OF THE IONA STUDY 26
ﬁnal models. In all cases the models shown in Sections 3.4 and 3.6 were those
generated by the stepwise variable selection procedure. As the change in risk
caused by an increase or decrease of one unit for some of the continuous variables
has little clinical signiﬁcance, especially if the range of the variable is large, the
following increases in the continuous variables were considered: an increase of 10
years in age, an increase of 10 cm in height, an increase of 5 kg in weight, an
increase of 2 kg/m2 in BMI, an increase of 10 mm Hg in SBP, an increase of 5
mm Hg in DBP and an increase of 10 bpm in heart rate. All other variables were
categorical with two categories, apart from the CCSF classiﬁcation, which had
three. In all of the analyses CCSF level I was used as the reference level to which
levels II an III/IV were compared. For the categorical variable sex, females were
coded as zero and males were coded as one.
3.2 Missing Baseline Values
When the variable selection procedures were implemented fewer than 5,126 pa-
tients were included in the analysis data set due missing values for one or more
of the baseline variables. There were no missing values for the cardiovascular
medications. Details of the missingness of the data are given in Table 3.1. It
can be seen that a maximum of 50 (1.9%) patients were removed from the nico-
randil group and 30 (1.2%) from the placebo group leaving 2,515 patients in the
nicorandil group and 2,531 patients in the placebo group due to missingness of
baseline data and a new total of 5,046 patients. As all the data is baseline data
it can be assumed that it is missing at random. Values could have been imputedCHAPTER 3. FURTHER MODELLING OF THE IONA STUDY 27
Table 3.1: The numbers (%) of patients with missing baseline characteristics
Variable Nicorandil (n = 2,565) Placebo (n= 2,561)
Height 20 (0.8%) 15 (0.6%)
Weight 14 (0.5%) 11 (0.4%)
BMI 29 (1.1%) 20 (0.8%)
SBP 2 (0.08%) 0 (0.0%)
DBP 2 (0.08%) 0 (0.0%)
Heart Rate 7 (0.3%) 2 (0.08%)
Current Smoker 0 (0.0%) 1 (0.04%)
Previous PTCA 0 (0.0%) 1 (0.04%)
Previous Stroke or TIA 0 (0.0%) 1 (0.04%)
History of LVH 10 (0.4%) 2 (0.08%)
History of LVD 3 (0.1%) 1 (0.04%)
CCSF Classiﬁcation 2 (0.08%) 2 (0.08%)
Patients With Missing Values 50 (1.9%) 30 (1.2%)
for the missing data but as the level of missingness was so low this was not at-
tempted. Most of the missingness was caused by patients not having their height
and or weight measured at baseline. To minimise any problems associated with
missing data models identiﬁed by the variable selection procedure were reﬁtted
using patients who had data for all of the selected variables.
3.3 Model Building
Two diﬀerent methods for producing the multivariable predictive models for both
the primary endpoint of the study and the GI events patients suﬀered were used.
This was again due to the large number of potential explanatory variables avail-
able for inclusion. By using two diﬀerent model building approaches, in addition
to using a stepwise variable selection procedure to actually select the variables
for inclusion in the models, the ﬁnal models produced should model the data asCHAPTER 3. FURTHER MODELLING OF THE IONA STUDY 28
accurately as possible given the available data. The ﬁrst method used the set
of baseline variables as a whole. It would be possible to use a stepwise variable
selection procedure on all the available baseline variables. For each type of event
this procedure could be carried out twice once with the CCBs included as a whole
and secondly with the CCBs separated in to the three most commonly prescribed
ones. Instead the univariate signiﬁcance of the variables was ﬁrstly investigated
for both types of event and then a stepwise variable selection procedure performed
on the sub-group of variables found to be univariately signiﬁcant for each type
of event.
The second method used involved splitting the baseline variables into three
categories: traditional risk factors for CHD, clinical indicators for CHD and back-
ground cardiovascular medication. Prognostic models were produced for each of
the categories of baseline variables, using a stepwise variable selection procedure,
and from the variables selected in these models a further model was then pro-
duced, again using a stepwise variable selection procedure, and this was carried
out for both the primary endpoint and the GI events. The randomised treatment
that patients were receiving was included in each of the three categories. As
some of the traditional risk factors for CHD, such as the age and sex of patients,
are also clinical indicators for suﬀering from CHD they were included in both
categories. There were two variations for the baseline cardiovascular medication
category, ﬁrstly the CCBs were included as a whole and secondly amlodipine, dil-
tiazem and nifedipine were included separately. The variables that were included
in the three categories are shown in Table 3.2.CHAPTER 3. FURTHER MODELLING OF THE IONA STUDY 29
Table 3.2: The baseline variables included in the diﬀerent categories
Traditional Risk Clinical Indicators Background Cardiovasular
Factors for CHD for CHD Medications
Randomised Treatment Randomised Treatment Randomised Treatment
Age Age ACE Inhibitors
Height Sex Antiplatelets (and Aspirin)
Weight Hypertensive β-Blockers
BMI Previous MI Long Acting Nitrates
SBP Previous CABG Ordinary Diuretic
DBP Previous PTCA Loop Diuretic
Heart Rate Previous Angiogram Statins
Sex Previous Stroke or TIA Calcium Channel Blockers∗
Diabetic History of LVH Amlodipine†
Current Smoker History of LVD Diltiazem†
History of PVD Nifedipine†
CCSF Classiﬁcation
∗ Included in the background cardiovascular medication category used in Model A
† Included in the background cardiovascular medication category used in Model B
3.4 The Primary Endpoint Model
The two methods of model building were implemented to produce models for the
primary endpoint of the IONA Study.
3.4.1 Method One
The univariate signiﬁcance of the baseline variables for the primary endpoint was
investigated using Cox proportional hazards models and the results can be seen in
Table 3.3. The p-values for those variables found to be univariately signiﬁcant for
either the primary endpoint or GI events are highlighted. The following variables
were found to be individually signiﬁcant prognostic factors for whether patients
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lower BMI, higher heart rate, current smoking, previous MI, previous stroke or
TIA, history of LVH, history of LVD, history of PVD, higher angina status as
classiﬁed by the CCSF classiﬁcation, treatment with an ACE inhibitor, non-
treatment with a β-blocker, treatment with a long acting nitrate, treatment with
a loop diuretic, non-treatment with a statin and treatment with a CCB. This
sub-group of variables was then used to build a model for the primary endpoint.
From the variables that were univariately signiﬁcant the following nine vari-
ables were selected in the model by the variable selection procedure: treatment
with nicorandil, lower BMI, current smoking, previous MI, previous stroke or
TIA, history of LVH, increased angina status as assessed by the CCSF classiﬁ-
Table 3.4: Multivariable predictive model for the primary endpoint of the
IONA Study found from the univariately signiﬁcant baseline vari-
ables. For this model n = 5,059. The table contains estimated
hazard ratios, 95% CIs and p-values
Variable Hazard 95% Conﬁdence P-Value
Ratio Interval
Nicorandil 0.83 0.71 – 0.96 0.010
BMI (increase of 2 kg/m2) 0.96 0.92 – 0.99 0.0065
Current Smoker 1.27 1.06 – 1.52 0.0095
Previous MI 1.43 1.22 – 1.71 <0.0001
Previous Stroke or TIA 1.38 1.07 – 1.77 0.012
History of LVH 1.42 1.14 – 1.75 0.0014
CCSF level II vs. level I 1.20 0.99 – 1.45 0.060
CCSF level III/IV vs. level I 2.00 1.58 – 2.53 <0.0001
Long Acting Nitrates 1.41 1.20 – 1.64 <0.0001
Loop Diuretics 1.53 1.30 – 1.80 <0.0001
cation, treatment with a long acting nitrate and treatment with a loop diuretic.
This model was then reﬁtted to maximise the number of patients without miss-
ing data and the results can be seen in Table 3.4. The results were qualitativelyCHAPTER 3. FURTHER MODELLING OF THE IONA STUDY 32
unchanged.
3.4.2 Method Two
Separate sub-models for the three categories of baseline variables were produced
and from these models a predictive model for the primary endpoint was produced.
3.4.2.1 Traditional Risk Factors for CHD Category
From the traditional risk factors for CHD category the variables that were selected
by the variable selection procedure were: treatment with nicorandil, older age,
higher heart and current smoking. This sub-model was then reﬁtted to maximise
the number of patients without missing data and the results can be seen in
Table 3.5.
Table 3.5: Traditional risk factors for CHD sub-model for the primary end-
point of the IONA Study. For this model n = 5,114. The table
contains estimated hazard ratios, 95% CIs and p-values
Variable Hazard 95% Conﬁdence P-Value
Ratio Interval
Nicorandil 0.84 0.73 – 0.97 0.018
Age (increase of 10 years) 1.16 1.06 – 1.27 0.013
Heart Rate (increase of 10 bpm) 1.07 1.01 – 1.41 0.027
Current Smoker 1.43 1.19 – 1.72 0.0001
3.4.2.2 Clinical Indicators for CHD Category
The variables that were selected by the variable selection procedure in the clinical
indicators for CHD category sub-model were: treatment with nicorandil, previous
MI, previous stroke or TIA, history of LVH, history of LVD and increased anginaCHAPTER 3. FURTHER MODELLING OF THE IONA STUDY 33
status as assessed by the CCSF classiﬁcation. The results of ﬁtting this sub-model
outwith the variable selection procedure to maximise the number of patients
without missing data can be seen in Table 3.6.
Table 3.6: Clinical indicator variables for CHD sub-model for the primary
endpoint of the IONA Study. For this model n = 5,109. The
table contains estimated hazard ratios, 95% CIs and p-values
Variable Hazard 95% Conﬁdence P-Value
Ratio Interval
Nicorandil 0.84 0.72 – 0.97 0.016
Previous MI 1.58 1.34 – 1.87 <0.0001
Previous Stroke or TIA 1.42 1.10 – 1.82 0.0062
History of LVH 1.46 1.18 – 1.80 0.0005
History of PVD 1.25 1.02 – 1.53 0.031
CCSF level II vs. level I 1.27 1.05 – 1.53 0.012
CCSF level III/IV vs. level I 2.33 1.85 – 2.92 <0.0001
3.4.2.3 Baseline Cardiovascular Medication Category
For the primary endpoint the same variables were selected by the stepwise vari-
ables selection procedure from both variations of the baseline cardiovascular med-
ication category, those selected were: treatment with nicorandil, treatment with
a long acting nitrate and treatment with a loop diuretic. The models produced
by the variable selection procedure and outwith the procedure were the same
as there were no missing values for the baseline cardiovascular medication that
patients were receiving. The results for the sub-model can be seen in Table 3.7.
3.4.2.4 Multivariable Predictive Model
From the three categories of baseline variables the following variables were se-
lected as being prognostic in at least one of the models: treatment with nicorandil,CHAPTER 3. FURTHER MODELLING OF THE IONA STUDY 34
Table 3.7: Baseline cardiovascular medications sub-model for the primary
endpoint of the IONA Study. For this model n = 5,126. The
table contains estimated hazard ratios, 95% CIs and p-values
Variable Hazard 95% Conﬁdence P-Value
Ratio Interval
Nicorandil 0.83 0.72 – 0.96 0.013
Long Acting Nitrates 1.56 1.34 – 1.82 <0.0001
Loop Diuretics 1.69 1.44 – 1.98 <0.0001
older age, higher heart rate, current smoking, previous MI, previous stroke or
TIA, history of LVH, history of PVD, higher angina status of patients as assessed
by the CCSF classiﬁcation, treatment with a long acting nitrate and treatment
with a loop diuretic. Using a stepwise variable selection procedure a model was
built from these variables. This generated a prognostic model containing eight
of the variables with age, heart rate and a history of PVD the variables omitted.
This model was then reﬁtted outwith the variable selection procedure, to max-
imise the number of patients without missing data, and the results can be seen
in Table 3.8.
3.5 Interpretation of the Primary Endpoint Mod-
els
The multivariable predictive models for the primary endpoint produced by the
diﬀerent methods used were the same apart from the inclusion of the BMI of
patients in the ﬁrst model and exclusion of it from the second model. The dif-
ferences in HRs, 95% CIs and p-values between the two versions of the model
were minor and caused by the inclusion and exclusion of the variable BMI. FromCHAPTER 3. FURTHER MODELLING OF THE IONA STUDY 35
Table 3.8: Multivariable predictive model for the primary endpoint of the
IONA Study based on the sub-models produced from the baseline
variable categories. For this model n = 5,108. The table contains
estimated hazard ratios, 95% CIs and p-values
Variable Hazard 95% Conﬁdence P-Value
Ratio Interval
Nicorandil 0.83 0.72 – 0.96 0.012
Current Smoker 1.29 1.08 – 1.54 0.0058
Previous MI 1.46 1.23 – 1.73 <0.0001
Previous Stroke or TIA 1.38 1.07 – 1.76 0.012
History of LVH 1.46 1.18 – 1.80 0.0004
CCSF level II vs. level I 1.18 0.98 – 1.42 0.091
CCSF level III/IV vs. level I 1.94 1.54 – 2.45 <0.0001
Long Acting Nitrates 1.42 1.21 – 1.67 <0.0001
Loop Diuretics 1.50 1.28 – 1.76 <0.0001
the prognostic models for the primary endpoint it was reinforced that the risk
of patients suﬀering CHD events was reduced for those who were treated with
nicorandil. It can be seen from version one of the model that patients who were
treated with nicorandil had a reduced risk of 17% (95% CI: 4%, 29%) of suﬀering
a primary endpoint. The results were similar for the second version of the model
as well as to those seen previously in Section 2.4.1. The HR point estimate for the
reduction in risk of suﬀering a primary endpoint associated with treatment with
nicorandil was the same in both versions of the multivariable predictive model as
it had been for the original time-to event analysis shown in Section 2.4.1. This
suggests that balance was achieved between the two treatment arms of the study.
The age of patients is a known risk factor for CHD, with the risk of patients
suﬀering CHD events increasing as their age increases but the variable age was
not included in the either of the ﬁnal models for the primary endpoint. From
Table 3.3 it can be seen that age was a signiﬁcant univariate predictor. HoweverCHAPTER 3. FURTHER MODELLING OF THE IONA STUDY 36
the BMI of patients at baseline was included in the ﬁrst version of the model, with
the risk of a primary endpoint decreased with a higher BMI. In contrast to this it
has been shown elsewhere that the risk of CHD events is actually increased with
higher BMI. (Kim et al., 2006) Through further investigation it became apparent
that there was a relationship between age and BMI. The general trend was that
with increasing age the BMI of patients decreased. There was a statistically
signiﬁcant negative Pearson correlation of -0.20 between age and BMI, p-value
<0.0001. Older patients are more likely to suﬀer from poorer health and weight
loss, which leads to a decrease in BMI, is a common sign that the health of
patients is deteriorating. This in turn could imply that these patients are more
likely to suﬀer CHD events. Decreasing BMI was therefore acting as a marker
for increasing age and deteriorating health in patients. Due to this fact and
confounding factors with the other variables included in the model age was not
selected in the ﬁnal model. For the sub-model produced from the traditional risk
factors for CHD, see Table 3.5, age was included whereas BMI was not. BMI
could then not be included in the ﬁnal prognostic model found via method two.
Even with the removal of BMI from possible inclusion the confounding factors
between age and the other variables that were included in the model meant that
age was not included in this model either.
The other baseline variables included in the ﬁnal model were all known indi-
cators of patients who will have an increased risk of suﬀering CHD events. These
variables included smoking history, previous MI, previous stroke or TIA, history
of LVH and more severe symptoms of angina. As the CCSF classiﬁcation mea-
sures the severity of angina it is likely that those patients who were classiﬁed
higher on the scale would be at a higher risk of suﬀering from CHD events. WithCHAPTER 3. FURTHER MODELLING OF THE IONA STUDY 37
level I, the mildest level of angina, used as the reference level for the other two
levels to be compared against it can be see from Tables 3.4 and 3.8 that there
was a non-statistically signiﬁcant trend to increased risk between levels I and II.
The comparison between levels I and III/IV, the mildest and the most severe
levels, is highly signiﬁcant in both models, with the p-value being <0.0001. In
this case the risk between those patients classiﬁed as level III/IV compared to
level I was increased by 100% (95% CI: 58%, 153%), according to the ﬁrst version
of the model. The results for the second version were comparable. In additional
analysis that was carried out levels II and III/IV were compared. The HR of
patients classiﬁed as level III/IV compared to level II of the CCSF classiﬁcation
was 1.67 (95% CI: 1.38 - 2.02) and the p-value was <0.0001. This was for version
one of the model with similar results seen for version two. The sub-groups of
patients classiﬁed as level III/IV had a signiﬁcantly increased risk of suﬀering a
primary endpoint compared to those classiﬁed as level II.
The results of the models for the primary endpoint show that those patients
who were being treated with a long acting nitrate or a loop diuretic at baseline
had an increased risk of suﬀering a CHD event. As both of these are classes
of cardiovascular medications these ﬁndings may appear to be strange at ﬁrst
glance. This is likely to be due to confounding by indication. Patients with
angina are prescribed long acting nitrates in order to help with the pain caused
by angina but nitrates are not the front line treatment. In normal circumstances
patients are ﬁrstly prescribed β-blockers, then calcium antagonists and probably
nitrates third, thus identifying that those patients who end up being treated with
nitrates as a more diﬃcult sub-group of patients and hence possibly at a higher
risk of suﬀering CHD events. Loop diuretics are given to patients who suﬀer fromCHAPTER 3. FURTHER MODELLING OF THE IONA STUDY 38
heart failure to relieve one of the potential symptoms: ﬂuid accumulation in the
body. Patients with congestive heart failure (CHF) are at particularly high risk.
Hence these cardiovascular medications were markers of patients at high risk of
clinical endpoints. Even though the medications should help the patients who
were being treated with them with symptomatic relief they were at an increased
risk of suﬀering a CHD event because of the underlying history that led to the
medications being prescribed to the them in the ﬁrst place.
Looking at the three sub-models produced from the diﬀerent categories of
baseline variables of the variables selected in at least one of the sub-models three
were not selected in the ﬁnal version of the model for the primary endpoint
produced by method two: age, which has previously been discussed, heart rate
and history of PVD. There is supporting evidence of an association between a
higher resting heart rate and the likelihood of suﬀering a CHD event (Shaper
et al., 1993; Hjalmarson, 2007) and having a history of PVD is a known risk
indicator for being at an increased risk of suﬀering a CHD event. In the presence
of the other variables selected in the ﬁnal model these variables did not provide
any additional signiﬁcant prognostic information.
As the Cox model was used to model the data the underlying assumption of
proportional hazards should be checked. All of the variables included in the mul-
tivariable predictive models for the primary endpoint produced by the two model
building methods met this assumption with the exception of whether patients
had suﬀered a previous stroke or TIA. As both models contained a large number
of variables it was not unexpected that one of the variables would violate the
assumption of proportional hazards. As a result the models were reﬁtted with
the variable whether patients had suﬀered a previous stroke or TIA omitted. ToCHAPTER 3. FURTHER MODELLING OF THE IONA STUDY 39
ascertain what eﬀect the removal of the variable whether patients had suﬀered a
previous stroke or TIA had on the models ﬁtting the data Akaike’s Information
Criterion (AIC) (Akaike, 1974) was compared for the two versions of each model.
For both models the values of AIC were lower for the model containing the vari-
able whether patients had suﬀered a previous stroke or TIA. As a result the
variable whether patients had suﬀered a previous stroke or TIA was not removed
from either model.
Having produced two multivariable predictive models for the primary end-
point a decision had to be made on which to use in later analyses. The value of
AIC was compared for the two versions of the model for the primary endpoint
and the model produced by method one had a lower value indicating it to be the
better ﬁtting model. However, to gain an understanding of the predictive per-
formance of the models their C-statistic values were calculated. (Harrell et al.,
1982) The C-statistic can be though of as being equivalent to calculating the area
under a receiver operating characteristic (ROC) curve (Hanley and McNeil, 1982)
in that the C-statistic can have values between 0 and 1, with a value close to 1
indicating that the predictive performance of the model is good. The value of the
C-statistic for the model produced by method one was 0.6421 (95% CI: 0.6211 -
0.6630) and for the model produced by method two it was 0.6409 (95% CI: 0.6201
- 0.6617). The point estimates for the C-statistic are very close together and the
CIs overlap considerably but as the value of the C-statistic was marginally larger
for the model produced by method one this is the model that will be used in later
analyses.CHAPTER 3. FURTHER MODELLING OF THE IONA STUDY 40
3.6 The Gastrointestinal Event Model
The two methods of model building were implemented to produce models for the
ﬁrst GI events patients suﬀered during the IONA Study. For both of the methods
for producing predictive models for the GI events two models were explored. This
was due to whether the CCBs were included as a whole or whether amlodipine,
diltiazem and nifedipine were included separately. Model A incorporates the
CCBs as a whole and Model B includes amlodipine, diltiazem and nifedipine
separately
3.6.1 Method One
The univariate signiﬁcance of the baseline variables for the GI events was inves-
tigated using Cox proportional hazards models and the results can be seen in
Table 3.3. For the GI events the following variables were found to be individually
signiﬁcant predictors: treatment with nicorandil, older age, lower weight, lower
BMI, being female, previous MI, history of LVD, higher angina status as classi-
ﬁed by the CCSF classiﬁcation, treatment with an ACE inhibitor, non-treatment
with a β-blocker, treatment with a long acting nitrate, treatment with a loop
diuretic, non-treatment with a statin and, although the combined variable of
whether patients were being prescribed a CCB was non signiﬁcant, treatment
with diltiazem. This sub-group of variables was then used to build models for
the GI events.
For Model A1 the following six variables were included in the model by the
variable selection procedure: treatment with nicorandil, lower weight, higher
angina status as assessed by the CCSF classiﬁcation, treatment with a long actingCHAPTER 3. FURTHER MODELLING OF THE IONA STUDY 41
Table 3.9: Multivariable predictive model, Model A1, for the GI events pa-
tients suﬀered during the IONA Study found from the univariately
signiﬁcant baseline variables. For this model n = 5,097. The table
contains estimated hazard ratios, 95% CIs and p-values
Variable Hazard 95% Conﬁdence P-Value
Ratio Interval
Nicorandil 1.44 1.13 – 1.84 0.0038
Weight (increase of 5 kg) 0.95 0.91 – 0.99 0.014
CCSF level II vs. level I 1.39 1.01 – 1.92 0.046
CCSF level III/IV vs. level I 1.74 1.14 – 2.64 0.010
Long Acting Nitrates 1.50 1.15 – 1.95 0.0024
Loop Diuretics 1.43 1.09 – 1.88 0.0093
Statins 0.71 0.55 – 0.90 0.0053
nitrate, treatment with a loop diuretic and non-treatment with a statin. This
model was reﬁtted to maximise the numbers of patients without missing values
and the results can be seen in Table 3.9.
For Model B1 the following seven variables were included in the model by
the variable selection procedure: treatment with nicorandil, lower weight, higher
Table 3.10: Multivariable predictive model, Model B1, for the GI events pa-
tients suﬀered during the IONA Study found from the univari-
ately signiﬁcant baseline variables. For this model n = 5,097.
The table contains estimated hazard ratios, 95% CIs and p-values
Variable Hazard 95% Conﬁdence P-Value
Ratio Interval
Nicorandil 1.44 1.13 – 1.84 0.0036
Weight (increase of 5 kg) 0.95 0.91 – 0.99 0.012
CCSF level II vs. level I 1.37 0.99 – 1.89 0.060
CCSF level III/IV vs. level I 1.70 1.11 – 2.58 0.014
Long Acting Nitrates 1.48 1.14 – 1.93 0.0032
Loop Diuretics 1.44 1.10 – 1.89 0.0088
Statins 0.71 0.55 – 0.90 0.0018
Diltiazem 1.31 1.01 – 1.70 0.046CHAPTER 3. FURTHER MODELLING OF THE IONA STUDY 42
angina status as assessed by the CCSF classiﬁcation, treatment with a long acting
nitrate, treatment with a loop diuretic, non-treatment with a statin and treatment
with a diltiazem. The result of re-ﬁtting the model, Model B1, can be seen in
Table 3.10. It can be seen that the common explanatory variables between Models
A1 and B1 had the same implications for the risk of patients suﬀering GI events.
The additional variable included in Model B1 was treatment with diltiazem.
3.6.2 Method Two
Separate sub-models for the three categories of baseline variables were produced
and from these models predictive models for the GI events were produced.
3.6.2.1 Traditional Risk Factors for CHD Category
From the traditional risk factors for CHD the following variables were selected in
the sub-model for the GI events: treatment with nicorandil, older age, decreasing
SBP and being female. This model was then ﬁtted outwith the variable selection
procedure to minimise the numbers of patients with missing values and the results
can be seen in Table 3.11.
Table 3.11: Traditional risk factors for CHD sub-model for the GI events
patients suﬀered during the IONA Study. For this model n =
5,124. The table contains estimated hazard ratios, 95% CIs and
p-values
Variable Hazard 95% Conﬁdence P-Value
Ratio Interval
Nicorandil 1.46 1.14 – 1.87 0.0025
Age (increase of 10 years) 1.24 1.07 – 1.45 0.0049
SBP (increase of 10 mm Hg) 0.92 0.87 – 0.98 0.013
Male 0.74 0.56 – 0.96 0.025CHAPTER 3. FURTHER MODELLING OF THE IONA STUDY 43
3.6.2.2 Clinical Indicators for CHD Category
The following variables were selected in the sub-model for the GI events from
the category of clinical indicators for CHD: treatment with nicorandil, older age,
being female, a history of LVD and higher angina status as assessed by the CCSF
classiﬁcation. When the sub-model was ﬁtted outwith the variable selection pro-
cedure, so that the number of patients without missing data was maximised, the
sex of patients was no longer a signiﬁcant predictor. This was due to the diﬀering
sizes of data set used to produce the models. For the variable selection procedure
the data set contained 5,104 patients and sex was signiﬁcant, but it was on the
borderline of signiﬁcance as the p-value = 0.049, highlighted in Table 3.12. Out-
with the selection procedure the data set contained 5,118 patients, a diﬀerence
of only 14 patients, and sex was no longer signiﬁcant. Shown in the left half of
Table 3.12 are the results produced by the variable selection procedure and shown
in the right half are the results when the model was reﬁtted with sex removed
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3.6.2.3 Baseline Cardiovascular Medication Category
Firstly, from the category of cardiovascular medications that will be used to
produce Model A2, the following variables were selected in the sub-model for GI
events: treatment with nicorandil, treatment with a long acting nitrate, treatment
with a loop diuretic and non-treatment with a statin. Secondly, the following
variables were included in the sub-model that will be used to produce Model B2:
treatment with nicorandil, treatment with a long acting nitrate, treatment with
a loop diuretic, non-treatment with a statin and additionally treatment with the
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3.6.2.4 Multivariable Predictive Model
From the categories of baseline variables the following variables were selected as
being prognostic in at least one of the sub-models for the GI events: treatment
with nicorandil, older age, decreasing SBP, being female, history of LVD, higher
angina status of patients as assessed by the CCSF classiﬁcation, treatment with
a long acting nitrate, treatment with a loop diuretic and non-treatment with a
statin. In addition treatment with diltiazem was also included in the sub-model
for the category of cardiovascular medications that will be used to produce Model
B2. Using a stepwise variable selection procedure two further models were then
built using these variables. Prognostic models containing six and seven variables
respectively were produced. The only variable not included in either model was
the SBP of patients. Models A2 and B2 were ﬁtted outwith the variable selection
procedure to maximise the number of patients without missing data and the
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3.7 Interpretation of the Gastrointestinal Event
Models
Models A1 and B1, produced by the ﬁrst method of model building, were similar
with the only diﬀerence being the inclusion of treatment with diltiazem in Model
B1. Models A2 and B2, produced by the second method, were also similar.
The diﬀerences were that the angina status of patients as assessed by the CCSF
classiﬁcation was included in Model A2 whereas in Model B2 a history of LVD and
treatment with diltiazem were included. Comparing the two version of Model A
they were the same except the ﬁrst included weight and the second included sex,
the same diﬀerence was seen for the two versions of Model B. The angina status of
patients was included in Model B1 but not in Model B2, where a history of LVD
was included. The weight of patients was not available for inclusion in the ﬁnal
models produced by method two as weight was not selected in the traditional risk
factors for CHD sub-model. In all of the models, even in the presence of other
explanatory variables, treatment with nicorandil was shown to be associated with
an increased risk of GI complications. In Model A1 the increase in risk of patients
suﬀering a GI event who were in the nicorandil group was 44% (95% CI: 12%,
86%). The results for the other models were similar.
The results from both Models A1 and B1 show that the risk of suﬀering a
GI event decreased by 5% (95% CI: 1%, 9%) for an increase in weight of 5 kg.
The point raised earlier in Section 3.5 is noteworthy. Age in the IONA Study
was negatively correlated with both BMI and weight. The Pearson correlation
between age and weight was -0.31, p-value <0.0001. As people get older they are
more susceptible to illness and this fact may be being reﬂected in the GI eventCHAPTER 3. FURTHER MODELLING OF THE IONA STUDY 50
models with decreasing weight being a surrogate for increasing age in the model.
In younger individuals an overweight status is associated with high risk. However
in older diseased populations maintenance of weight is important as evidence of
weight loss is often a sign of a deterioration in health. As weight was not available
for inclusion in either Models A2 or B2 the sex of patients may be acting as a
maker for weight in these models. Being male was associated with a lower risk
of GI events and the mean (SD) weight of males was 83 kg (14) and for females
it was 70 kg (13).
With patients who have the mildest level of angina being used as the reference
level it was shown that in Models A1, B1 and A2 that those patients with severe
levels of angina were at a higher risk of suﬀering GI events. Those patients
who were classiﬁed a level II had an increased risk of 39% (95% CI: 1%, 93%)
and those patients classiﬁed as level III/IV had an increased risk of 74% (95%
CI: 18%, 171%), according to Model A1, compared to those classiﬁed as level
I. In Model B1 the change in risk between levels I and II was non-signiﬁcant
but the trend was of increased risk for patients classiﬁed as level II, otherwise
the result for Models B1 and A2 were similar to those for Model A1. There
was no signiﬁcant diﬀerence in the risk of patients suﬀering GI events between
those classiﬁed as levels II and III/IV. Patients who had more severe levels of
angina may in general be in poorer health so more susceptible to other forms of
illness such as GI events. The same reasoning could be applied to why having
a history of LVD, included in the clinical indicators for CHD sub-model, would
lead to an increased risk of GI events. A further possible reason to why increasing
severity of angina may lead to a higher risk of GI events is that patients with
worse levels of angina symptoms may well have been prescribed a higher numberCHAPTER 3. FURTHER MODELLING OF THE IONA STUDY 51
of cardiovascular medications and these medications could have been causing the
increase in the risk of suﬀering GI events.
Many diﬀerent types of medication have GI events as documented side-eﬀects,
including: long acting nitrates, loop diuretics and diltiazem as well as other CCBs.
Those patients who were treated with a long acting nitrate, a loop diuretic or
diltiazem had an increased risk of suﬀering GI events. As in the IONA Study it
was only treatment with nicorandil that was randomised and due to confounding
with other factors it cannot be claimed that these types of medications caused
an increase in the risk of suﬀering GI events based on these ﬁndings alone. The
ﬁndings suggest that there is an association between the treatment with these
types of medication and increased risk of GI events. According to the GI models
treatment with a statin was associated with a reduced risk of suﬀering GI events
even though GI events are documented side-eﬀects of statins. If statins do reduce
the risk of patients treated with them from suﬀering GI events there is potentially
some conﬁrmatory evidence that statins do reduce the risk of patients suﬀering
certain types of GI events. (Atar et al., 2006) However, this ﬁnding may just be
a manifestation on the IONA Study itself or be related to the types of patients
that were being treated with a statin. The issue of statins will be returned to in
Section 3.8
It should be noted that it was likely that patients recruited in the IONA
Study were being prescribed other forms of medication in addition to cardiovas-
cular medications. It was not readily known what other types of medications
patients were been prescribed. However, it is likely that some of the patients
who participated in the IONA Study would have been prescribed non-steroidal
anti-inﬂammatory drugs (NSAIDs). NSAIDs are associated with an increasedCHAPTER 3. FURTHER MODELLING OF THE IONA STUDY 52
risk of suﬀering GI events. (Richy et al., 2004) It was unclear whether there was
a diﬀerence in the percentage of patients in the two treatment groups who were
being prescribed NSAIDs. Therefore, it was unknown what eﬀect, if any, treat-
ment with NSAIDs had on the risk of patients suﬀering GI events. Although,
the number of patients who were being prescribed antiplatelets (and aspirin) was
recorded and this class of medications has similar properties to NSAIDs, in that
they increase the risk of patients suﬀering GI events. Whether patients were
being prescribed antiplatelets (and aspirin) was not found to be univariately sig-
niﬁcant of whether patients would suﬀer a GI event. However, this was likely due
to the fact that such a high proportion of patients who took part in the IONA
Study were being prescribed antiplatelets (and aspirin), see Table 2.2, that any
eﬀect on the risk of suﬀering GI events was being masked. In addition if patients
had previously experienced GI events as a result of being prescribed antiplatelets
(and aspirin) they would have most likely stopped taking them, so the increased
risk of suﬀering GI events they had caused would not be seen.
Looking at the sub-models based on the diﬀerent categories of baseline vari-
ables the only variable selected in one of the sub-models not included in either
Models A2 or B2 was the SBP of patients. Patients who have higher than nor-
mal BP and are not able to lower it by lifestyle changes are often prescribed
medication to lower it. If the BP lowering medications, such as ACE inhibitors,
β-blockers, loop diuretics or CCBs, were associated with an increase in the risk of
GI events then it would appear that those patients with a higher SBP, who were
unlikely to be taking any medication to lower it, were at a reduced risk of suf-
fering GI events. With the cardiovascular medications available for inclusion in
Models A2 and B2 SBP no longer provides any signiﬁcant prognostic informationCHAPTER 3. FURTHER MODELLING OF THE IONA STUDY 53
over and above that provided by the cardiovascular medications.
Again as had been the case for the primary endpoint multivariable predictive
model as the Cox model was used to model the data the underlying assumption
of proportional hazards should be checked. All of the variables included in the
multivariable predictive models for the GI events produced by the two model
building methods met this assumption. AIC was again used to compare how the
diﬀerent models ﬁtted the data. Model A1 had a lower value of AIC than Model
A2 and Model B1 and a lower value of AIC than Model B2. When the values
of AIC were compared for Models A1 and B1 it was found that Model B1 had a
lower value indicating that Model B1 was the best ﬁt to the data.
As for the primary endpoint a decision had to be made on which of the GI
event multivariable predictive models should be used in later analyses. Thus was
again done by calculating the C-statistic for the four models to ascertain their
predictive performance. The point estimates and accompanying 95% CI for the C-
statistic for the GI event multivariable predictive models are shown in Table 3.15.
The point estimates for the C-statistic were all close together and the four sets
Table 3.15: C-statistic point estimates and accompanying 95% CIs for the
GI event multivariable predictive models
GI Event Model Point Estimate 95% Conﬁdence Interval
Model A1 0.6307 0.5971 – 0.6644
Model B1 0.6333 0.5992 – 0.6675
Model A2 0.6268 0.5941 – 0.6615
Model B2 0.6297 0.5956 – 0.6638
of CIs overlap one another but Model B1 has the highest point estimate for the
C-statistic and will therefore be used in later analyses. It can also been see that
the predictive performance of the GI event models were marginally poorer thanCHAPTER 3. FURTHER MODELLING OF THE IONA STUDY 54
for the primary endpoint models. Although, for both the primary endpoint and
the GI events the predictive performance of the multivariable models were better
than for the analyses shown in Sections 2.4.1 and 2.4.3, where the only covariate
ﬁtted in the model was the randomised treatment patients were receiving.
3.8 Interactions Between the Cardiovascular Med-
ications
Having produced multivariable predictive models for the primary endpoint and
GI events it was found that all the models contained at least two of the diﬀerent
classes of cardiovascular medications in addition to the randomised treatment pa-
tients were receiving. It was investigated whether any interactions would be found
between these diﬀerent classes of cardiovascular medications and nicorandil. This
was again done by using a stepwise variable selection procedure. At the start of
the stepwise variable selection procedure the variables that had already been in-
cluded in the models were forced into the model and the only variables that were
under consideration for inclusion were the interaction terms between nicorandil
and the diﬀerent classes of cardiovascular medications.
3.8.1 Primary Endpoint Model Interactions
When the stepwise variable selection procedure was carried out on the models for
the primary endpoint neither the interaction between treatment with nicorandil
and a long acting nitrate nor the interaction between treatment with nicorandilCHAPTER 3. FURTHER MODELLING OF THE IONA STUDY 55
and a loop diuretic were added to the models. In addition there was no inter-
action found between treatment with a long acting nitrate and a loop diuretic.
It was also investigated whether there were any interactions between treatment
with nicorandil and the traditional risk factors for CHD variables or the clinical
indicators for CHD variables included in the models and none were found.
3.8.2 Gastrointestinal Event Model Interactions
When the stepwise variable selection procedure was run on both versions of Mod-
els A and B in all cases the only interaction term added was the one between
treatment with nicorandil and a statin. No signiﬁcant interactions were found
between the diﬀerent classes of cardiovascular medications or individual drug, in
the case of diltiazem. In addition no interactions were found between treatment
with nicorandil and the traditional risk factors for CHD variables or the clinical
indicators for CHD variables included in the models. Both versions of Models A
and B were then reﬁtted with the combination of whether patients were being
treated with neither nicorandil nor a statin, only nicorandil, only a statin or both
nicorandil and a statin included as a categorical variable in addition to the other
variables in the model. Through investigation and by altering the group used as
the reference level the only comparisons that were found to be statistically sig-
niﬁcant were the three comparisons involving the patients who were only treated
with a statin. Therefore, the patients who were treated with placebo and a statin
were used as the reference level to compare the other three groups with. The re-
sults produced for all the models were similar and as this was an exploratory
analysis only one of the models will be shown here, Model B1. The results areCHAPTER 3. FURTHER MODELLING OF THE IONA STUDY 56
shown in Table 3.16.
Table 3.16: Multivariable predictive model, Model B1, for the GI events pa-
tients suﬀered during the IONA Study including the nicorandil
statin interaction terms with those patients treated with placebo
and a statin used as the reference level. For this model n =
5,097. The table contains estimated hazard ratios, 95% CIs and
p-values
Variable Hazard 95% Conﬁdence P-Value
Ratio Interval
Weight (increase of 5 kg) 0.95 0.91 – 0.99 0.012
CCSF level II vs. level I 1.36 0.98 – 1.88 0.064
CCSF level III/IV vs. level I 1.69 1.11 – 2.58 0.014
Long Acting Nitrates 1.49 1.15 – 1.94 0.0028
Loop Diuretics 1.43 1.09 – 1.88 0.0095
Diltiazem 1.31 1.01 – 1.70 0.043
Neither vs.
Placebo and Statins
1.96 1.33 – 2.89 0.0007
Nicorandil vs.
Placebo and Statins
2.21 1.52 – 3.23 <0.0001
Nicorandil and Statins vs.
Placebo and Statins
1.94 1.33 – 2.81 0.0005
It can be seen that compared to the other three groups the patients who
were only being treated with a statin had a decreased risk of suﬀering GI events.
The increase in risk of suﬀering a GI event was smallest for the group being
treated with nicorandil and a statin, followed by the group treated with either
and the increase was greatest for the group only being treated with nicorandil.
The apparent reduction in the risk of suﬀering GI events linked to treatment with
a statin, seen previously in Section 3.6, is reinforced by these results. It may not
actually have been treatment with a statin that was causing patients to be at a
reduced risk of GI events, it may have been the type of patients who were treated
with a statin and the state of their health. Treatment with nicorandil was stillCHAPTER 3. FURTHER MODELLING OF THE IONA STUDY 57
shown to be associated with an increased risk of GI events.
A possible explanation to why those patients who were treated with a statin
were at a reduced risk of GI events is that those patients who were being treated
with a statin were naturally resistant to GI events. Patients who had previ-
ously experienced GI events during treatment with a statin may have stopped
treatment. Those patients who remained on a statin may have had a naturally
lower risk of suﬀering GI events. This was reﬂected in the reduction in risk of
GI events for patients who were treated with a statin. Patients who were treated
with a statin had a lower underlying risk of GI events so although treatment
with nicorandil increased the risk in conjunction with treatment with a statin
those patients were still at a lower risk than patients who were not treated with
a statin. Those patients treated with nicorandil but not a statin did not have a
lower underlying risk of GI events and this group of patients were at the highest
risk of suﬀering from GI events.
A second possible explanation is these ﬁnding may be due to confounding by
indication. It is believed that patients with heart failure have an increased risk
of GI events, this may be as a result of: the heart failure itself (Weil et al., 2000),
the medication that patients are treated with (Verhamme et al., 2006) or that
patients with heart failure are in a poorer state of health so are more susceptible to
other forms of illness. Typically patients with heart failure are treated with ACE
inhibitors and loop diuretics in addition to other types of medication. Treatment
with a loop diuretic was included in all of the GI event models. If treatment
with a loop diuretic was removed from the variable set then treatment with an
ACE inhibitor was included in all the models for GI events. Those patients who
were treated with an ACE inhibitor were at an increased risk of GI events. ThatCHAPTER 3. FURTHER MODELLING OF THE IONA STUDY 58
patients were treated with either of these classes of cardiovascular medication
may indicate that these patients suﬀered from heart failure. It is unclear whether
treatment with a statin is eﬀective in patients with heart failure, although their
use is becoming more prevalent. (Krum and McMurray, 2002) During the IONA
Study those patients who were suﬀering from heart failure may not have been
treated with a statin hence the apparent reduced risk of suﬀering GI events for
those patients. It is not known which patients were suﬀering from heart failure
so the validity of this argument cannot be assessed. The interaction analysis was
exploratory in nature so no deﬁnitive conclusions are able to be drawn from these
ﬁndings.Chapter 4
Recurrent Event Models
In the majority of cases when survival analysis is being used the analysis that is
carried out is based on only the ﬁrst event that a patient suﬀers and the time
to that event. However, once patients who are taking part in a clinical trial
have suﬀered a ﬁrst event it is likely that they will continue to be monitored
until the end of the trial. During this time patients may experience further
events. In traditional survival analysis this additional information would not be
considered. In order that all the available information on patients can be taken
into consideration in any analysis, models that incorporate the recurrent events
have been developed and in this Chapter the reasoning behind three of the most
familiar types of recurrent event models will be explained.
4.1 Cox Proportional Hazards Model
The proportional hazards model was ﬁrst presented in the paper by Cox (1972)
and since then it has became the model of choice for censored survival analysis.
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The notation used in the proportional hazards model is as follows. For each
patient a number of variables, p, will be recorded and these variables can be
time dependent. For the ith patient these variables can be denoted as zi(t) =
(z1i(t),.,zpi(t)) and the proportional hazards model is deﬁned as:
λ(t,z(t)) = λ0(t)exp(z(t)β) (4.1)
where β is a p×1 vector of unknown parameters and λ0(t) is an unknown baseline
hazard function for the standard set of conditions when z(t) = 0. (Cox, 1972)
4.2 Introduction to the Recurrent Event Mod-
els
It should be noted that as multiple events for each patient are being modelled it is
likely that there will be correlation among the observations for individual patients
and as a result Lin and Wei (1989) developed a robust sandwich estimator for the
covariance matrix of the estimated parameters. When analysing recurrent event
data it is advisable that this robust sandwich estimator for the covariance matrix
be used leading to a robust standard error for the parameter estimates calculated
in the modelling process. Secondly, a cut-oﬀ point is needed for the number
of recurrent events to be included so that there are still suﬃcient numbers of
patients at risk to make the model ﬁtting eﬀective. If there are small numbers of
recurrent events the beneﬁt of using a recurrent event model to analyse the data
may be lost. A counting process model, a marginal model and two variations of
a conditional model for analysing recurrent events will be described.CHAPTER 4. RECURRENT EVENT MODELS 61
4.3 Anderson-Gill Model
The Anderson-Gill model, which will be referred to as the AG model, was in-
troduced in the paper by Andersen and Gill (1982). The AG model is based on
a counting process. A counting process, deﬁned by N(t) where t is time, is a
process which is constant between events and only moves one unit at each event
time. In the recurrent event setting a counting process can be considered as a
stochastic process where the occurrence of a number of types of disjoint discrete
events in time is recorded. (Andersen et al., 1993) The AG model is deﬁned as:
λ(t,z(t)) = Y (t)λ0(t)exp(z(t)β) (4.2)
Equation 4.2 is the same as the Cox proportional hazards model seen in Equa-
tion 4.1 apart from the inclusion on the additional Y (t) term. The term Y (t)
is known as the risk indicator and in theory it could also be included in Equa-
tion 4.1. The reason that it can be omitted from the Cox proportional hazards
model is due to the diﬀerent deﬁnition of the risk indicator between the two mod-
els. For patient i, when the Cox proportional hazards model is being used, once
patient i has suﬀered the event of interest they are no longer at risk of suﬀering
that event so the risk indicator, Yi(t), becomes zero. Therefore, for the Cox model
once patient i has suﬀered the event of interest they can no longer provide any
more information for the modelling process. In the AG model the risk indicator
for patient i, Yi(t), remains at one for as long as patient i is being monitored no
matter how many or few events they suﬀer during that period of time. For the
AG model even when patient i has suﬀered the event of interest for the ﬁrst time
they can still provide information to use in the modelling process.CHAPTER 4. RECURRENT EVENT MODELS 62
In the AG model all events that patients suﬀer are assumed to be independent.
There is no distinction made between whether an event patient i suﬀers is a ﬁrst,
second or third event as all the events are treated the same. The time scale used
in the AG model is continuous with it starting at time zero, when the patient
begins the period of observation, and running until time T, when they leave
the study. The clock is not reset to zero after an event occurs. As indicated
previously, patient i contributes to the risk set for time Ti, the total time they
are under observation, no matter what the event number that is being modelled
for and whether patient i has or will go onto suﬀer that number of events. Patient
i contributes the event deﬁning the risk set at times when they suﬀer events. As
events are treated as being independent and the number of events suﬀered is not
diﬀerentiated between the events patient i suﬀers could in eﬀect be treated as
single events experienced by n diﬀerent patients, with n depending on the number
of events patient i suﬀered, with the time scale starting for each patient at the
time of the previous event.
4.4 Wei, Lin and Weissfeld Model
The Wei, Lin and Weissfeld model, which will be referred to as the WLW model,
was introduced in the paper by Wei et al. (1989). The WLW model is a marginal
model as the correlations among events are not modelled. The model is deﬁned
as:
λk(t,zk(t)) = λ0k(t)exp(zk(t)β
k) (4.3)CHAPTER 4. RECURRENT EVENT MODELS 63
Equation 4.3 is the same as Equation 4.1 with the exception on the inclusion on
the subscript k, where k refers to the kth event that patients suﬀer. Implying
that each event has a diﬀerent unknown underlying hazard function, λ0k(t), and
set of parameter estimates, β
k. The time scale for the WLW model starts at zero,
when patients are ﬁrst under observation, and this is the case for all events being
modelled for. In the WLW model only the time since the start of the observation
period for patients is important and no consideration is given to the time between
events or when the previous event occurred. When using the WLW model if k
events are being modelled for each patient is thought to be a risk for those k
events. Therefore in the WLW model each patient is artiﬁcially considered to
be at risk of suﬀering an event whether or not they have suﬀered the preceding
event.
4.5 Prentice, Williams and Peterson Model
The Prentice, Williams and Peterson model, which will be referred to as the PWP
model, was introduced in the paper by Prentice et al. (1981). The PWP model
is a conditional model and there are two variations of the model. The PWPa
model uses the total time and is deﬁned as:
λ(t|N(t),z(t)) = λ0s(t)exp(z(t)β
s) (4.4)
Whereas the PWPb model uses the gap time and is deﬁned as:
λ(t|N(t),z(t)) = λ0s(t − tn(t))exp(z(t)β
s) (4.5)CHAPTER 4. RECURRENT EVENT MODELS 64
The subscript s represents a stratiﬁcation variable where s = s(N(t),z(t),t)
which may change as a function of time for a given patient. N(t) is the number
of events patients have suﬀered prior to time t. (Prentice et al., 1981) Both
models PWPa and PWPb are conditional due to the fact that patients cannot
be at risk of suﬀering an event until they have suﬀered the previous event. The
order in which patients suﬀer events is therefore important. In the PWPa model
the time scale is the same as that used in the AG model in that the time starts at
zero and is continuous throughout the period of observation for patients, with the
total time being of interest in the PWPa model. Whereas in the PWPb model
the gap time between the successive events patients suﬀer is of interest. The time
scale for the ﬁrst event starts at zero, when the observation period for patients
begins, and after every subsequent event patients suﬀer it is then reset back to
zero. This is shown in Equation 4.5 by the underlying hazard term, λ0s(t−tn(t)),
where t is the time till the current event of interest and tn(t) was the time until
the previous event. In the PWPa model the underlying baseline hazard is taken
as a function of the time since the start of the period of observation but in the
PWPb model the baseline hazard is taken as a function of the time since the
previous event.
4.6 Recurrent Event Data Example
To aid the understanding of the diﬀerent recurrent models and the diﬀerences
between them an example of recurrent data will be given. The example data
used is from patients who were enrolled in the IONA Study. (The IONA Study
Group, 2002) In this example only the ﬁrst four primary endpoints that patientsCHAPTER 4. RECURRENT EVENT MODELS 65
could suﬀer will be considered and the recurrent event data for three patients will
be presented. Patient one, as denoted in Table 4.1, suﬀered the maximum four
events that are being considered at 313 days, 315 days, 691 days and 863 days
after randomisation. Patient two suﬀered an event 402 days after randomisation
and then 958 days after randomisation the observation period ended for patient
two without them suﬀering a further event, this may have been as the study
follow-up had come to an end or patient two may have been censored for another
reason. Patient three suﬀered no events during their period of observation and
that ended 966 days after randomisation. The example recurrent event data is
shown in Table 4.1. In Table 4.1 if the event indicator equals zero then a patient
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Firstly, looking at the data set up for the AG model it can be seen that patient
one is in the risk set for any event from 0 days until 863 days and has an event
which deﬁnes the risk set at four time points: 313 days, 315 days, 691 days and
863 days. In the AG model events are assumed to be independent and the order
in which they take place is not considered. As a result the stratum indicator is
set to 1 for all events for all patients. Patient two is in the risk set from 0 days
until 958 days and has only one event that deﬁnes the risk set and that is at 402
days. Patient three suﬀered no events so has not events which deﬁne the risk set
but is contained within the risk set from 0 days until 966 days.
Secondly, looking at the data set up for the WLW model the stratum indicator
is important for this model and increases as the event number increases. For the
WLW model the time interval each patient is at risk for always starts at the time
patients were enrolled in the study. As patient one experiences four events the
time intervals in this case are straightforward with them running from: 0 days
until 313 days, 0 days until 315 days, 0 days until 691 days and 0 days until 863.
In the WLW model each patient is thought to be at risk of suﬀering the total
number of events being modelled. In this example this is four events. As a result
of this even though patients two and three did not suﬀer four events they still
have to have four time intervals as they are still thought to be at risk of suﬀering
all four events. As a consequence of this the dataset used in the modelling process
for the WLW model is very large. Patient two suﬀered an event 402 days after
randomisation so the time interval for the ﬁrst event or stratum is from 0 days
until 402 days. Patient two continued to be monitored for a further 556 days
without experiencing a second event so the time interval for the second stratum
is from 0 days until 958 days, with the event indicator set to 0. For both theCHAPTER 4. RECURRENT EVENT MODELS 68
third and fourth strata a time interval is still required. The time interval used
for the missing events is just the last available time interval repeated. As a result
the time intervals for both the third and fourth strata are from 0 days until 958
days. As patient two did not suﬀer a third or fourth event the event indicators
for both of these strata are set to 0. Patient three did not suﬀer any events
and the inclusion of them in Table 4.1 is mainly to illustrate a drawback of the
WLW model. The time intervals for all four strata for patient three are from 0
days until 966 days. Even though this patient suﬀered no events they are still
artiﬁcially considered to be at risk of suﬀering the four events. The information
known about patients and the number of events that they suﬀer and in turn are
at risk of suﬀering from is not utilised in the ﬁtting of the WLW model.
Thirdly, the data set up for the PWPa model is exactly the same as for the AG
model but this time the stratum indicator is used in a meaningful way. For both
forms of the PWP model the order in which patients suﬀer events is important
as they can only be a risk of suﬀering the kth event once they have suﬀered the
k−1th event. For the PWPb model the stratum variable is again meaningful but
the time intervals are set up diﬀerently from in the AG model. As was stated in
Section 4.5 the gap time between events is of importance when the PWPb model
is being used so once a patient suﬀers an event the time interval is reset back
to zero. Therefore, for patient one the time intervals for the four events they
suﬀered or strata are: 0 days until 313 days, 0 days until 2 days, 0 days until 376
days and 0 days until 172 days. The two time intervals for patient two are from 0
days until 402 days, when they suﬀered an event, and from 0 days until 556 days
when their period of study observation ended. The time interval for the one and
only stratum for patient three is from 0 days until 966 days.CHAPTER 4. RECURRENT EVENT MODELS 69
4.7 Summary of the Recurrent Event Models
Having described the diﬀerent recurrent event models and illustrated how the
data is set up for each of the models through an example it will now be discussed
how the recurrent events models ﬁt to the reality of a clinical trial and in particu-
lar the IONA Study. The AG model is the simplest of the models to use but due
to its underlying assumption of independence it is unlikely that the AG model
would be able to suitably model what happens during a clinical trial. Especially,
in the case of CHD were it is known that once patients have suﬀered a CHD event
they are at a heightened risk of suﬀering another CHD event. This would then
also violate the assumption of constant risk for the AG model. It would therefore
appear that the AG model would not be the most appropriate model to use to
analyse recurrent event data where the events of interest are CHD events.
In the WLW, PWPa and PWPb models events are not assumed to be in-
dependent. It would therefore appear that one of these models would be more
appropriate to model recurrent event data from a clinical trial involving CHD
events. In the WLW model all patients are required to have a time interval for
all the events being modelled for regardless of how many they actually suﬀered.
This could potentially lead to problem in a recurrent event setting, especially if
the numbers of later events are low, as earlier time intervals are carried forward
and this could potentially bias the results. In addition, another potential problem
is that as the time interval for all events in the WLW model start at the time
patients are ﬁrst under observation no consideration is given to the time between
events. As a result the WLW model may be better suited to a competing risks
(Crowder, 2001) setting as opposed to a recurrent event one.CHAPTER 4. RECURRENT EVENT MODELS 70
When using either of the PWP models to analyse recurrent event data the
models condition on post-randomisation events. This could potentially lead to
bias in the results. However, when the recurrent event models were used to
analyse the recurrent event data from the IONA Study, see Section 5.3, the
estimates for the treatment eﬀect for the PWP models were similar to those for
the AG and WLW models. Neither the AG model nor the WLW model conditions
on post-randomisation events. Therefore, if there is bias in the results for the
PWP models due to conditioning on post-randomisation events the bias appears
to be minor and have minimal eﬀect on the results for the models. In both the
PWPa and PWPb models the order in which patients suﬀer events is considered
and patients are not artiﬁcially considered to be at risk of suﬀering the total
number of events being modelled for if they did not actually suﬀer that number
of events. Of the two versions of the PWP model the most appropriate model to
analyse data from a clinical trial involving CHD events would appear to be the
PWPb model. This is as a result of the fact that the time between events that
patients suﬀer is used in the modelling process as opposed to just the total time,
as is the case in the PWPa model. The PWPb model makes the best use of the
available information to model the recurrent events.
Having introduced the four recurrent events in this Chapter and discussed
the merits of using them to analyse recurrent event data from clinical trials the
models will be used in Chapter 5 to model the recurrent event data recorded
during the IONA Study. It should be noted that in Equations 4.3, 4.4 and 4.5
the full deﬁnitions of the WLW, PWPa and PWPb models are shown. When
using with the full versions of the models each of the diﬀerent event numbers has
a separate treatment eﬀect ﬁtted. This is indicated in Equations 4.3, 4.4 and 4.5CHAPTER 4. RECURRENT EVENT MODELS 71
by the fact that the vector of unknown parameters, β, has a subscript attached
to it. As there is no distinction made between event numbers in the AG model
separate treatment eﬀects for the diﬀerent event numbers cannot be ﬁtted. When
the recurrent event data from the IONA Study was analysed of interest was the
overall treatment eﬀect as opposed to the treatment eﬀect for the individual event
numbers. As a result the actual versions of the WLW, PWPa and PWPb models
ﬁtted to the data were as follows:
1. The WLW Model
λk(t,zk(t)) = λ0k(t)exp(z(t)β) (4.6)
2. The PWPa Model
λ(t|N(t),z(t)) = λ0s(t)exp(z(t)β) (4.7)
3. The PWPb model
λ(t|N(t),z(t)) = λ0s(t − tn(t))exp(z(t)β) (4.8)Chapter 5
Recurrent Event Modelling of
the IONA Study
In Section 2.4 survival analysis was carried out on the time-to-ﬁrst event for the
primary and secondary endpoints of the IONA Study as well as the GI events
patients suﬀered. Patients were at risk of suﬀering more than one of each type
of event and in this Chapter the recurrent event models introduced in Chapter 4
will be applied to the three diﬀerent types of event.
5.1 The Number of Recurrent Events Patients
Suﬀered
After patients had suﬀered a ﬁrst primary or secondary endpoint or a GI event
their period of follow-up did not end. They continued to be monitored until the
study ended or they were lost to follow-up for other reasons. Any subsequent
CHD and GI events that patients suﬀered were recorded.
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5.1.1 Numbers of Primary Endpoints
The distribution of patients by the number of primary endpoints suﬀered can be
seen in Table 5.1. The numbers of patients who suﬀered a particular number
of events and the cumulative numbers are given. From Table 5.1 it can be seen
that 337 (13.1%) patients suﬀered at least one primary endpoint in the nicorandil
Table 5.1: Distribution of the number (%) of patients by the number of re-
current primary endpoints suﬀered
Number of Patients with ≥ k Events Number of Patients with k Events
k Nicorandil Placebo Nicorandil Placebo
(n = 2,565) (n = 2,561) (n = 2,565) (n = 2,561)
0 2,228 (86.9%) 2,163 (84.5%) 2,228 (86.9%) 2,163 (84.5%)
1 337 (13.1%) 398 (15.5%) 247 (9.6%) 291 (11.4%)
2 90 (3.5%) 107 (4.2%) 67 (2.6%) 66 (2.6%)
3 23 (0.9%) 41 (1.6%) 14 (0.5%) 17 (0.7%)
4 9 (0.3%) 24 (0.9%) 6 (0.2%) 11 (0.4%)
5 3 (0.1%) 13 (0.5%) 1 (0.04%) 3 (0.1%)
6 2 (0.08%) 10 (0.4%) 1 (0.04%) 6 (0.2%)
7 1 (0.04%) 4 (0.2%) 0 (0.0%) 3 (0.1%)
8 1 (0.04%) 1 (0.04%) 0 (0.0%) 0 (0.0%)
9 1 (0.04%) 1 (0.04%) 1 (0.04%) 0 (0.0%)
10 0 (0.0%) 1 (0.04%) 0 (0.0%) 0 (0.0%)
11 0 (0.0%) 1 (0.04%) 0 (0.0%) 0 (0.0%)
12 0 (0.0%) 1 (0.04%) 0 (0.0%) 0 (0.0%)
13 0 (0.0%) 1 (0.04%) 0 (0.0%) 0 (0.0%)
14 0 (0.0%) 1 (0.04%) 0 (0.0%) 1 (0.04%)
group and of those 337 patients 247 (9.6%) suﬀered only one primary endpoint in
total and 24 (0.9%) patients in the placebo group suﬀered at least four primary
endpoints and of those 24 patients 11 (0.4%) suﬀered exactly four primary end-
points. The greatest number of primary endpoints a patient suﬀered was fourteen
and this patient was in the placebo group of the study. All fourteen of the eventsCHAPTER 5. RECURRENT EVENT MODELLING OF IONA 74
this patient suﬀered were unplanned hospital admissions for cardiac chest pain.
The maximum number of events suﬀered by a patient in the nicorandil group
was nine and of these nine events eight were unplanned hospital admissions for
cardiac chest pain and the remaining event was a non-fatal MI. The distribution
of the number of patients who suﬀered primary endpoints of the IONA Study is
also illustrated graphically in Figure 5.1.
Figure 5.1: Cumulative distribution of the number of primary endpoints pa-
tients suﬀered during the IONA Study
The overall impression is that patients in the nicorandil group suﬀered fewer
recurrent primary endpoints. This could imply that nicorandil not only reduced
the risk of ﬁrst CHD events but also the risk of recurrent CHD events. It canCHAPTER 5. RECURRENT EVENT MODELLING OF IONA 75
also be seen that a limited number of patients suﬀered more than six events,
1 (0.04%) patient in the nicorandil group and 4 (0.2%) patients in the placebo
group. Whether the diﬀerence in the risk of patients suﬀering primary endpoints
between the nicorandil and placebo groups remained signiﬁcant with the inclusion
of the recurrent events patients suﬀered, as it was for the time-to-ﬁrst event, will
be examined using the four models discussed in Chapter 4 for analysing recurrent
event data.
5.1.2 Numbers of Secondary Endpoints
The numbers of secondary endpoints are presented in an analogous fashion in
Table 5.2. The distribution of the number of patients who suﬀered secondary
endpoints of the IONA Study is also illustrated graphically in Figure 5.2. There
were fewer secondary endpoints than primary endpoints and far fewer recurrent
Table 5.2: Distribution of the number (%) of patients by the number of re-
current secondary endpoints suﬀered
Number of Patients with ≥ k Events Number of Patients with k Events
k Nicorandil Placebo Nicorandil Placebo
(n = 2,565) (n = 2,561) (n = 2,565) (n = 2,561)
0 2,458 (95.8%) 2,427 (94.8%) 2,458 (95.8%) 2,427 (94.8%)
1 107 (4.2%) 134 (5.2%) 95 (3.7%) 117 (4.6%)
2 12 (0.5%) 17 (0.7%) 12 (0.5%) 15 (0.6%)
3 0 (0.0%) 2 (0.08%) 0 (0.0%) 2 (0.08%)
events. This is mainly due to the large number of primary endpoints that were
due to unplanned hospital admissions for cardiac chest pain. In the secondary
endpoint only the harder clinical outcomes of CHD death and non-fatal MI were
considered. The largest number of secondary endpoints that a patient suﬀeredCHAPTER 5. RECURRENT EVENT MODELLING OF IONA 76
Figure 5.2: Cumulative distribution of the number of secondary endpoints
patients suﬀered during the IONA Study
was three and 2 (0.08%) patients in the placebo group suﬀered three events. The
greatest number of secondary endpoints a patient in the nicorandil group suﬀered
was two and 12 (0.5%) patients suﬀered two events. Patients in the placebo group
suﬀered more recurrent secondary endpoints that those patients in the nicorandil
group but the diﬀerence between the two treatment groups appears less marked
in comparison to the diﬀerence for the primary endpoint.
5.1.3 Numbers of Gastrointestinal Events
The number of GI events that patients suﬀered can be seen in Table 5.3. The
distribution of the number of patients who suﬀered secondary endpoints of the
IONA Study is also illustrated graphically in Figure 5.3. It can be seen that in
the nicorandil group 2 (0.08%) patients suﬀered four GI events and in the placeboCHAPTER 5. RECURRENT EVENT MODELLING OF IONA 77
Table 5.3: Distribution of the number (%) of patients by the number of re-
current GI events suﬀered
Number of Patients with ≥ k Events Number of Patients with x Events
k Nicorandil Placebo Nicorandil Placebo
(n = 2,565) (n = 2,561) (n = 2,565) (n = 2,561)
0 2,408 (93.9%) 2,453 (95.8%) 2,408 (93.9%) 2,453 (95.8%)
1 157 (6.1%) 108 (4.2%) 135 (5.3%) 91 (3.6%)
2 22 (0.9%) 17(0.7%) 17 (0.7%) 13 (0.5%)
3 5 (0.2%) 4 (0.2%) 4 (0.2%) 4 (0.2%)
4 2 (0.08%) 0 (0.0%) 2 (0.08%) 0 (0.0%)
group the largest number of GI events was three and 4 (0.2%) patients suﬀered
three GI events. Even though in total the number of GI events that patients
suﬀered in the nicorandil group was larger than the number in the placebo group
the diﬀerence after the ﬁrst GI events was not substantial. In the placebo group
15.7% of patients compared to 14.0% in the nicorandil group went on to suﬀer a
subsequent GI event among those suﬀering a ﬁrst GI event.
5.2 Changing Risk of Successive Events
Before ﬁtting the recurrent event models the distributions of times to recurrent
events for the three types of event were explored. In order to do this Kaplan-Meier
(Kaplan and Meier, 1958) estimates were constructed to estimate the time-to-
event distributions for each event conditional on the previous event and measuring
time from the calendar time of the previous event. This is equivalent to how the
PWPb model models recurrent event data. The numbers of successive events
studied has been limited based on the number of patients suﬀering that number
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Figure 5.3: Cumulative distribution of the number of GI events patients suf-
fered during the IONA Study
5.2.1 Risk of Successive Primary Endpoints
For the primary endpoint only the ﬁrst four events were considered due to the
limited number of patients who suﬀered more than four primary endpoints. The
Kaplan-Meier estimates for the ﬁrst four events for the nicorandil and placebo
groups can be seen in Figure 5.4. Once a patient had suﬀered a ﬁrst primary
endpoint their risk of suﬀering a second primary endpoint was increased and the
same was true for the risk of suﬀering a third and then a fourth event. The
primary endpoints were clearly not independent and this will have implications
for ﬁtting the AG model. There were two stages to the increased risk. Firstly,
there was an acute increase immediately after patients had suﬀered an event.
Secondly, after this initial acute phase was over the increase in risk ﬂattenedCHAPTER 5. RECURRENT EVENT MODELLING OF IONA 79
(a) The nicorandil group
(b) The placebo group
Figure 5.4: Risk of successive primary endpoints for patients in the nicorandil
and placebo groups of the IONA StudyCHAPTER 5. RECURRENT EVENT MODELLING OF IONA 80
out to a level that was greater that the risk of suﬀering the previous event. The
increasing risk between successive primary endpoints appears to be greater in the
placebo group, Figure 5.4b, than in the nicorandil group, Figure 5.4a. Indicating
that nicorandil may not only reduce the risk of patients suﬀering a ﬁrst primary
endpoint but also reduce the risk of patients suﬀering subsequent CHD events.
5.2.2 Risk of Successive Secondary Endpoints
As no patients suﬀered three secondary endpoints in the nicorandil group and
only 2 (0.08%) did in the placebo group, see Table 5.2, only the ﬁrst two sec-
ondary endpoints were considered. The Kaplan-Meier estimates for the ﬁrst two
secondary endpoints that patients suﬀered in both the nicorandil and placebo
groups can be seen in Figure 5.5. As was the case for the primary endpoint in
both the nicorandil and placebo groups the risk of suﬀering a second secondary
endpoint was increased compared to the risk of suﬀering a ﬁrst secondary end-
point. The increase in risk was greatest immediately after a patient’s ﬁrst event
then lessened. As only a small number of patients suﬀered recurrent events there
may well be insuﬃcient patient data available to draw any reliable conclusions
from the Kaplan-Meier curves.
5.2.3 Risk of Successive Gastrointestinal Events
The risk of suﬀering the ﬁrst three GI events was studied. The Kaplan-Meier
estimates for the ﬁrst three GI events that patients suﬀered in both the nicorandil
and placebo groups can be seen in Figure 5.6. As with the primary and secondary
endpoints the risk of suﬀering a second and then a third event was increasedCHAPTER 5. RECURRENT EVENT MODELLING OF IONA 81
(a) The nicorandil group
(b) The placebo group
Figure 5.5: Risk of successive secondary endpoints for patients in the nico-
randil and placebo groups of the IONA StudyCHAPTER 5. RECURRENT EVENT MODELLING OF IONA 82
(a) The nicorandil group
(b) The placebo group
Figure 5.6: Risk of successive GI events for patients in the nicorandil and
placebo groups of the IONA StudyCHAPTER 5. RECURRENT EVENT MODELLING OF IONA 83
signiﬁcantly after each previous event. The diﬀerence between the Kaplan-Meier
estimates for the ﬁrst and second GI events in both the nicorandil and placebo
groups was substantial. Any diﬀerence between the curves for the second and
third GI events was less evident.
5.3 Recurrent Event Analysis
The four recurrent event models that were introduced in Chapter 4 were applied
to the data from the IONA Study for the recurrent primary and secondary end-
points that patients suﬀered as well as the recurrent GI events. (Ford et al.,
2007) The robust sandwich estimator for the covariance matrix devised by Lin
and Wei (1989) and previously introduced in Section 4.2 will be used in all of
the recurrent event analyses. Additionally, as was stated in Section 4.2, a cut-oﬀ
point is needed for the number of recurrent events to be included in the mod-
elling process. The cut-oﬀ point was judged individually for each diﬀerent type of
event, based on the number of recurrent events that patients suﬀered. In the ini-
tial recurrent event analyses the only explanatory variable included in the models
was the randomised treatment patients were receiving.
5.3.1 Primary Endpoints
It can be seen from Table 5.1 that only 5 patients, 1 (0.04%) in the nicorandil
group and 4 (0.2%) patients in the placebo group, suﬀered more that six primary
endpoints and due to the small number of patients and events that they went on
to suﬀer the recurrent event analysis was carried out on only the ﬁrst six events,
resulting in 14 (1.3%) of the 1,071 primary endpoints that patients suﬀered beingCHAPTER 5. RECURRENT EVENT MODELLING OF IONA 84
omitted from the analysis. Even using only the ﬁrst six primary endpoints there
were 322 more primary endpoints used in the modelling process and nicorandil
prevented an additional 68 events that were not considered in the time-to-ﬁrst
event analysis. The results for the four recurrent event models as well as the
original time-to-ﬁrst event Cox Model are shown in Table 5.4.
Table 5.4: The time-to-ﬁrst event Cox model and recurrent event analyses
based on the ﬁrst six primary endpoints patients suﬀered during
the IONA Study. The table contains estimated hazard ratios, 95%
CIs and p-values
Model Hazard 95% Conﬁdence P-Value
Ratio Interval
Cox 0.83 0.72 – 0.97 0.014
AG 0.78 0.66 – 0.91 0.0024
WLW 0.77 0.65 – 0.91 0.0028
PWPa 0.82 0.73 – 0.93 0.0015
PWPb 0.82 0.73 – 0.92 0.0012
It can be seen that, based on the ﬁndings of the recurrent event models,
treatment with nicorandil was not only eﬀective at reducing the risk of patients
suﬀering ﬁrst primary endpoints but also recurrent primary endpoints. Analysis
was carried out using the recurrent event models on the total number of primary
endpoints that patients suﬀered and the ﬁndings were similar to those seen in
Table 5.4. The HRs and 95% CIs were broadly similar for the four diﬀerent
recurrent event models, the AG and WLW models gave almost identical results,
as did the PWPa and PWPb models. Compared to the time-to-ﬁrst event analysis
the HRs and 95% CIs for the AG and WLW models were shifted downward away
from the null value of 1. The point estimates for the reduction in risk of suﬀering
recurrent primary endpoints were 22% (95% CI: 9%, 34%) and 23% (95% CI: 9%,CHAPTER 5. RECURRENT EVENT MODELLING OF IONA 85
35%), respectively for the AG and WLW models compared to 17% (95% CI: 3%,
28%) for the time-to-ﬁrst event analysis. The noticeable diﬀerence between the
four recurrent event models and the time-to-ﬁrst event analysis for the primary
endpoint was in the p-values. The p-values for the four recurrent event models
were considerably sharper than for the time-to-ﬁrst event analysis, the p-values
were 0.0024, 0.0028, 0.0015 and 0.0012 for the recurrent event models compared
to 0.014 for the original Cox Model.
5.3.2 Secondary Endpoints
As there were only 2 (0.08%) patients in the placebo group and no patients in
the nicorandil group who suﬀered three secondary endpoints the recurrent event
analysis was carried out on only the ﬁrst two secondary endpoints that patients
suﬀered. With the inclusion of the second secondary endpoints there were an
additional 29 events included in the modelling process and nicorandil prevented
an additional 5 events compared to the time-to-ﬁrst event analysis. The recurrent
event models were used to see whether the inclusion of these additional events
made the reduction in risk of suﬀering secondary endpoints that treatment with
nicorandil caused in patients nominally statistically signiﬁcant. The results for
the recurrent event models as well as the Cox Model for the time-to-ﬁrst analysis
can be seen in Table 5.5.
The results for the recurrent events models were almost identical to the result
for the time-to-ﬁrst event analysis in terms of HRs and 95% CIs. The only real
diﬀerence was in terms of the p-values and that was for the PWPa and PWPb
models where the p-values were numerically larger and therefore further awayCHAPTER 5. RECURRENT EVENT MODELLING OF IONA 86
Table 5.5: The time-to-ﬁrst event Cox model and recurrent event analyses
based on the ﬁrst two secondary endpoints patients suﬀered during
the IONA Study. The table contains estimated hazard ratios, 95%
CIs and p-values
Model Hazard 95% Conﬁdence P-Value
Ratio Interval
Cox 0.79 0.61 – 1.02 0.068
AG 0.78 0.60 – 1.02 0.066
WLW 0.78 0.60 – 1.02 0.065
PWPa 0.80 0.63 – 1.03 0.079
PWPb 0.80 0.63 – 1.02 0.072
from the statistically signiﬁcant threshold of 0.05. The point estimates for the
reduction in risk of suﬀering recurrent secondary endpoints were between 20%
and 22% for the recurrent event models. If the four models were ﬁtted again
but this time with the inclusion of the third secondary endpoints that patients
suﬀered, the results were similar to the ﬁndings shown in Table 5.5. The results
for the secondary endpoint remain non-signiﬁcant even with the inclusion of the
recurrent events patient suﬀered and this may be due to the small number of
recurrent events that patients did suﬀer, so the potential beneﬁts of using the
recurrent events models to analyse the data were lost.
5.3.3 Gastrointestinal Events
With only 2 (0.08%) patients in the nicorandil group and no patients in the
placebo group suﬀering four GI events the recurrent event analysis was based on
the ﬁrst three GI events that patients suﬀered. More patients in the nicorandil
group suﬀered a ﬁrst GI event and this was reﬂected in the time-to-ﬁrst eventCHAPTER 5. RECURRENT EVENT MODELLING OF IONA 87
analysis, shown in Section 2.4.3, showing a signiﬁcant increase in the risk of pa-
tients suﬀering a GI event in the nicorandil group compared to the placebo group.
After the ﬁrst GI event patients suﬀered the numbers of patients who suﬀered
further GI events in the nicorandil and placebo groups were similar but the per-
centages were higher in the placebo group. This may imply that the increase in
risk of patients suﬀering a GI event that treatment with nicorandil caused was
restricted to ﬁrst events only or that due to the small number of recurrent GI
events the continued increase in risk caused by treatment with nicorandil was
masked. The four recurrent event models were ﬁtted to the GI event data and
the results are shown in Table 5.6, along with the results for original time-to-ﬁrst
event Cox Model.
Table 5.6: The time-to-ﬁrst event Cox model and recurrent event analyses
based on the ﬁrst three GI events patients suﬀered during the
IONA Study. The table contains estimated hazard ratios, 95%
CIs and p-values
Model Hazard 95% Conﬁdence P-Value
Ratio Interval
Cox 1.46 1.14 – 1.86 0.0027
AG 1.41 1.09 – 1.83 0.0082
WLW 1.43 1.10 – 1.86 0.0082
PWPa 1.34 1.07 – 1.69 0.012
PWPb 1.36 1.08 – 1.71 0.0087
It can be seen that the results of the four recurrent event models all indicate
that nicorandil did increase the risk of patients suﬀering recurrent GI events. The
results for the AG and WLW models were broadly similar to the results for the
time-to-ﬁrst event analysis with only minimal changes in the point estimates for
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for the HRs were shifted downward towards the null value of 1 as were the 95%
CIs compared to the time-to-ﬁrst event analysis. The p-values for the recurrent
event models were less sharp compared to the time-to-ﬁrst event analysis. The
p-values for the AG, WLW and PWPb models ranged from 0.0082 to 0.0087,
with the p-value for the PWPa model numerically larger still at 0.012 compared
to 0.0027 for the time-to-ﬁrst event analysis. The recurrent event models were
run again to include the fourth GI events that patients suﬀered and only the ﬁrst
two GI events and results all indicated that treatment with nicorandil caused an
increase in the risk of patients suﬀering GI events.
5.4 Interpreting the Performance of the Recur-
rent Event Models
In Section 5.3 the four recurrent event models were ﬁtted to data for the primary
and secondary endpoints of the study as well as the GI events patients suﬀered.
For each of the three types of recurrent event analysed all of the recurrent event
models gave broadly similar results but each method has diﬀerent underlying
assumptions and treats the time interval when patients were at risk of suﬀering
events diﬀerently. It is important that any method used to analyse the data
reﬂects what actually happened. Due to the limited recurrent event data available
for both the secondary endpoint and the GI events the model interpretation will
be based on the primary endpoint analysis
Firstly, looking at the AG model it assumes that the recurrent events for each
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suﬀering an event does not change as patients suﬀer further events. Once patients
have suﬀered a non-fatal MI or an unplanned hospital admission for cardiac chest
pain they are likely to be at an elevated risk of suﬀering a further CHD event.
The elevated risk in both treatment groups is conﬁrmed by looking at Figure 5.4.
The increase in risk would also depend on the severity of the CHD they suﬀered.
This implies that the recurrent primary endpoints patients suﬀered could not be
classed as being independent. The assumptions that there is a constant risk of
events and that the events are independent, which are fundamental to the AG
model, were violated so the use of this model in this situation is not valid.
Secondly, with regard to the WLW model there is an issue with using this
model which is due to the underlying theory behind the model, which is that
every patient is at risk of suﬀering the total number of events being considered in
the analysis and therefore must have a time interval for each event. As a result
when the WLW model is being used each patient is artiﬁcially considered to be at
risk of recurrent events whether or not they have had a preceding event. As the
time intervals used in the WLW model always start at the point when patients
are ﬁrst under observation the time between events that patients suﬀer is not
considered in the model. Only the time between the start of the observation
period and the actual events is used in the modelling process. Therefore, the use
of the WLW model is not appropriate.
Thirdly, looking at both the PWPa and PWPb models the theory behind
the models does not assume that all the events are independent, the order in
which events occur is considered and patients are not artiﬁcially considered to
be at risk of recurrent events whether or not they have had a preceding event.
However, there are potential drawbacks to using either of the PWP models. OneCHAPTER 5. RECURRENT EVENT MODELLING OF IONA 90
of the drawbacks to using either of the PWP models is the potential for bias
in the results of the models with increasing rates of recurrent events. Although
the recurrent event rate during the IONA Study was not suﬃciently high to
signiﬁcantly bias the results of the PWP models. It would therefore appear that
the use of one of the PWP models would be most appropriate in this situation.
The choice of which of the PWP models to use was based on the diﬀerences
between how the time intervals for the recurrent events are set up for the two
diﬀerent versions of the model. In the PWPa model the total time patients have
been under observation is considered as the time scale is continuous from the start
of the period of observation whereas in the PWPb model the gap times between
successive events is of interest as the time scale is reset to zero after every event
patients suﬀer. This results in a diﬀerence in the risk for the diﬀerent events or
strata for the PWP models. For the ﬁrst event both PWP models are the same as
well as being identical to the Cox model for a time-to-ﬁrst event analysis but for
subsequent events this is not true. In the PWPa model the subsequent risk is for
patients who have suﬀered k events, where k ≥ 2, and have been observed for the
same length of time since the start of the study. Whereas, for the PWPb model
the risk is for patients who have suﬀered k events, where k ≥ 2, and have been
at risk of suﬀering the k + 1th event for the same period of time with the total
length of time patients have been in the study for not considered. (Prentice et al.,
1981) The increased risk patients were at after suﬀering recurrent events is better
reﬂected in the PWPb model. The use of the PWPb model is recommended in
the case of the IONA Study as this model most faithfully reﬂects the observed
patterns in the data.
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to use. For example if the events could be considered to be independent and the
underlying risk of suﬀering events did not alter as patients suﬀered events then
the AG model may well be the most eﬃcient model to use. The AG model also has
the advantage that it is the simplest of the models to implement. (Hosmer and
Lemeshow, 1999) For each diﬀerent set of circumstances the choice of which model
to use should be carefully considered and based on all the available information.
5.5 Multivariable Models for the Recurrent Event
Data
In Sections 3.4 and 3.6 multivariable predictive models for the ﬁrst primary end-
point and GI events that patients suﬀered were produced. Having ﬁtted recurrent
event models to the primary endpoints and GI events, with the only explanatory
variable included in the models being the randomised treatment patients were re-
ceiving, the multivariable predictive models produced for the time-to-ﬁrst event
analysis were ﬁtted to the recurrent event data. As was discussed in Section 5.4
the PWPb model appears to model the data most accurately so the multivariable
model results will only be shown for the PWPb model.
5.5.1 Primary Endpoints
The results for the multivariable recurrent event model for the ﬁrst six primary
endpoints that patients were at risk of suﬀering using the PWPb model can
be seen in Table 5.9. The model for the primary endpoint used was the one
produced by the ﬁrst method of model building. All of the nine variables selectedCHAPTER 5. RECURRENT EVENT MODELLING OF IONA 92
in the time-to-ﬁrst event model as being statistically signiﬁcant remained so in
the multivariable recurrent event model. In both models the comparison between
CCSF levels I and II were non-signiﬁcant but were still included in the models
to aid their use and interpretation.
Table 5.7: The multivariable recurrent event model for the primary endpoint
ﬁtted using the PWPb model based on the ﬁrst six primary end-
points patients suﬀered during the IONA Study. For this model
n = 5,059. The table contains estimated hazard ratios, 95% CIs
and p-values
Variable Hazard 95% Conﬁdence P-Value
Ratio Interval
Nicorandil 0.81 0.72 – 0.92 0.0010
BMI (increase of 2 kg/m2) 0.97 0.94 – 1.00 0.048
Current Smoker 1.22 1.05 – 1.43 0.0097
Previous MI 1.40 1.21 – 1.63 <0.0001
Previous Stroke or TIA 1.30 1.07 – 1.57 0.0082
History of LVH 1.37 1.15 – 1.64 0.0005
CCSF level II vs. level I 1.14 0.96 – 1.36 0.15
CCSF level III/IV vs. level I 1.57 1.28 – 1.93 <0.0001
Long Acting Nitrates 1.30 1.12 – 1.50 0.0004
Loop Diuretics 1.39 1.22 – 1.59 <0.0001
The HRs were not greatly changed in the recurrent event model from those
seen in the time-to-ﬁrst event model apart from the HR for the comparison be-
tween CCSF levels I and III/IV where the increased risk for patients classiﬁed as
level III/IV compared to level I dropped from 100% to 57%. The 95% CIs were
narrower when the recurrent events were included and this may be as a result
of more information being utilised in the modelling process. Looking at the p-
values there were more apparent diﬀerences when the models were compared. As
was seen with the original recurrent event analysis for the multivariable recurrent
event model the p-value for treatment with nicorandil was signiﬁcantly sharperCHAPTER 5. RECURRENT EVENT MODELLING OF IONA 93
than it was for the time-to-ﬁrst event analysis, it was 0.0010 compared to 0.010.
For the recurrent event model the p-value for the BMI of patients was close to be-
ing non-signiﬁcant at 0.048 as opposed to 0.0065 for the time-to-ﬁrst event model.
Although, the point estimates for the HRs were virtually the same for the two
models. If either of the AG or WLW models were ﬁtted BMI no longer remained
a signiﬁcant predictor. In the time-to-ﬁrst event multivariable model the p-value
for the comparison between CCSF levels I and II was bordering on the signiﬁcant
threshold at 0.060. In the recurrent event model the p-value was larger at 0.15.
The p-values for the remaining variables included in the model were not greatly
altered between the time-to-ﬁrst event and recurrent event models.
5.5.2 Gastrointestinal Events
Four multivariable time-to-ﬁrst event models were produced for the GI events
patients suﬀered and recurrent event versions were produced of all models but
only Model B1 will be shown. However, when recurrent event versions of Models
B1 and B2 were produced in all cases apart from when the PWPa model was
used with Model B2 the variable treatment with diltiazem no longer remained
signiﬁcant, although the trend was still to an increased risk of GI events. As a
consequence the results for the multivariable recurrent event model, Model B1,
using the PWPb model can be seen in the left half of Table 5.8 and in the right half
is shown Model B1 with the variable treatment with diltiazem removed. With the
variable treatment with diltiazem removed Model B1 becomes Model A1. The
interpretation of the model will therefore be based on the results for Model A1.
With the inclusion of the ﬁrst three GI events patients were at risk of suﬀeringCHAPTER 5. RECURRENT EVENT MODELLING OF IONA 94
all the variables which were selected in the time-to-ﬁrst event model remained
signiﬁcant apart from the comparison between CCSF levels I and II, which in
the recurrent event version of Model A1 was non-signiﬁcant. The comparison
between CCSF levels I and II was still included in the model, as it had previously
been for the primary endpoint models.
Comparing the time-to-ﬁrst event and recurrent event models there were min-
imal changes in the HRs and p-values. For the comparison between CCSF levels
I and III/IV the increased risk dropped from 76% to 56% and the p-value in-
creased from 0.010 to 0.023. Additionally the p-value for treatment with loop
diuretics was sharper. The increased risk of GI events associated with treatment
with nicorandil dropped by 9% to 35% with the inclusion of the recurrent events
in the analysis. The p-value for treatment with nicorandil was numerically larger
and therefore closer to being non-signiﬁcant. These points further indicate that
while treatment with nicorandil increased the risk of patients suﬀering a ﬁrst GI
event, the eﬀect of treatment with nicorandil on the risk of suﬀering subsequent
GI events was reduced. The signiﬁcant diﬀerence in the risk of suﬀering ﬁrst GI
events, associated with treatment with nicorandil, may be behind the increased
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5.6 Fitting a Shared Frailty Model to the Re-
current Event Data
Having produced multivariable predictive models for the ﬁrst primary endpoint
and GI events in Chapter 3 it was seen that other variables apart from treatment
with nicorandil had a signiﬁcant eﬀect on the risk of patients suﬀering both types
of event. This was also the case when these models were ﬁtted to the recurrent
event data in Section 5.5. With the inclusion of additional variables the models
should explain much of the distribution for the risk of suﬀering events, especially
for the time-to-ﬁrst event analysis. However, the heterogeneity of patients is
unlikely to be fully explained as other factors, some that were recorded and
others that were not, would likely inﬂuence the risk of patients suﬀering events.
In ﬁtting the same multivariable predictive models to the recurrent event
data as for the time-to-ﬁrst event the level of heterogeneity that was explained
was likely decreased. This will be for a variety of reasons. Firstly, the models
were not speciﬁcally developed for the recurrent event data so more appropriate
models may exist. Secondly, as the recurrent events were being modelled it is
likely other developing risk factors will play a larger roll in determining the risk of
patients. Factors which inﬂuence second and subsequent events, such as the type
of previous event patients suﬀered, are not included in the modelling process.
In order to try and account for the unknown heterogeneity for the multivari-
able recurrent event model a shared frailty model was ﬁtted. This involved adding
a frailty parameter to the model in addition to the other prognostics variables
already included. A Gamma frailty parameter was added to the multivariableCHAPTER 5. RECURRENT EVENT MODELLING OF IONA 97
recurrent event model for the primary endpoint. A shared frailty model was ﬁt-
ted to the GI recurrent event data but the frailty parameter was found not to be
signiﬁcant so will not be shown here. As in Section 5.5 the results for the only
the PWPb model will be shown. The results of ﬁtting the model including the
frailty parameter can be seen in Table 5.9.
Table 5.9: The multivariable recurrent event model for the primary endpoint
ﬁtted with a Gamma frailty parameter using the PWPb model
based on the ﬁrst six primary endpoints patients suﬀered during
the IONA Study. For this model n = 5,059. The table contains
estimated hazard ratios, 95% CIs and p-values
Variable Hazard 95% Conﬁdence P-Value
Ratio Interval
Nicorandil 0.77 0.65 – 0.90 0.0011
BMI (increase of 2 kg/m2) 0.96 0.93 – 0.99 0.018
Current Smoker 1.34 1.09 – 1.65 0.0048
Previous MI 1.56 1.31 – 1.87 <0.0001
Previous Stroke or TIA 1.37 1.02 – 1.84 0.036
History of LVH 1.55 1.22 – 1.98 0.0004
CCSF level II vs. level I 1.19 0.98 – 1.45 0.084
CCSF level III/IV vs. level I 1.97 1.51 – 2.58 <0.0001
Long Acting Nitrates 1.43 1.21 – 1.69 <0.0001
Loop Diuretics 1.57 1.30 – 1.90 <0.0001
Frailty SD = 1.65 <0.0001
It can be seen that the frailty parameter did add signiﬁcantly to the model as
the p-value for it was <0.0001. The general eﬀect of adding the frailty parameter
was to increase the eﬀect of the variables included in the model on the risk of
patients suﬀering CHD events. The CIs were also wider. With the inclusion of
the frailty parameter the decrease in the risk of patients who were treated with
nicorandil increased from 19% to 23%. The p-values were not greatly altered with
the exception of the variable whether patients had suﬀered a previous stroke orCHAPTER 5. RECURRENT EVENT MODELLING OF IONA 98
TIA. The variable remained a signiﬁcant predictor but the p-value was increased
and was therefore much nearer the signiﬁcance threshold of 0.05. The addition
of the frailty parameter did add signiﬁcantly to the model and altered the point
estimates of the HRs and accompanying CIs but it did not change the overall
ﬁndings. It is noted that the use of a single frailty term suﬀers from some of the
weakness associated with the use of adjustment for baseline covariates in that it
cannot deal with evolving frailty as a patient experiences recurrent events.Chapter 6
Simulation of Recurrent Event
Data
In Chapter 4 the various recurrent event models were introduced and it was seen
that they have diﬀerent underlying assumptions, hence their use may not be
appropriate for every situation. In this Chapter the performance of the models
will be assessed through the simulation of recurrent event data.
6.1 The Simulation Process
The recurrent event models were introduced in Chapter 4 and then applied to the
recurrent event data from the IONA Study in Chapter 5. It was seen that the
models have diﬀerent underlying assumptions and that they gave slightly diﬀerent
results when applied to the IONA Study data. The diﬀerences were small in the
case of the IONA Study. In order to assess the performance of the models under
diﬀerent known conditions, simulations were carried out. The data simulated
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were the gap times between events for patients. The gap times were generated
from Weibull distributions. The parameters used to generate the gap times were
chosen in relation to what had been observed for the primary endpoint of the
IONA Study. In addition it is known that patients have diﬀerent underlying
risks of suﬀering events, such as CHD events. This is due to the heterogeneity
of patients. To reﬂect this heterogeneity a random subject eﬀect was included in
some of the simulations.
In each simulation there were two treatment groups indexed by i, with the
placebo group = 1 and the treatment group = 2. Each simulation contained 2n
patients, indexed by j, j = 1,...,n. The recurrent events patients were at risk
of suﬀering from were indexed by k, k = 1,...,K, 1 for the ﬁrst event, 2 for the
second etc. There were two models for the gap times. The ﬁrst did not include
a random subject eﬀect, see Equation 6.1, and the second did, see Equation 6.2.
log(yijk) = α + Tik + log(j);i = 1,2,j = 1,...,n,k = 1,...,K (6.1)
log(yijk) = α + Tik + log(j) + log(ηj);i = 1,2,j = 1,...,n,k = 1,...,K (6.2)
where yijk is the gap time for patient j for event k in treatment group i, α is
the intercept, Tik is the treatment eﬀect for group i for event k, j is the random
error term for patient j, which is an Exponential random variable, and ηj is the
random subject eﬀect for patient j, which is a positive stable random variable.
In the simulations patients were at risk of suﬀering four events, K = 4, or being
followed for a maximum time interval of two years, whichever occurred ﬁrst. At
the two year point patients who were still at risk of suﬀering further events had
their current time interval censored.CHAPTER 6. SIMULATION OF RECURRENT EVENT DATA 101
Three groups of simulations were performed:
1. The No Treatment Eﬀect Group of Simulations
In order that the calibration of the simulation process could be assessed a
group of null simulations were performed. In this group of simulations the
treatment eﬀect was set to zero and T1k = T2k for k = 1,2,3,4.
2. The Treatment Eﬀect Group of Simulations
Simulations were performed where the treatment was eﬀective compared to
the placebo for all four events and T1k < T2k for k = 1,2,3,4.
3. The Treatment Eﬀect for First Event Group of Simulations
Simulations were performed were the treatment was eﬀective compared to
the placebo for only the ﬁrst event after which the treatment eﬀect was set
to zero. In this group of simulations T1k < T2k for k = 1 and T1k = T2k for
k = 2,3,4.
When the treatment was eﬀective it reduced the risk of patients suﬀering events
compared to the placebo.
The risk of suﬀering a primary endpoint of the IONA Study increased with
each successive event patients suﬀered, see Figure 5.4. This increase in risk was
also seen for the secondary endpoint as well as the GI events. Therefore, as well
as keeping the risk of events constant over time the risk of patients suﬀering a
second, third and fourth event were increased. This was done using the increased
risk of suﬀering a primary endpoint. The hazard for a second event was increased
by a factor of four compared to that for a ﬁrst event. For the third events the
hazard was increased by a further factor of one and a half and ﬁnally for theCHAPTER 6. SIMULATION OF RECURRENT EVENT DATA 102
fourth events by another factor of one and a half. There were then four diﬀerent
sets of conditions for each group of simulations:
1. The First Set of Simulation Conditions
The risk of patients suﬀering events did not increase as patients suﬀered
events and a random subject eﬀect was not applied.
2. The Second Set of Simulation Conditions
The risk of patients suﬀering events did increase as patients suﬀered events
and a random subject eﬀect was not applied.
3. The Third Set of Simulation Conditions
The risk of patients suﬀering events did not increase as patients suﬀered
events and a random subject eﬀect was applied.
4. The Fourth Set of Simulation Conditions
The risk of patients suﬀering events did increase as patients suﬀered events
and a random subject eﬀect was applied.
6.2 Generating the Recurrent Event Data
There were 10,000 replicates of each simulation performed. The individual repli-
cates contained 1,000 patients in both the placebo and treatment groups, n =
1,000. The random patient eﬀect, η, was generated from the family of positive
stable random variables so that the assumption of proportional hazards was main-
tained for both the model conditioning on this term and for the unconditional
model. (Hougaard, 1986; Crowder, 1989) The patient eﬀect was generated asCHAPTER 6. SIMULATION OF RECURRENT EVENT DATA 103
a positive stable random variable with index 1
2. This stable random variable is
equivalent to an inverse Gaussian which in turn is equivalent to the inverse of
a χ2 random variable with one degree of freedom (Ford et al., 1995), which was
used to generate the subject eﬀect. The eﬀect of increasing the risk of patients
suﬀering events and adding a random subject eﬀect was to increase the event
rate. Shown in Table 6.1 are the distributions used to generate the gap times
between events for the four sets of simulation conditions.
Table 6.1: Distributions used to generate the gap times between events for
patient j for the four sets of simulation conditions
Group Distribution for Gap Times
Event One Event Two Event Three Event Four
The First Set of Simulation Conditions
Placebo We(λ1,γp) We(λ2,γp) We(λ3,γp) We(λ4,γp)
Treatment We(λ1,γp) We(λ2,γp) We(λ3,γp) We(λ4,γp)
The Second Set of Simulation Conditions
Placebo a1We(λ1,γp) a2We(λ2,γp) a3We(λ3,γp) a4We(λ4,γp)
Treatment a1We(λ1,γp) a2We(λ2,γp) a3We(λ3,γp) a4We(λ4,γp)
The Third Set of Simulation Conditions
Placebo ηWe(λ1,γp) ηWe(λ2,γp) ηWe(λ3,γp) ηWe(λ4,γp)
Treatment ηWe(λ1,γp) ηWe(λ2,γp) ηWe(λ3,γp) ηWe(λ4,γp)
The Fourth Set of Simulation Conditions
Placebo ηa1We(λ1,γp) ηa2We(λ2,γp) ηa3We(λ3,γp) ηa4We(λ4,γp)
Treatment ηa1We(λ1,γp) ηa2We(λ2,γp) ηa3We(λ3,γp) ηa4We(λ4,γp)
The scale parameters of the Weibull distributions, λ, are indexed by m, m
= 1,2,3,4, as the values of λm were dependent on which group of simulations
were being performed. Show in Table 6.2 are the diﬀerent values of λm used
in the simulations. The shape parameters of the Weibull distributions, γ, are
indexed by p, p = 1,2, as two diﬀerent shape parameters were used. Firstly,
γ1 = 1 and secondly γ2 = 0.75. The second value of γ was used to reﬂect theCHAPTER 6. SIMULATION OF RECURRENT EVENT DATA 104
Table 6.2: Scale parameters used in the diﬀerent groups of simulations
Simulation Parameter
Group λ1 λ2 λ3 λ4
The No Treatment Eﬀect Group
Placebo 0.1116 0.1116 0.1116 0.1116
Treatment 0.1116 0.1116 0.1116 0.1116
The Treatment Eﬀect Group
Placebo 0.1116 0.1116 0.1116 0.1116
Treatment 0.0558 0.0558 0.0558 0.0558
The Treatment Eﬀect for First Event Group
Placebo 0.1116 0.1116 0.1116 0.1116
Treatment 0.0558 0.1116 0.1116 0.1116
change in risk seen for patients after they had suﬀered a primary endpoint. There
was an immediate acute increase in risk after which the increase ﬂattened out
to a level above that for the previous event. In order to achieve this eﬀect the
shape parameter of the Weibull distribution has to be 0 < γ < 1. (Metalfe and
Thompson, 2006) However, patients who enrolled in the IONA Study had not
just suﬀered a CHD event so they would not have been at an initial heightened
risk of suﬀering a further event. Therefore, to reﬂect the patient population of
the IONA Study for the ﬁrst events γp = γ1 in all cases. The hazard increasing
factors, a, indexed by q, q = 1,2,3,4, discussed in Section 6.1 were only applied
in the second and fourth sets of simulations conditions. The hazard of a ﬁrst
event was not increased so a1 = 1. As a result the event times for the ﬁrst and
second sets of simulation conditions were the same. This was also true for the
third and fourth sets of simulation conditions. The random subject eﬀect η was
only applied in the third and fourth sets of simulation conditions.
The gap times between events were of a proportional hazards form. This wasCHAPTER 6. SIMULATION OF RECURRENT EVENT DATA 105
true for the individual events independently from the other events and of censor-
ing. The inclusion of the random subject eﬀect, η, should halve the parameter
estimate. (Ford et al., 1995) As a result the expected parameters estimates and
the resulting HRs for the individual events were known in advance of the sim-
ulations. Therefore, the results for the recurrent event analyses, under perfect
conditions, could be inferred for the ﬁrst and second groups of simulations. For
the ﬁrst group of simulations the parameter estimate should equal 0 and the
HR should equal 1. For the second group of simulation the parameter estimate
should equal -0.6931 and the HR should equal 0.5 for the ﬁrst and second sets of
simulation conditions. For the third and fourth sets of simulation conditions the
parameter estimates should equal -0.3466 and the HR should equal 0.7071. As
the treatment eﬀect for the ﬁrst event group of simulations contained a mixture
of events where the treatment was both eﬀective compared to the placebo and
the same as the placebo the expected results for this group of simulations were
unknown. The simulation program was written and performed in SAS version
9.1.3 (SAS, Cary, North Carolina). The SAS code used to generate the gap time
data for the three groups of simulations is shown in Appendix B. Additionally,
shown in Appendix B is an example of the SAS code used to incorporate censor-
ing into the gap time data and then analyse it using the diﬀerent recurrent event
models.
6.3 The Simulation Results
The results shown are the mean and standard error (SE) for the parameter es-
timates and HRs for the 10,000 replicates of each simulation. In addition theCHAPTER 6. SIMULATION OF RECURRENT EVENT DATA 106
percentage of replicates that showed a signiﬁcant eﬀect for either the placebo or
treatment are shown. A replicate was judged to have shown a signiﬁcant eﬀect if
the p-value was below the signiﬁcance threshold of 0.05. The Cox model results
for the ﬁrst event only are also shown. The gap times for the ﬁrst event were
the same for the ﬁrst and second and the third and fourth sets of simulation
conditions. As a result for each pair of simulation conditions the results for the
time-to-ﬁrst analysis were the same. With the introduction of the increased risk
of patients suﬀering events this was not the case for subsequent events. The re-
sults for the mean HRs are also illustrated graphically. For each set of simulation
conditions the mean of the estimated HRs, with 95% CIs, for the diﬀerent recur-
rent event models are shown. Due to the narrowness of the 95% CIs and that the
results for the models varied the results for the AG and WLW models are shown
on diﬀerent axes from the results for the PWPa and PWPb models. For the
no treatment eﬀect and the treatment eﬀect groups of simulations the expected
HRs were known. Therefore, where the simulation results allow a reference line
indicating the expected HR is shown for these two groups of simulations.
6.3.1 The No Treatment Eﬀect Group of Simulations
The results for the no treatment eﬀect group of simulations where the treatment
eﬀect was set to zero are shown ﬁrst. The simulation results for γ = 1 are shown
in Table 6.3 and the results for the HRs only are shown in Figures 6.1 and 6.2.
The simulation results for γ = 0.75 are shown in Table 6.4 and the results for the
HRs only are shown in Figures 6.3 and 6.4.
The aim of performing this group of simulations was to ascertain if there wasCHAPTER 6. SIMULATION OF RECURRENT EVENT DATA 107
Table 6.3: Results for the no treatment eﬀect group of simulations where
γ = 1. The table contains the mean of the estimated parameter
estimates (SE), hazard ratios (SE) and the percentage of replicates
that showed a signiﬁcant eﬀect for either treatment group
Model Parameter Hazard Signiﬁcant Replicates
Estimate (SE) Ratio (SE) Treatment (%) Placebo (%)
The First Set of Simulation Conditions
Cox 0.0017 (0.0010)) 1.0066 (0.0010) 2.26% 2.41%
AG 0.0010 (0.0009) 1.0054 (0.0009) 2.22% 2.52%
WLW 0.0011 (0.0010) 1.0064 (0.0010) 2.22% 2.49%
PWPa 0.0009 (0.0009) 1.0053 (0.0009) 2.23% 2.50%
PWPb 0.0009 (0.0009) 1.0054 (0.0009) 2.19% 2.54%
The Second Set of Simulation Conditions
Cox 0.0017 (0.0010) 1.0066 (0.0010) 2.26% 2.41%
AG 0.0011 (0.0010) 1.0066 (0.0011) 2.45% 2.60%
WLW 0.0012 (0.0011) 1.0075 (0.0011) 2.43% 2.54%
PWPa 0.0008 (0.0008) 1.0041 (0.0008) 2.39% 2.62%
PWPb 0.0008 (0.0008) 1.0041 (0.0008) 2.31% 2.67%
The Third Set of Simulation Conditions
Cox <0.0001 (0.0006) 1.0021 (0.0006) 2.68% 2.25%
AG -0.0001 (0.0007) 1.0021 (0.0007) 2.66% 2.46%
WLW -0.0002 (0.0007) 1.0024 (0.0007) 2.74% 2.37%
PWPa -0.0001 (0.0004) 1.0008 (0.0004) 2.74% 2.64%
PWPb 0.0002 (0.0005) 1.0013 (0.0005) 2.61% 2.41%
The Fourth Set of Simulation Conditions
Cox <0.0001 (0.0006) 1.0021 (0.0006) 2.68% 2.25%
AG -0.0003 (0.0007) 1.0018 (0.0006) 2.64% 2.31%
WLW -0.0003 (0.0007) 1.0020 (0.0007) 2.64% 2.31%
PWPa -0.0003 (0.0005) 1.0008 (0.0005) 2.66% 2.77%
PWPb 0.00006 (0.0004) 1.0010 (0.0004) 2.50% 2.67%CHAPTER 6. SIMULATION OF RECURRENT EVENT DATA 108
(a) The ﬁrst set of simulation conditions
(b) The second set of simulation conditions
Figure 6.1: Hazard ratios for the ﬁrst and second sets of simulation condi-
tions for the no treatment eﬀect group of simulations where γ =
1 with accompanying 95% CIsCHAPTER 6. SIMULATION OF RECURRENT EVENT DATA 109
(a) The third set of simulation conditions
(b) The fourth set of simulation conditions
Figure 6.2: Hazard ratios for the third and fourth sets of simulation condi-
tions for the no treatment eﬀect group of simulations where γ =
1 with accompanying 95% CIsCHAPTER 6. SIMULATION OF RECURRENT EVENT DATA 110
Table 6.4: Results for the no treatment eﬀect group of simulations where γ
= 0.75. The table contains the mean of the estimated parameter
estimates (SE), hazard ratios (SE) and the percentage of replicates
that showed a signiﬁcant eﬀect for either treatment group
Model Parameter Hazard Signiﬁcant Replicates
Estimate (SE) Ratio (SE) Treatment (%) Placebo (%)
The First Set of Simulation Conditions
Cox -0.0013 (0.0010) 1.0037 (0.0010) 2.70% 2.57%
AG -0.0015 (0.0010) 1.0033 (0.0010) 2.57% 2.58%
WLW -0.0017 (0.0011) 1.0041 (0.0011) 2.60% 2.54%
PWPa -0.0014 (0.0009) 1.0029 (0.0009) 2.59% 2.47%
PWPb -0.0013 (0.0009) 1.0028 (0.0009) 2.52% 2.55%
The Second Set of Simulation Conditions
Cox -0.0013 (0.0010) 1.0037 (0.0010) 2.70% 2.57%
AG -0.0017 (0.0011) 1.0041 (0.0011) 2.57% 2.61%
WLW -0.0018 (0.0011) 1.0048 (0.0012) 2.62% 2.51%
PWPa -0.0011 (0.0008) 1.0021 (0.0008) 2.67% 2.66%
PWPb -0.0010 (0.0008) 1.0020 (0.0008) 2.54% 2.72%
The Third Set of Simulation Conditions
Cox -0.0007 (0.00064) 1.0013 (0.0006) 2.49% 2.66%
AG 0.0001 (0.0007) 1.0022 (0.0007) 2.36% 2.46%
WLW <0.0001 (0.0007) 1.0025 (0.0007) 2.25% 2.56%
PWPa 0.0001 (0.0004) 1.0010 (0.0004) 2.67% 2.36%
PWPb 0.0004 (0.0004) 1.0013 (0.0004) 2.26% 2.59%
The Fourth Set of Simulation Conditions
Cox -0.0007 (0.0006) 1.0013 (0.0006) 2.49% 2.66%
AG -0.0004 (0.0006) 1.0017 (0.0006) 2.37% 2.66%
WLW -0.0005 (0.0007) 1.0018 (0.0007) 2.41% 2.67%
PWPa 0.0002 (0.0005) 1.0013 (0.0005) 3.06% 2.84%
PWPb 0.0002 (0.0004) 1.0011 (0.0004) 2.17% 2.44%CHAPTER 6. SIMULATION OF RECURRENT EVENT DATA 111
(a) The ﬁrst set of simulation conditions
(b) The second set of simulation conditions
Figure 6.3: Hazard ratios for the ﬁrst and second sets of simulation condi-
tions for the no treatment eﬀect group of simulations where γ =
0.75 with accompanying 95% CIsCHAPTER 6. SIMULATION OF RECURRENT EVENT DATA 112
(a) The third set of simulation conditions
(b) The fourth set of simulation conditions
Figure 6.4: Hazard ratios for the third and fourth sets of simulation condi-
tions for the no treatment eﬀect group of simulations where γ =
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any form of bias in the simulation process. As all the HRs approximately equalled
1 there was no bias. As the treatment eﬀect was set to zero it would be expected
that roughly 2.5% of the replicates would show a signiﬁcant eﬀect for both the
placebo and the treatment. This was reﬂected in the percentage of replicates
that were signiﬁcant. In this group of simulations even though the parameter
estimates were close to zero the inclusion of the random subject eﬀect did halve
the parameter estimates. For the third and fourth sets of simulations conditions,
where the random subject eﬀect was included, the 95% CIs for the HRs were
narrower than for the ﬁrst and second sets of simulation conditions.
6.3.2 The Treatment Eﬀect Group of Simulations
The results for the treatment eﬀect group of simulations where the treatment
was eﬀective compared to the placebo for all four events are now shown. The
simulation results for γ = 1 are shown in Table 6.5 and the results for the HRs
only are shown in Figures 6.5 and 6.6. The simulation results for γ = 0.75 are
shown in Table 6.6 and the results for the HRs only are shown in Figures 6.7
and 6.8.
As the parameter estimates were not so close to zero for this group of sim-
ulations it is clearer that the random subject eﬀect did halve the parameter
estimates. Looking at the HRs, starting with the ﬁrst set of simulation condi-
tions when γ = 1 the AG, PWPa and PWPb models gave the expected results
whereas the WLW model overestimates the treatment eﬀect. When γ = 0.75 the
AG model gives close to the expected result and the PWPa and PWPb models
underestimated the treatment eﬀect. The WLW model again overestimated theCHAPTER 6. SIMULATION OF RECURRENT EVENT DATA 114
Table 6.5: Results for the treatment eﬀect group of simulations where γ = 1.
The table contains the mean of the estimated parameter estimates
(SE), hazard ratios (SE) and the percentage of replicates that
showed a signiﬁcant eﬀect for either treatment group
Model Parameter Hazard Signiﬁcant Replicates
Estimate (SE) Ratio (SE) Treatment (%) Placebo (%)
The First Set of Simulation Conditions
Cox -0.6982 (0.0012) 0.5011 (0.0006) 100% 0.0%
AG -0.6982 (0.0012) 0.5008 (0.0006) 100% 0.0%
WLW -0.7485 (0.0012) 0.4767 (0.0006) 100% 0.0%
PWPa -0.6983 (0.0012) 0.5008 (0.0006) 100% 0.0%
PWPb -0.6983 (0.0012) 0.5008 (0.0006) 100% 0.0%
The Second Set of Simulation Conditions
Cox -0.6982 (0.0012) 0.5011 (0.0006) 100% 0.0%
AG -0.8465 (0.0013) 0.4323 (0.0005) 100% 0.0%
WLW -0.8887 (0.0013) 0.4148 (0.0005) 100% 0.0%
PWPa -0.6979 (0.0011) 0.5004 (0.0005) 100% 0.0%
PWPb -0.6979 (0.0011) 0.5004 (0.0005) 100% 0.0%
The Third Set of Simulation Conditions
Cox -0.3469 (0.0007) 0.7086 (0.0005) 99.90% 0.0%
AG -0.3343 (0.0007) 0.7178 (0.0005) 99.51% 0.0%
WLW -0.3641 (0.0008) 0.6969 (0.0005) 99.67% 0.0%
PWPa -0.1635 (0.0005) 0.8500 (0.0004) 95.81% 0.0%
PWPb -0.1715 (0.0005) 0.8435 (0.0004) 93.28% 0.0%
The Fourth Set of Simulation Conditions
Cox -0.3469 (0.0007) 0.7086 (0.0005) 99.90% 0.0%
AG -0.3567 (0.0007) 0.7017 (0.0005) 99.54% 0.0%
WLW -0.3712 (0.0007) 0.6917 (0.0005) 99.95% 0.0%
PWPa -0.1488 (0.0005) 0.8629 (0.0004) 85.53% 0.0%
PWPb -0.1546 (0.0005) 0.8577 (0.0004) 90.62% 0.0%CHAPTER 6. SIMULATION OF RECURRENT EVENT DATA 115
(a) The ﬁrst set of simulation conditions
(b) The second set of simulation conditions
Figure 6.5: Hazard ratios for the ﬁrst and second sets of simulation condi-
tions for the treatment eﬀect group of simulations where γ = 1
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(a) The third set of simulation conditions
(b) The fourth set of simulation conditions
Figure 6.6: Hazard ratios for the third and fourth sets of simulation condi-
tions for the treatment eﬀect group of simulations where γ = 1
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Table 6.6: Results for the treatment eﬀect group of simulations where γ =
0.75. The table contains the mean of the estimated parameter
estimates (SE), hazard ratios (SE) and the percentage of replicates
that showed a signiﬁcant eﬀect for either treatment group
Model Parameter Hazard Signiﬁcant Replicates
Estimate (SE) Ratio (SE) Treatment (%) Placebo (%)
The First Set of Simulation Conditions
Cox -0.6964 (0.0012) 0.5020 (0.0006) 99.99% 0.0%
AG -0.7138 (0.0012) 0.4932 (0.0006) 100% 0.0%
WLW -0.7617 (0.0013) 0.4706 (0.0006) 100% 0.0%
PWPa -0.6775 (0.0011) 0.5112 (0.0006) 100% 0.0%
PWPb -0.6772 (0.0011) 0.5113 (0.0006) 100% 0.0%
The Second Set of Simulation Conditions
Cox -0.6964 (0.0012) 0.5020 (0.0006) 99.99% 0.0%
AG -0.8366 (0.0013) 0.4367 (0.0006) 100% 0.0%
WLW -0.8754 (0.0013) 0.4204 (0.0006) 100% 0.0%
PWPa -0.6519 (0.0010) 0.5239 (0.0005) 100% 0.0%
PWPb -0.6479 (0.0010) 0.5260 (0.0005) 100% 0.0%
The Third Set of Simulation Conditions
Cox -0.3475 (0.0007) 0.7082 (0.0005) 99.93% 0.0%
AG -0.3331 (0.0007) 0.7186 (0.0005) 99.64% 0.0%
WLW -0.3636 (0.0008) 0.6973 (0.0005) 99.72% 0.0%
PWPa -0.1632 (0.0005) 0.8503 (0.0004) 94.90% 0.0%
PWPb -0.1715 (0.0005) 0.8434 (0.0004) 93.87% 0.0%
The Fourth Set of Simulation Conditions
Cox -0.3475 (0.0007) 0.7082 (0.0005) 99.93% 0.0%
AG -0.3543 (0.0007) 0.7034 (0.0005) 99.88% 0.0%
WLW -0.3696 (0.0007) 0.6929 (0.0005) 99.90% 0.0%
PWPa -0.1488 (0.0005) 0.8629 (0.0004) 82.89% 0.0%
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(a) The ﬁrst set of simulation conditions
(b) The second set of simulation conditions
Figure 6.7: Hazard ratios for the ﬁrst and second sets of simulation condi-
tions for the treatment eﬀect group of simulations where γ = 0.75
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(a) The third set of simulation conditions
(b) The fourth set of simulation conditions
Figure 6.8: Hazard ratios for the third and fourth sets of simulation condi-
tions for the treatment eﬀect group of simulations where γ = 0.75
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treatment eﬀect. For the second set of simulation conditions when γ = 1 the
PWPa and PWPb models gave the expected results. However, when γ = 0.75
they underestimated the treatment eﬀect. For both values of γ the AG and WLW
models overestimated the treatment eﬀect. The results for the third and fourth
sets of simulation condition were very similar for both values of γ. The results for
the AG model were around the expected value and the WLW model slightly over-
estimated the treatment eﬀect. The PWPa and PWPb models underestimated
the expected treatment eﬀect by around 15% for the third set of conditions and
16% for the fourth set of conditions. This percentage underestimation of the
treatment eﬀect by the PWPa and PWPb models was an absolute percentage
diﬀerence as opposed to a relative percentage diﬀerence. The PWPa model un-
derestimated the treatment eﬀect marginally more than the PWPb model.
For the ﬁrst and second sets of simulation conditions 100% of the replicates
showed a signiﬁcant treatment eﬀect. This changed for the third and fourth
sets of conditions. For the AG and WLW models there was no real change as the
percentage of replicates that showed a signiﬁcant treatment eﬀect remained above
99%. This was not the case for the PWPa and PWPb models. For the third set
of simulation conditions the percentage of replicates that showed a signiﬁcant
treatment eﬀect remained in the nineties but for the fourth set of simulation
conditions the percentage decreased further. The decrease in percentage was
most apparent for the PWPa model where the percentage dropped to 85.53%
when γ = 1 and 82.89% when γ = 0.75. No replicates were found to show a
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6.3.3 The Treatment Eﬀect for First Event Group of Sim-
ulations
The results for the treatment eﬀect for the ﬁrst event group of simulations where
the treatment was eﬀective compared to the placebo for only the ﬁrst event after
which the treatment eﬀect was set to zero are now shown. The simulation results
for γ = 1 are shown in Table 6.7 and the results for the HRs only are shown in
Figures 6.9 and 6.10. The simulation results for γ = 0.75 are shown in Table 6.8
and the results for the HRs only are shown in Figures 6.11 and 6.12.
For the ﬁrst and second set of simulation conditions the WLW model gave
results very close to the Cox model for the time-to-ﬁrst event analysis, whereas
the results for the AG model were slightly higher. The HRs for the PWPa and
PWPb models were all higher than 0.5, which was the HR for the time-to-ﬁrst
event analysis. For the ﬁrst set of simulation conditions the results were still
relatively close to 0.5. However, for the second set of simulation conditions the
results were pulled away from 0.5. The eﬀect was more apparent for both sets of
simulations conditions when γ = 0.75. A similar patter as seen in Section 6.3.2 for
the third and fourth sets of simulation conditions emerged. The AG and WLW
models gave similar results and the PWPa and PWPb models gave similar results.
The results for the AG and WLW models were relatively close to the time-to-ﬁrst
event results. They were pulled towards the null value but still showed a large
reduction in risk for the treatment group. However, this was not the case for the
PWPa and PWPb models where apart from the PWPb model for the third set
of simulation conditions the HRs were greater than the null value of 1.
The percentage of replicates that showed a signiﬁcant treatment eﬀect for theCHAPTER 6. SIMULATION OF RECURRENT EVENT DATA 122
Table 6.7: Results for the treatment eﬀect for the ﬁrst event group of simula-
tions where γ = 1. The table contains the mean of the estimated
parameter estimates (SE), hazard ratios (SE) and the percentage
of replicates that showed a signiﬁcant eﬀect for either treatment
group
Model Parameter Hazard Signiﬁcant Replicates
Estimate (SE) Ratio (SE) Treatment (%) Placebo (%)
The First Set of Simulation Conditions
Cox -0.6967 (0.0012) 0.5019 (0.0006) 100% 0.0%
AG -0.6445 (0.0012) 0.5286 (0.0006) 100% 0.0%
WLW -0.6937 (0.0013) 0.5037 (0.0006) 100% 0.0%
PWPa -0.6349 (0.0012) 0.5338 (0.0006) 100% 0.0%
PWPb -0.6348 (0.0012) 0.5338 (0.0006) 99.99% 0.0%
The Second Set of Simulation Conditions
Cox -0.6967 (0.0012) 0.5019 (0.0006) 100% 0.0%
AG -0.6510 (0.0013) 0.5260 (0.0007) 99.94% 0.0%
WLW -0.6902 (0.0014) 0.5062 (0.0007) 99.94% 0.0%
PWPa -0.4838 (0.0011) 0.6201 (0.0007) 99.70% 0.0%
PWPb -0.4835 (0.0011) 0.6202 (0.0007) 99.71% 0.0%
The Third Set of Simulation Conditions
Cox -0.3468 (0.0007) 0.7086 (0.0005) 99.90% 0.0%
AG -0.1938 (0.0007) 0.8259 (0.0006) 77.79% 0.0%
WLW -0.2299 (0.0008) 0.7969 (0.0006) 85.82% 0.0%
PWPa 0.0226 (0.0005) 1.0239 (0.0005) 0.72% 8.05%
PWPb -0.0221 (0.0005) 0.9793 (0.0005) 6.08% 0.80%
The Fourth Set of Simulation Conditions
Cox -0.3468 (0.0007) 0.7086 (0.0005) 99.90% 0.0%
AG -0.2535 (0.0007) 0.7780 (0.0005) 95.32% 0.0%
WLW -0.2758 (0.0007) 0.7609 (0.0005) 96.68% 0.0%
PWPa 0.0916 (0.0005) 1.0975 (0.0006) 0.01% 43.13%
PWPb 0.0206 (0.0005) 1.0220 (0.0005) 0.90% 6.51%CHAPTER 6. SIMULATION OF RECURRENT EVENT DATA 123
(a) The ﬁrst set of simulation conditions
(b) The second set of simulation conditions
Figure 6.9: Hazard ratios for the ﬁrst and second sets of simulation condi-
tions for the treatment eﬀect for the ﬁrst event group of simula-
tions where γ = 1 with accompanying 95% CIsCHAPTER 6. SIMULATION OF RECURRENT EVENT DATA 124
(a) The third set of simulation conditions
(b) The fourth set of simulation conditions
Figure 6.10: Hazard ratios for the third and fourth sets of simulation condi-
tions for the treatment eﬀect for the ﬁrst event group of simu-
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Table 6.8: Results for the treatment eﬀect for the ﬁrst event group of sim-
ulations where γ = 0.75. The table contains the mean of the
estimated parameter estimates (SE), hazard ratios (SE) and the
percentage of replicates that showed a signiﬁcant eﬀect for either
treatment group
Model Parameter Hazard Signiﬁcant Replicates
Estimate (SE) Ratio (SE) Treatment (%) Placebo (%)
The First Set of Simulation Conditions
Cox -0.6933 (0.0012) 0.5035 (0.0006) 100% 0.0%
AG -0.6417 (0.0012) 0.5302 (0.0006) 100% 0.0%
WLW -0.6881 (0.0013) 0.5066 (0.0006) 100% 0.0%
PWPa -0.5934 (0.0012) 0.5562 (0.0006) 100% 0.0%
PWPb -0.5936 (0.0012) 0.5560 (0.0006) 100% 0.0%
The Second Set of Simulation Conditions
Cox -0.6933 (0.0012) 0.5035 (0.0006) 100% 0.0%
AG -0.6484 (0.0013) 0.5274 (0.0007) 99.93% 0.0%
WLW -0.6849 (0.0014) 0.5089 (0.0007) 99.94% 0.0%
PWPa -0.4466 (0.0011) 0.6434 (0.0007) 99.47% 0.0%
PWPb -0.4469 (0.0010) 0.6431 (0.0007) 99.57% 0.0%
The Third Set of Simulation Conditions
Cox -0.3462 (0.0007) 0.7091 (0.0005) 99.88% 0.0%
AG -0.1986 (0.0007) 0.8220 (0.0006) 79.72% 0.0%
WLW -0.2354 (0.0008) 0.7927 (0.0006) 87.14% 0.0%
PWPa 0.0208 (0.0005) 1.0222 (0.0005) 0.86% 7.23%
PWPb -0.0300 (0.0005) 0.9716 (0.0005) 8.99% 0.51%
The Fourth Set of Simulation Conditions
Cox -0.3462 (0.0007) 0.7091 (0.0005) 99.88% 0.0%
AG -0.2529 (0.0007) 0.7785 (0.0005) 95.20% 0.0%
WLW -0.2759 (0.0007) 0.7609 (0.0006) 96.87% 0.0%
PWPa 0.0879 (0.0006) 1.0936 (0.0006) 0.0% 37.20%
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(a) The ﬁrst set of simulation conditions
(b) The second set of simulation conditions
Figure 6.11: Hazard ratios for the ﬁrst and second sets of simulation condi-
tions for the treatment eﬀect for the ﬁrst event group of simu-
lations where γ = 0.75 with accompanying 95% CIsCHAPTER 6. SIMULATION OF RECURRENT EVENT DATA 127
(a) The third set of simulation conditions
(b) The fourth set of simulation conditions
Figure 6.12: Hazard ratios for the third and fourth sets of simulation condi-
tions for the treatment eﬀect for the ﬁrst event group of simu-
lations where γ = 0.75 with accompanying 95% CIsCHAPTER 6. SIMULATION OF RECURRENT EVENT DATA 128
ﬁrst and second sets of simulation conditions was greater than 99%. This was not
the case for the third and fourth sets of simulation conditions. For the AG and
WLW models the percentage of replicates that showed a signiﬁcant treatment
eﬀect remained high, especially for the fourth set of simulation conditions. No
replicates showed a signiﬁcant placebo eﬀective. For the PWPa model for the
third set of conditions less than 1% of the replicates showed a signiﬁcant treatment
eﬀect whereas 7% or 8%, depending on the value of γ, showed a signiﬁcant placebo
eﬀect. For the PWPb model 6% or 9%, depending on the value of γ, of the
replicates showed a signiﬁcant treatment eﬀect whereas less than 1% showed a
signiﬁcant placebo eﬀect. For the fourth set of simulation conditions no replicates
showed a signiﬁcant treatment eﬀect for the PWPa model. For the PWPb model
around 1% of the replicates did show a signiﬁcant treatment eﬀect. For the PWPb
model 4% or 7%, depending on the value of γ, of replicates showed a signiﬁcant
placebo eﬀect but for the PWPa model this jumped to 37% or 43%, depending
on the value of γ.
6.4 Interpretation of the Simulation Results
From the results for the no treatment eﬀect group of simulations it was seen that
the simulation process was unbiased. The results for the treatment eﬀect and
treatment eﬀect for the ﬁrst event groups of simulations can then be interpreted
in the knowledge that there was no form of bias in the simulation process. When
examining the results of the simulations the diﬀerent underlying assumptions of
the recurrent event models have to be taken into account. For the ﬁrst set of
simulation conditions very few patients suﬀered a third or fourth event. WithCHAPTER 6. SIMULATION OF RECURRENT EVENT DATA 129
the increased risk of suﬀering events under the second set of simulation conditions
the number of patients suﬀering later events did increase. The inclusion of the
random subject for the third and fourth sets of simulation conditions dramatically
increased the number of patients who suﬀered third and fourth events. The
increased event rate caused by the random subject eﬀect was far greater than
purely increasing the risk of patients suﬀering events. For the third and fourth
sets of simulation conditions the event rate was substantially higher than in the
IONA Study. The second set of simulation conditions, when γ = 0.75, most
accurately reﬂected the IONA Study data.
The results for the treatment eﬀect group of simulations are considered ﬁrst.
For the AG model it is assumed that the risk of events remains constant over
time and that the events are independent. The gap times were generated inde-
pendently. However, given patients were followed for a maximum of two years
the length of the ﬁrst gap time would impact on the length of the later gap times.
Therefore, the assumption of independence could be questioned. The assump-
tion of constant risk was violated under the second and fourth sets of simulation
conditions and to a lesser extent for all simulations where γ = 0.75. The ideal
conditions for the AG model were the ﬁrst set of simulation conditions. From
the results in Section 6.3.2 it is seen that the AG model performed well under
these conditions. Even with the inclusion of the random subject eﬀect for the
third set of simulation conditions the AG model still performed well. For the
second set of simulation conditions where the risk of patients suﬀering events was
increased the AG model overestimated the treatment eﬀect. Under the fourth
set of conditions this overestimation of the treatment eﬀect was not seen. The
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increasing the risk of patients suﬀering events did not have such an impact on
the simulation results as it did for the second set of simulations conditions.
The overall pattern of the results for the WLW model was that the treatment
eﬀect was overestimated. This was most obvious for the ﬁrst and second sets
of simulation conditions where the event rate was lower. For the WLW model
all patients are required to have risk intervals for all events regardless of how
many events they actually suﬀer. If a treatment is eﬀective less patients who are
receiving the treatment will suﬀer a ﬁrst event within a given time period or if
they do suﬀer an event it will be later. A long ﬁrst time interval will impact
when patients suﬀer a second event and the same is true for third and fourth
events. In the WLW model if patients do not suﬀer the number of events being
modelled for the last observed time interval for the patient is carried forward for
the remaining events. In doing this the reduced risk of suﬀering events caused
by the treatment was artiﬁcially replicated once, twice or even three times. This
would then lead to the overestimation of the treatment eﬀect. With the inclusion
of the random subject eﬀect the event rate was greatly increased and this led to
less time intervals being carried forward and as a result the overestimation of the
treatment eﬀect was reduced. Even for the third and fourth sets of simulation
conditions the results for the WLW model slightly overestimated the treatment
eﬀect. In general when the event rate was low the AG and WLW models overes-
timated the treatment eﬀect. When the event rate was higher the results for the
AG and WLW models were near the expected values.
The PWPa and PWPb models gave the expected results for the ﬁrst and
second sets of simulation conditions when γ = 1. When γ = 0.75 and as a
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treatment eﬀect. The underestimation of the treatment eﬀect was again seen in
the results for the third and fourth sets of simulation conditions. For the third and
fourth sets of conditions the PWPa and PWPb models estimated the treatment
eﬀect to be only half of what it should have been. Unlike the WLW model and
to a lesser extent the AG model the PWPa and PWPb models performed better
when the event rate was lower. These ﬁnding may be explained by selection bias
for patients. As the treatment was eﬀective those patients who suﬀered events in
the treatment group had a higher underlying frailty than patients who did not
suﬀer events. These patients were predisposed to suﬀer more events and suﬀer
them earlier. Therefore for later events, even though the treatment was eﬀective,
these patients were at an elevated risk of suﬀering events compared to those in
the placebo group. This resulted in the HRs being pulled towards the null value
of 1. When the event rate was lower the selection bias had a smaller eﬀect. With
the inclusion of the random subject eﬀect and the resultant increased event rate
the bias was exaggerated.
The results for the treatment eﬀect for the ﬁrst event group of simulations are
now considered. For the ﬁrst set of simulation conditions, where the event rate
was lowest, the WLW model gave almost identical results as the Cox model for
the time-to-ﬁrst event analysis whereas the other models estimated the treatment
eﬀect to be smaller. The WLW model again gave almost identical results to the
time-to-ﬁrst event analysis for the second set of simulation conditions. The fact
that the treatment eﬀect was set to zero after the ﬁrst event was not reﬂected in
the results for the WLW model. The results for the other models for the second
set of simulation conditions showed a reduced treatment eﬀect. The lessening
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and fourth sets of simulation conditions where the event rates were considerably
higher the AG and WLW models showed that the treatment did reduce the
risk of patients suﬀering recurrent events. The treatment eﬀect was near to
the treatment eﬀect seen in the treatment eﬀect group of simulations. The AG
model does not consider the order in which patients suﬀer events. For the ﬁrst
and second sets of simulation conditions the majority of events suﬀered were ﬁrst
events, where the treatment was eﬀective. The greater occurrence of ﬁrst events
was reﬂected in the results for the AG model. For the third and fourth sets of
simulation conditions the PWPa and PWPb models indicated that were was a
small placebo eﬀect, apart from the PWPb model for the third set of simulation
conditions. In this case the results showed the treatment was eﬀective but it only
reduced the risk of patients suﬀering events by 2% or 3%. Here the selection bias
of patients was having a larger eﬀect than seen in the treatment eﬀect group of
simulations.
The patients in the treatment group who suﬀered ﬁrst events had a high level
of frailty as they suﬀered events even though the treatment was eﬀective. For
subsequent events these patients still had a high level of frailty but the treatment
was no longer eﬀective. The result of which was that for the second, third and
fourth events, even though there was no diﬀerence between the treatment groups,
it appeared that the placebo was eﬀective at reducing the risk of patients suﬀering
events. The results for the PWPa and PWPb models were heavily inﬂuenced by
the recurrent events over the ﬁrst events. This was reinforced by looking at the
percentage of replicates that showed a signiﬁcant diﬀerence between the treatment
groups. For the third and fourth sets of simulation conditions the majority of
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the replicates showed a signiﬁcant placebo eﬀect. The percentage of replicates
that showed a signiﬁcant placebo eﬀect was higher for the PWPa model than
the PWPb model. For the fourth set of simulation conditions the percentage of
replicates that showed a signiﬁcant placebo eﬀect was particularly high at 37%
or 43%, depending on the value of γ, for the PWPa model.
The reason why this percentage was so high is not clear but may be as a
result of the total time being used in the PWPa model as opposed to the gap
time in the PWPb model. The selection bias for the treatment group that the
most frail patients suﬀered ﬁrst events was applicable to both the PWPa and
PWPb models. There may however be an additional form of bias only applicable
to the PWPa model. This second form of bias was highlighted under the fourth
set of simulation conditions as this was the scenario were patients suﬀered the
highest number of recurrent events. For the PWPa model the time patients enter
the risk set for the second event and when they suﬀer a second event are aﬀected
by the time to the ﬁrst event as the total time is used. For the PWPb model
this is not the case as the time is reset to zero after an event. The most frail
patients will suﬀer early ﬁrst events and then early second events whereas the
least frail patients will have longer times to both events. For patients who were
at risk of a second event those patients who were in the treatment group would
tend to have a higher level of frailty than patients in the placebo group. These
patients would then suﬀer a second event earlier and this would be reﬂected in
the PWPa model as the total time is used. This would then double up the bias
in the PWPa model compared to the PWPb model where there was only the
selection bias with respect to the ﬁrst event. However, further simulations would
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replicates that showed a signiﬁcant placebo eﬀect for the PWPa model. These
simulations have shown that the recurrent event models do perform diﬀerently
under known conditions and that they can give measurably diﬀerent results.
6.5 Summary of the Main Findings of the Sim-
ulations
The main ﬁndings of the simulations were as follows:
1. Under the ideal conditions for the AG model, the ﬁrst set of simulation
conditions, the model performed well.
2. When the risk of suﬀering events was not constant, the second set of simu-
lation conditions, the AG model overestimated the treatment eﬀect.
3. The overall pattern of the results for the WLW model was that the treat-
ment eﬀect was overestimated. This was most apparent for the ﬁrst and
second sets of simulation conditions.
4. In general when the event rate was low the AG and WLW models overes-
timated the treatment eﬀect.
5. When the event rate was higher the results for the AG and WLW models
were near the expected values.
6. The results for the AG and WLW models were inﬂuenced more by the ﬁrst
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7. For the ﬁrst and second sets of simulations conditions, where the event rate
was low, the PWPa and PWPb models performed well.
8. For the third and fourth sets of conditions, where the event rate was highest,
the PWPa and PWPb models estimated the treatment eﬀect to be only half
of what it should have been.
9. The results for the PWPa and PWPb models were heavily inﬂuenced by
the recurrent events over the ﬁrst events.
10. In the simulations that most accurately reﬂected what happened in the
IONA Study for the primary endpoint, the second set of simulation con-
ditions with γ = 0.75 for the treatment eﬀect group of simulations, the
models that performed best were the PWPa and PWPb models.Chapter 7
Health Economics
The economic evaluation of the IONA Study was carried out by Walker et al.
(2006). Before details of the analysis are given and expanded upon in Chapter 8
an introduction to the topic of health economics will be given. With the increasing
costs of providing healthcare for the population and the increased patient aware-
ness of the possible interventions and treatments available to them, decisions
made about the potential use of any such interventions cannot be based solely on
the results of clinical trials. The economic impact of the intervention has to be
considered. As a result the area of health economics has recently seen its proﬁle
raised. A good example of this involved the breast cancer drug Herceptin and the
debate surrounding whether it should be prescribed or not. (Dent and Clemons,
2005; Anon, 2005; Barrett et al., 2006) Due to the limited amount of money
available it is not possible to satisfy everyone. If one treatment is recommended
it could well have a direct impact on another treatment not being recommended,
as if one is recommended there may well be insuﬃcient money available to fund
both. The undertaking of economic evaluations, alongside clinical trials and in
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general, is therefore gaining increasing importance. In this Chapter the diﬀerent
types of economic evaluations that are used will be explained and leading on from
that Incremental Cost-Eﬀectiveness Ratios and Quality-Adjusted Life Years will
be further discussed. The use of sensitivity analysis in economic evaluations will
also be covered.
7.1 Economic Evaluations
A product, for example a treatment, that is judged to be cost-eﬀective is one
that based on the beneﬁts it produces and all the associated costs is thought eco-
nomical to use. An economic evaluation involves the comparison of two or more
interventions in terms of both their costs and consequences. In health economics
the interventions will commonly be drugs or devices and the consequences will
be in terms of the clinical beneﬁts they give. When an economic evaluation of a
treatment is being carried out an important factor to consider is the overall net
cost of that treatment. The net cost of a treatment includes all the cost savings
that the treatment makes, for example through the reduction in the number of
hospitalisations that patients who are receiving the treatment would have gone
on to suﬀer and any other reductions in costs versus the cost of the actual treat-
ment itself and any accompanying costs. These supplementary costs can include
additional out-patient hospital visits and GP appointments for patients or the
cost of extra laboratory tests that are required to be undertaken to monitor the
patients and how they are responding to the treatment. There are ﬁve main
types of economic evaluations that are used. They are Cost-Eﬀectiveness Anal-
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Cost-Consequence Analysis (CCA) and Cost-Beneﬁt Analysis (CBA). A short
explanation of each will be given.
7.1.1 Cost-Eﬀectiveness Analysis
In a Cost-Eﬀectiveness Analysis (Lopert et al., 2003) the costs of two treatments
are compared to each other as well as comparing the beneﬁts in terms of one single
clinical outcome. The costs are measured in monetary terms and the beneﬁts are
measured in natural units pertaining to the given situation, for example the
number of deaths prevented or the number of symptom free days. As the costs
and beneﬁts are being measured in non-comparable units the comparison takes
the form of a ratio known as an Incremental Cost-Eﬀectiveness Ratio (ICER). For
comparing two treatments, A and B, the following formula for an ICER would
be used:
ICER =
(Total Cost of Treatment A) − (Total Cost of Treatment B)
(Total Beneﬁt of Treatment A) − (Total Beneﬁt of Treatment B)
=
Diﬀerence in Costs Between Treatments A and B
Diﬀerence in Beneﬁts Between Treatments A and B
(7.1)
In health economics ICER is a generic term with no standard deﬁnition and it
can be and is used in a variety of situations whenever cost and beneﬁts are being
compared. The topic of ICERs will be returned to in Section 7.2. A limitation
of CEA is that as natural units of clinical beneﬁt are being compared the ability
to assess the relative beneﬁts of introducing diﬀerent types of new treatments
using this method of economic evaluation is limited to those that have the same
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7.1.2 Cost-Utility Analysis
In a Cost-Utility Analysis (Brinsmead and Hill, 2003), as in a CEA, the costs of
two treatments are compared to each other as well as comparing the beneﬁts in
terms of one single clinical outcome. Costs are measured in monetary terms but
this time the beneﬁts are measured in a common outcome called a utility. When
comparing the two treatments an ICER is again used. A frequently used utility
in health economics is the Quality-Adjusted Life Year (QALY). Life-years are
a familiar concept to epidemiologists and statisticians as a measure of changes
in survival. However, they take no account of the quality of life of the patient,
whereas QALYs do. When looking at QALYs states of health are graded on a
scale of 0 to 1, with 0 being dead or the equivalent of being dead and 1 being in
perfect health. In some cases the scale can have negatives values where patients
are still alive but considered to be in a worse state than death, such as patients
suﬀering advanced cancer pain or advanced degenerative disease. The QALY val-
ues assigned to diﬀerent health states are known as health utilities. For example
the utility for a person who is an insulin dependent diabetes mellitus suﬀerer is
0.84 and for someone who is on dialysis it is 0.41. How the utility values are
assigned and the use of QALYs will be discussed in Section 7.3.
7.1.3 Cost-Minimisation Analysis
In a Cost-Minimisation Analysis (Newby and Hill, 2003) it is assumed that the
two treatments being compared have been shown to oﬀer equivalent clinical ben-
eﬁt. As a consequence unlike CEA and CUA the beneﬁts of the two treatments
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the cost of the two treatments, with the treatment with the overall lower cost be-
ing favoured. It is important to remember that when the costs of two treatments
are being compared it is not just the cost of the treatments themselves but also
the associated costs that are being compared. For example, the cost of one treat-
ment may be lower but patients may have to be closely monitored when they have
been prescribed that treatment. The monitoring may include attending GP visits
and having laboratory tested carried out. This will then impact on the overall
cost of the treatment. The impact on patients also has to be considered. If one
treatment involves patients taking a course of tablets whereas another involves
them attending hospital outpatient clinics for the duration of their treatment the
costs associated with the two treatments for patients will diﬀer greatly. This type
of evaluation is often used when a new treatment comes to market that has been
shown to be as clinically eﬀective as the current standard but is believed to be
more cost-eﬀective to use.
7.1.4 Cost-Consequence Analysis
In a Cost-Consequence Analysis (Mauskopf et al., 1998), as in a CEA and a CUA,
the costs of two treatments are compared to each other as well as comparing the
beneﬁts. In a CCA the beneﬁts can be presented as more than one outcome
and are presented in a disaggregated manner and are also not combined with the
costs in the form of a ratio. The diﬀerent beneﬁts are given in their natural units.
When carrying out a CCA all the major costs for both treatments are set out as
well as all the beneﬁts and these can then be compared and if investigators wish
they can apply their own weighting to the diﬀerent types of beneﬁts.CHAPTER 7. HEALTH ECONOMICS 141
7.1.5 Cost-Beneﬁt Analysis
In a Cost-Beneﬁt Analysis (Sugden and Williams, 1979), as in a CCA, the beneﬁts
that treatments give to patients can be presented as more than one outcome but
they are not measured in their natural units or in utilities but they are assigned
monetary values as are the costs associated with the treatments. As a result
the net beneﬁt of a treatment can be calculated by comparing the total costs of
the treatment with the total gain in monetary terms of the beneﬁts associated
with it. As both the cost and beneﬁts are measured using the same units, be it
pounds, dollars or euros, CBA can be used to compare treatments for diﬀerent
conditions using the net beneﬁt principle. One way of assigning monetary values
to health beneﬁts is based on the idea of willingness to pay (WTP). In WTP
people are asked how much money they would be willing to pay for a health
beneﬁt, such as controlling high blood pressure, and this value is then assigned
to that beneﬁt. As health beneﬁts have to be expressed in monetary terms, even
taking into consideration the use of WTP and other such techniques, the use of
CBA can be problematic in health economics.
7.2 Incremental Cost-Eﬀectiveness Ratios
When using Incremental Cost-Eﬀectiveness Ratios the costs will almost always
be measured in monetary values and the beneﬁts can be measured in a number
of diﬀerent ways. For example, if a CEA is being carried out, natural units of
measurement, such as symptom free days, can be used. Whereas if a CUA is
being carried a utility such as QALYs will be used. Regardless of the unit of
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an ICER involves the comparison of two treatments. There is no direct three-
way ICER equivalent. However individual pairwise comparisons can be used. If
one of the three treatments was a placebo or an existing treatment, comparisons
could be made with it and the other two, so as to gauge which of the two new
treatments is most cost-eﬀective.
Given that diﬀerences are being looked at, within the ratio, one or both of the
numerator and denominator could have a negatives value. From Equation 7.1 it
can be seen that if the diﬀerence in costs is negative this would imply that the net
cost of treatment A is lower than treatment B. If however the diﬀerence in beneﬁts
is negative this would imply that treatment B is more beneﬁcial than treatment
A. This is assuming that the beneﬁts are measured in a currency that is desirable,
such as lives saved or QALYs gained. If however the beneﬁts are being measured
in terms of undesirable events, such as the number of heart attacks avoided or
in the case of the IONA Study the number of primary endpoints prevented, the
converse would be true. If treatment A is a potentially new treatment then
ideally the cost diﬀerence would be negative and the beneﬁts diﬀerence would be
positive.
As ICERs are ratios there is a potential drawback with them in that if at
anytime the diﬀerence in costs is zero the ratio will then automatically be equal
to zero regardless of what the diﬀerence in beneﬁts is between the two treatments.
In addition if the diﬀerence in beneﬁts is zero or approaches zero, as would be the
case if the beneﬁts were shown to be equivalent in a clinical trial, then the ratio
will be undeﬁned or excessively large which will be problematic when it comes to
interpretation. In such circumstances a CEA or a CUA, which both use ICERs
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7.2.1 The Cost-Eﬀectiveness Plane
A concept that aids the understanding of ICERs and also illustrates some of
the problems with them is the cost-eﬀectiveness plane. (Black, 1990) This is
illustrated in Figure 7.1. The x-axis measures the eﬀectiveness and the y-axis
the costs.
Figure 7.1: The cost-eﬀectiveness plane
From Figure 7.1 it can be seen that the plane can be slit up into four quad-
rants, north-west (NW), north-east (NE), south-east (SE) and south-west (SW).
Here let treatment A be the new treatment and treatment B be the current stan-
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equally eﬀective and have the same net cost.
1. North-West
In the NW quadrant treatment A is totally dominated by treatment B in
that it has a higher net cost and is less eﬀective. Treatment B would be
favoured over treatment A in all situations. In this quadrant an ICER has
a negative value.
2. North-East
In the NE quadrant there has to be a trade-oﬀ between treatment A and
treatment B. Treatment A has a higher net cost than treatment B but it is
also more eﬀective. This is the most common situation. A judgement has
to be about how much more eﬀective does treatment A need to be than
treatment B and whether the resultant increase in the overall net cost due
to the use of treatment A is economically justiﬁable. In diﬀerent situations
WTP for increased eﬀectiveness will alter. In this quadrant an ICER has
a positive value.
3. South-East
In the SE quadrant treatment A totally dominates treatment B in that it
has a lower net cost and is more eﬀective. Treatment A would be favoured
over treatment B in all situations. In this quadrant an ICER has a negative
value.
4. South-West
In the SW quadrant there again has to be a trade-oﬀ between treatment A
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that treatment B. The decision to be made in this situation is whether
the saving in costs is suﬃcient to outweigh the decrease in eﬀectiveness
of treatment A over treatment B. This is the type of situation where a
pharmaceutical company will campaign for its new product to be used over
the current standard as it is overall cheaper to prescribe and only marginally
less eﬀective. How much less eﬀective the new treatment is, is the key issue
to be considered. In this quadrant an ICER has a positive value.
Looking at the four quadrants of Figure 7.1 illustrates a problem with ICERs
in that if the ratio lies in both the NW or SE quadrant the ratio will have a
negative value. If the only information quoted is the ICER value and no further
information about the values of the numerator and the denominator are given
then interpretation of negative ICERs could be problematic as the quadrants are
the polar opposites of each other. The fact that ICERs that lie in both the NE
and SW quadrants are positive should not be an issue as if the value does lie in
the SW quadrant then treatment A would have both a higher net cost and be less
eﬀective that treatment B so an economic evaluation is unlikely to be carried out.
There is a second problem with the interpretation of negative values of ICERs
and this is illustrated through an example given in the paper by Briggs and Fenn
(1998). Two treatments result in the same cost savings and both improve the
health of patients, treatment A by 0.5 units and treatment B by 1 unit. As the
denominator used in the calculation of the ICER for treatment A is a fraction the
ICER will have a larger value in magnitude than the ICER for treatment B. As
the ICERs are both negative this implies that treatment A is more cost-eﬀective,
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use. The magnitude of negative ICERs can be misleading. When ICERs are
being used in practice it is unlikely that information on the constituent parts
of both the numerator and denominator will not be available so any potential
problems with interpretation of ICER values will be avoided.
7.3 Quality-Adjusted Life Years
The concept of the Quality-Adjusted Life Year was introduced in Section 7.1
when CUA was being discussed. The main issue with using QALYs is how the
utility values are assigned to all the diﬀerent possible health states.
7.3.1 Assigning Utility Values
There are a number of diﬀerent methods used for assigning QALY utility values
and three of the most widely used are as follows:
1. Time-Trade-Oﬀ
Time-Trade-Oﬀ (TTO) (Torrance et al., 1972) is used to calculate QALYs
by the following method. People are told that they will remain in a given
state of health for ten years, for example, and they are then asked how many
of those ten years would they give up to live in perfect health. For example
if someone said they would give up four of the ten years in a particular
health state to live in perfect health for six years then that health state
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2. Standard Gamble
The Standard Gamble method (von Neumann and Morgenstern, 1944; Tor-
rance, 1976) assigns utilities to given health states as follows. People are
given the choice of remaining in a state of health for a given period of time
or the alternative of undergoing a treatment or procedure that will either
return them to perfect health or it will kill them. Then, given the state
of health that they are in, they are asked what probability or chance they
would want the treatment to have of success before they would agree to
undertake it. For example if a person was suﬀering from a common cold
the probability of success would have to be 0.99 or more likely 1 before
anyone would seriously consider undergoing the treatment. On the other
hand if they were told that they would be in a coma with little chance of
regaining consciousness the probability would most likely be considerably
lower.
3. Health Questionnaires
Health Questionnaires are used to assess the severity of a health state. An
example is the EuroQol Group EQ-5D questionnaire, http://www.euroqol.
org/. (Brooks, 1996) The EQ-5D questionnaire has ﬁve questions focusing
on ﬁve diﬀerent areas: mobility, pain and discomfort, self-care, anxiety and
depression and usual activities. Each question has three possible answers
corresponding to no problem, some problems and major problems. There
are 243 possible combinations of answers to the ﬁve questions and with the
inclusion of being unconscious or being dead they are 245 possible health
states in total. Each of theses health states has been assigned a utility valueCHAPTER 7. HEALTH ECONOMICS 148
and when a patient ﬁlls in a questionnaire their combination of answers is
matched to a look-up table of utilities. A second approach requires patients
to grade their state of health on a visual analogue scale of 0 to 100, with
100 being in perfect help. Other variations of patient questionnaires are
also available.
There are potential drawbacks with all three of these approaches. If the general
public are asked to assess the seriousness of a health state they are likely to
have had no direct experience with the condition and they may overestimate
the seriousness of the condition. Alternatively patients who have lived with a
condition for some time might have adjusted to living with it and as a result
might underestimate the seriousness of the condition. A possible way to combat
this is to ask doctors to assess the seriousness of the health state. They should
have an objective view and have more experience relating to the condition than
the general public on which to base their answers and at the same time they will
not have become accustomed to living with the condition as patients will have.
However, as patients are often likely to see doctors when their symptoms are at
their worst doctors may in fact overestimate the seriousness of the given health
state. Nurses are also asked and in some cases their answers are regarded as a
truer reﬂection of the seriousness of a disease as they will spend more time with
patients than doctors so may have a better insight into the health state and its
implications for the patients. For each of the three methods a large sample of
people or patients will be asked and the mean value of their answers, scaled to be
from 0 to 1, will be taken as the utility value for that particular state of health.CHAPTER 7. HEALTH ECONOMICS 149
7.3.2 Using Quality-Adjusted Life Years
Given that each state of health has been assigned a utility value the QALY
approach can then be used to compare diﬀerent medical interventions and treat-
ments. For example if there are two treatments that can be used to treat the
same medical condition their eﬀectiveness can be measured and compared by
looking at QALYs. This means that if treatment C prolongs life for 10 years and
treatment D prolongs life for 5 years, both compared to no treatment, on the
surface it would appear that treatment C has a clear advantage over treatment
D. However, the quality of the life the patient will have is not being taken into
consideration at this stage. If treatment D gives the patient a quality of life of
0.9, then treatment D would give the patient a QALY gain of 4.5 years. Whereas
if treatment C gives the patient a quality of life of 0.45, then treatment C would
also give the patient a QALY gain of 4.5 years. So when the quality of life is
considered as well as the quantity of life it appears that both treatments C and
D will be equally eﬀective. It would then be down to whether the quality of life
or the quantity of life is more important.
In real life situations and when faced with a limited budget the quality and
quantity of life gains are not the only things that have to be considered but also
the net cost of any such gains has to be taken into consideration and this is done
by looking at the net cost per QALY gained. For example let treatment E have
a QALY gain of 10 and treatment F have a QALY gain of 5, both compared to
standard current best practice. The treatments can be used to treat the same
or diﬀerent conditions. In terms of quality of life treatment E is the better of
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amount of money available but this is not the case so economic factors have to
be considered as well. If the net cost of prescribing treatment E was £200,000
per patient then the net cost per QALY would be £20,000 per patient and if the
net cost of prescribing treatment F was £25,000 per patient then the net cost
per QALY would be £5,000 per patient. In this example there is a diﬀerence
of cost per QALY of £15,000. Treatment E is superior in terms of QALY gains
but treatment F is superior in terms of cost per QALY. If the aim was to treat
the maximum number of patients then treating patients with treatment F, at a
lower net cost per QALY, would beneﬁt more patients and increase the number of
QALYs gained from treatment F than treating a few patients with treatment E, at
a higher net cost per QALY. It also has to be considered which conditions should
be treated if the treatments that treat them have the same net cost per QALY.
This is looking at the situation from the viewpoint of the NHS. For individual
patients the situation may well be diﬀerent. For those patients able to aﬀord to
pay for private healthcare they would want the treatment that is most eﬀective
for their condition and not the most cost-eﬀective treatment. The NHS cannot
aﬀord to give each patient the best possible treatment regardless of cost. The
NHS has to look at the population of the UK as a whole and not at patients on
an individual basis.
The QALY is a useful tool to health economists as it takes into account both
the quality of life of a patient as well as the quantity of that life. Any changes in
survival of patients as well as any change in the quality of that survival are both
considered in the calculation of QALYs but there are other relevant factors that
are not measured. If patients feel like they have no autonomy or involvement
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diminish their quality of life. These changes in the quality of life of patients
cannot be measured using a questionnaire, such as the EQ-5D questionnaire, but
they will be important to the patients themselves. The QALY is an important
measure and useful decision making tool especially when the net cost per QALY
gained can be calculated and used but other factors also need to be taken into
consideration.
7.3.3 Quality-Adjusted Life Years Used in Practice
Recommendations about which new treatments the NHS should advocate for use
are made by the Scottish Medicines Consortium (SMC) in Scotland and by the
National Institute for Health and Clinical Excellence (NICE) in England and
Wales. The net cost per QALY is just one factor that is looked at when a treat-
ment is put forward for use and other things have to be taken into consideration.
By looking at the net cost per QALY the cost-eﬀectiveness of the treatment can
be judged, but what net cost per QALY is too much? If the NHS budget was
inﬁnite this would not be a problem but it is not inﬁnite, so serious consideration
has to be taken in the allocation of budgets so that the best use of the money
available is made. There is no published ﬁxed cut-oﬀ point for the net cost per
QALY after which any treatment will not be recommended for use purely on
economic grounds, although NICE have issued guidelines on the matter. (NICE,
2004)
Below a most plausible ICER of £20,000/QALY, judgements about
the acceptability of a new technology as an eﬀective use of NHS re-
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a most plausible ICER of £20,000/QALY, judgements about the ac-
ceptability of the new technology as an eﬀective use of NHS resources
are more likely to make more explicit reference to factors including:
1. the degree of uncertainty surrounding the calculation of ICERs
2. the innovative nature of the technology
3. the particular features of the condition and population receiving
the technology
4. where appropriate, the wider societal costs and beneﬁts.
Above an ICER of £30,000/QALY, the case for supporting the tech-
nology on these factors has to be increasingly strong. The reasoning
for the Committee’s decision will be explained, with reference to the
factors that have been taken into account, in the ‘Considerations’
section of the guidance.
From this statement it would appear that if a treatment has a net cost per QALY
of below £20,000 it will be approved, between £20,000 and £30,000 it is likely
to be approved as long as there is convincing evidence of its worth and above
£30,000 it is unlikely that it will be approved unless the evidence of its beneﬁt is
extremely strong. These boundaries, if indeed they are actually the boundaries
used, are not set in stone and exceptions to the rules can and will be made. A
prime example of this is when an Orphan Medicinal Product (OMP) comes under
consideration. (Dear et al., 2006) Due to the nature of an OMP the cut-oﬀ points
would not be practical so each case has to be judged on its own merits. There is
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be accepted. Money used to fund OMPs to treat a few patients could be used to
treat a large number of patients suﬀering from a more common form of illness.
Whether money should be used to treat the few instead of the many is one of the
balancing acts that bodies such as the SMC and NICE face.
7.4 Sensitivity Analysis
In health economics and economics in general sensitivity analysis is a useful device
as costs of goods and services will not remain constant over time. An example
would be when a drug goes oﬀ patent. When oﬀ patent the manufacturing of a
drug is no longer restricted solely to the company that actually devised it. Other
pharmaceutical companies are free to produce generic copies of the drug usually
at a fraction of the price of the original. Additionally, any parameters that are
used in a model will have uncertainty surrounding their values. For example it is
unknown whether the results of a clinical trial will be transferable to day-to-day
clinical practice and whether utility values that are speciﬁed by a small number
of doctors are actually valid. Changes in any of these parameters could aﬀect the
ﬁndings of an economic evaluation. If changing costs and parameter estimates
can be incorporated into a cost-eﬀectiveness analysis they can be used to judge
how the cost-eﬀectiveness of a treatment will change over time.
When a sensitivity analysis is carried out the cost of one resource use is altered
by a ﬁxed quantity for each separate analysis. This type of analysis is an example
of a univariate sensitivity analysis. Usually when a univariate sensitivity analysis
is being carried out the cost of a number of resource uses can be altered. This
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of the individual univariate sensitivity analyses can then be presented together in
a tornado diagram. (Howard, 1988) The tornado diagram allows the investigator
to easily identify the resource uses that have the largest inﬂuence on the cost-
eﬀectiveness of the treatment.
However, no consideration is given to the distribution of the cost values that
are being altered in a univariate sensitivity analysis and the level of increase or
decrease in costs is arbitrarily set by the investigator. In some cases a number
of quantities are altered by ﬁxed levels and this is then a multi-way sensitivity
analysis. Both univariate and multi-way sensitivity analysis have limitations in
that only one or a small number of quantities can be altered at a time and
only by a ﬁxed level. As the number of quantities that are altered increases
the interpretation of the results can become complicated and the analysis itself
is computationally time consuming. (Claxton et al., 2005) These issues can be
overcome by using Probabilistic Sensitivity Analysis (PSA).
7.4.1 Probabilistic Sensitivity Analysis
Probabilistic Sensitivity Analysis is an alternative to deterministic sensitivity
analysis. Instead of the parameters within the cost-eﬀectiveness model being
altered individually by ﬁxed amounts, full distributions for the parameters are
speciﬁed. There are a large number of distributions that can be used but in
most cases the choice of which to use will be governed by the parameter itself
and what it is measuring. Once the distributions for the model parameters have
been decided upon the parameters for the distributions themselves have to be
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the clinical trial. Alternatively the probability distributions could be generated by
bootstrap sampling. (Pasta et al., 1999) A Bayesian approach can also be taken
to specifying the distributions so that prior beliefs of clinicians and economists
can be reﬂected in the analysis. It is not always possible or sensible to specify
whole distributions for some parameters such as drug costs, as these are ﬁxed and
unlikely to change in the short term. With the choice of probability distributions
having been made, Monte Carlo simulation can be used to investigate how altering
the diﬀerent parameters simultaneously impacts on the cost-eﬀectiveness of the
treatment. (Briggs et al., 2002b) In addition this will also allow any uncertainties
in other variables, including the costs of services or assigned utility values, to be
reﬂected in the analysis. The results of the PSA can then be presented by the
means of a Cost-Eﬀectiveness Acceptability Curve (CEAC).
7.4.2 Cost-Eﬀectiveness Acceptability Curves
The concept of the Cost-Eﬀectiveness Acceptability Curve was ﬁrst proposed as
a possible alternative to calculating conﬁdence intervals for ICERs as a method
of assessing the uncertainty surrounding them. (van Hout et al., 1994) The in-
terpretation of CIs for ICERs can be problematic. In the calculations of CEACs
the costs and eﬀects per patient are considered to be outcomes from random
variables. (O’Brien et al., 1994) Using the same notation as in Section 8.3.3 the
cost-eﬀectiveness plane, labelled as the ∆C/∆E plane, is a graphical representa-
tion of the joint probability density of ∆C and ∆E. Of interest is the probability
that the cost-eﬀectiveness ratio, C/E-ratio, is above or below R, where R is a
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terms of cost-eﬀectiveness. Above R and the treatment would not be recom-
mended on the grounds of cost-eﬀectiveness and below R it would be. The value
of R is the altered. The relationship between R and the C/E-ratio is deﬁned
by a ‘C/E-acceptability curve’. The probability that a treatment will be cost-
eﬀective over a range of values of R can then be seen by looking at the curve:
the higher the probability for that value of R the more likely that the treatment
will be accepted as being cost-eﬀective. A CEAC is shown in Figure 7.2. This is
Figure 7.2: An example of a Cost-Eﬀectiveness Acceptability Curve
only an illustrative example and does not imply that all CEACs are of this form.
(Fenwick et al., 2004) The structure of CEACs depend on which quadrants of the
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cuts the y-axis is the point where the WTP for the increased eﬀectiveness of one
treatment over another treatment is zero, the intercept does not automatically
occur at the origin. The use of PSA is becoming more widespread in economic
evaluations and NICE recently recommended that PSA should be included in
submissions to them. (NICE, 2004) Sensitivity analysis is an aid to let health
economists see how changing costs will aﬀect the cost-eﬀectiveness of treatments
in the future.Chapter 8
Health Economics of the IONA
Study
In addition to the clinical beneﬁts of nicorandil the economic implications of
implementing treatment with nicorandil into clinical practice were of great in-
terest when the IONA Study was devised. In this Chapter the rationale behind
the economic evaluation will be described. Following on from this the economic
evaluation will be expanded upon.
8.1 The Economic Evaluation of the IONA Study
From Section 7.1 it can be seen that there are a number of diﬀerent types of
economic evaluations that can be undertaken. As an active treatment, nicorandil,
and a placebo were being compared a CMA could not be undertaken. There
was one clear clinical outcome, the number of primary endpoints suﬀered, so the
advantages of using a CCA would not be fully utilised. In a CBA monetary values
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would have had to be assigned to preventing death due to CHD, non-fatal MIs
and unplanned hospital admissions for cardiac chest pain. This would have been
possible but due to the diﬀerent natures of the component parts of the primary
endpoint and the diﬀering severities of non-fatal MIs and unplanned hospital
admissions for cardiac chest pain that occurred as well as the diﬃculties of having
to assigning monetary values to clinical outcomes a CBA was not performed.
A CEA or a CUA could have been carried out but as there were no utility
values, speciﬁcally QALYs, readily available a CEA was used. A literature review
or a meta-analysis could have been carried out to assign utility values to the
component parts of the primary endpoint so that a CUA could have been carried
out but this was not attempted by Walker et al. (2006). Using a CEA the net cost
per primary endpoint prevented by treatment with nicorandil was calculated and
used as the basis for the analysis, with the results being expressed in the form of
an ICER.
8.2 Costs Associated with the IONA Study
The costs for the nicorandil and placebo groups had a number of constituent parts,
which were: the cost of nicorandil, the cost of cardiovascular and cerebrovascular
hospitalisations and the cost of hospital admissions due to adverse events. Costs
that were thought to be similar for both treatment groups, such as the cost
of background cardiovascular medications patients were being prescribed, would
have minimal impact on the cost-eﬀectiveness calculation so were not included.
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8.2.1 The Cost of Nicorandil
There were two parts that made up the cost of nicorandil, the cost of the actual
nicorandil tablets themselves and the cost of dispensing them and the adminis-
tration that went along with that. The cost of one 10 mg tablet of nicorandil was
13.6 pence and the cost of one 20 mg tablet was 25.9 pence. To the cost of each
prescription a 10% dispensing fee was added. For the initiation of treatment and
the up-titration of nicorandil the cost of two GP visits were included for each
patient. The cost per GP visit was £19. The costs associated with nicorandil
are shown in Table 8.1. The total cost of nicorandil for each patient was then
calculated as the number of 10 mg and 20 mg packs of nicorandil they received
plus the cost of the starter pack and the accompanying administration costs.
Table 8.1: The cost of nicorandil
Cost
Initial starter pack £28.12
10 mg pack £27.23
20 mg pack £51.85
GP visit £19.00
8.2.2 The Cost of Hospitalisations
There were two types of hospital admissions considered, ﬁrstly those for cardio-
vascular and cerebrovascular reasons and secondly those due to serious adverse
events related to treatment with nicorandil. The GI hospital admissions were
considered such events by the study investigators. For the cardiovascular and
cerebrovascular admissions there were a number of diﬀerent types of hospital
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with them. (Netten et al., 2001; Information and Statistics Divison, NHS Scot-
land, 2002) In the IONA Study patients were recruited from throughout the UK.
As a result UK costs were used in the analysis. The costs for the diﬀerent types
of ward are shown in Table 8.2. As the hospitalisation records did not distinguish
between whether patients had been admitted to intensive care or coronary care
units an average of the two costs was used. Patients who were admitted for GI
problems were either admitted to an intensive care unit or a general medical ward.
For each hospitalisation the costs of two hospital outpatient and two GP visits
were also included as follow-up costs after discharge. As records of the number
of hospital outpatient and GP visits that patients attended were not recorded
the number and resulting costs of these visits were arbitrarily included by Walker
et al. (2006) for each hospitalisation patients suﬀered. These costs are for the
year ending 31st March 2002.
Table 8.2: Hospital bed-day costs
Type of Hospital Bed Cost
General medical ward £242
Specialist cardiology £429
Cardiac surgery ward £666
Intensive care unit £1,323
Coronary care unit £610




Hospital outpatient visit £72
GP visit £19
In order to calculate the total hospital costs for both the nicorandil and
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took part in the study was recorded and this information is shown in Table 8.3.
The details of ward admissions and the speciﬁc reasons why patients were ad-
mitted to hospital are known but not shown here, see Walker et al. (2006). The
hospitalisation costs were then calculated as the number of days each patient
spent in the diﬀerent types of hospital ward multiplied by the bed-day cost of
that particular ward. The costs of any procedures or surgical operations that
were performed during the hospitalisations were not considered.
Table 8.3: Numbers of admissions to hospital and number of days spent in
hospital by patients
Nicorandil (n = 2,565) Placebo (n = 2,561)
Cardiovascular and Cerebrovascular Admissions
Number of patients hospitalised 609 683
Number of hospital admissions 968 1,132
Days spent in hopsital 5,230 6,154
Gastrointestinal Admissions
Number of patients hospitalised 157 108
Number of hospital admissions 186 129
Days spent in hopsital 934 571
8.2.3 Total Costs for the IONA Study
In the paper by Walker et al. (2006) the results of a primary and secondary anal-
ysis were both reported and when the separate ICERs were calculated diﬀerent
total costs for the two treatment groups were used. During the study when pa-
tients suﬀered GI events and resultant hospitalisations the investigator recorded
whether they thought the study treatment had caused the GI event. Whether
the study investigator thought that the study treatment had caused the GI event






In the total costs for the primary analysis only the cost of GI hospitalisations di-
rectly attributed to the study treatment that patients were receiving by the study
investigator were included. This corresponded to the GI events that had their
cause coded as certainly, probably and possibly related to the study treatment
patients were receiving. Additionally all the aftercare costs, no matter the reason
for the hospitalisation, were not included in the total costs used in the primary
analysis. In other studies it has been shown that although aftercare costs will be
diﬀerent between treatment groups, the total costs and the diﬀerence between the
costs of the two treatment groups will likely be small in comparison between the
actual hospitalisation costs themselves. (UK Prospective Diabetes Study Group,
1998) The main costs attributed to both treatment groups were due to hospital-
isation of patients. Using the information contained in Tables 8.1, 8.2 and 8.3
the total costs for both the nicorandil and placebo groups, that were used in the
primary analysis, can be calculated and these are shown in Table 8.4.
In the secondary analysis the costs of all the GI hospitalisations that patients
suﬀered during the study and not just those attributed to the study medication
by the study investigator were included in the total costs. The cost of two follow-
up hospital outpatient and two GP visits were also included. Again using theCHAPTER 8. HEALTH ECONOMICS OF THE IONA STUDY 164
Table 8.4: Costs associated with the IONA Study - Primary analysis





Gastrointestinal admissions 44,286 15,843
Total Cost £3,672,261 £3,672,576
information contained in Tables 8.1, 8.2 and 8.3 the total costs for both the
nicorandil and placebo groups, that were used in the secondary analysis, can be
calculated and these are shown in Table 8.5.
Table 8.5: Costs associated with the IONA Study - Secondary analysis








Gastrointestinal admissions 236,838 153,316
Gastrointestinal follow-up 32,578 22,932
Total Cost £4,065,559 £4,030,997
8.3 The Cost-Eﬀectiveness Analysis of the IONA
Study
Having all the cost information available, see Tables 8.4 and 8.5, and knowing
the number of ﬁrst primary endpoints that occurred in both groups, 337 (13.1%)
in the nicorandil group and 398 (15.5%) in the placebo group, see Table 2.5, theCHAPTER 8. HEALTH ECONOMICS OF THE IONA STUDY 165
CEA was then carried out and the ICERs for both the primary and secondary
analysis were calculated. In both the primary and secondary analyses only the
ﬁrst primary endpoints patients suﬀered were considered. In the case of the
IONA Study the diﬀerence in beneﬁts was measured in terms of an undesirable
event, namely the diﬀerence in the number of primary endpoints that patients
in the nicorandil and placebo groups suﬀered. As a result the total number of
primary endpoints suﬀered were assigned negative values, with the higher the
value numerically the more favourable it was. Of interest was the net cost per
primary endpoint prevented that treatment with nicorandil caused.
8.3.1 ICER Calculations
The calculation of the ICER for the primary economic analysis of the IONA
Study is shown in Equation 8.1. It can be seen that the Primary IONA ICER was
equal to -£5, implying that for every primary endpoint treatment with nicorandil
prevented it resulted in a net cost saving of £5. Here the cost saving in terms of
reducing the number of hospitalisations more than oﬀsets the cost of nicorandil.
This was a very favourable ﬁnding for nicorandil in terms of cost-eﬀectiveness.
Primary IONA ICER =
Diﬀerence in costs between the two groups
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The calculation of the ICER for the secondary economic analysis of the IONA
Study was equivalent to the calculation of the Primary IONA ICER. The calcu-
lation of the ICER is shown in Equation 8.2.




The Secondary IONA ICER was equal to £567. The net cost of treatment with
nicorandil was £567 for every primary endpoint prevented. As there was a higher
GI event rate for patients treated with nicorandil when the secondary analysis was
carried out, which included the costs of all the GI hospitalisations that patients
suﬀered as well as the costs of follow-up care, treatment with nicorandil no longer
resulted in a net cost saving per primary endpoint prevented. However, the overall
cost-eﬀectiveness of nicorandil still remained good.
8.3.2 ICER Interpretation
From Equations 8.1 and 8.2 it can be seen that the net cost of nicorandil prevent-
ing one primary endpoint in the IONA Study was -£5 for the primary analysis
and £567 for the secondary analysis. When compared to other new treatments
that were evaluated in a similar fashion these ﬁgure are very favourable. (Meads
et al., 2000; McDonagh et al., 2000; Robinson et al., 2002) The net saving of
£5 for every CHD event that treatment with nicorandil prevented was clearly
very good but even the ﬁgure of £567 seems a small price to pay for preventing a
CHD event. However, other facts have to be considered. Firstly, the IONA Study
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a result the reduction in risk of suﬀering events that nicorandil caused was mag-
niﬁed and any comparison to the population as a whole cannot be made directly.
Allowances for the reduced risk in the general population have to be inferred.
This may well reduce the overall cost-eﬀectiveness of treatment with nicorandil
in the population treated in routine cardiology clinics. It could therefore be said
that the external validity, or generalisability, of the results may well be poor.
Secondly, as the data comes from a clinical trial the follow-up of patients was for
a ﬁnite time and it was therefore unknown what would happen to these patients
in the future and how this may eﬀect the cost-eﬀectiveness of nicorandil. This is
true for the vast majority of economic evaluations that are derived from clinical
trials. Any modelling of costs and outcomes beyond the end of a clinical trial
can be problematic (Raftery, 1999) and was not attempted in this case as it was
felt that the economic evaluation of the IONA Study had already achieved its
objectives of showing treatment with nicorandil to be cost-eﬀective. Thirdly, due
to the composite nature of the primary endpoint of the IONA Study the interpre-
tation of both ICERs may be awkward in that one event prevented could be CHD
death whereas another could be an unplanned admission to hospital for cardiac
chest pain. To prevent a death as opposed to an unplanned admission to hospital
would be of more beneﬁt but this diﬀerence was not taken into consideration.
The recording of whether the GI events patients suﬀered was due to the study
treatment they were receiving was subjectively done by the study investigator and
the reliability of this assignment cannot be guaranteed. It was therefore thought
more appropriate to include the costs of all the GI events in the CEA. After
each hospitalisation patients suﬀered they will have likely received some form of
after care. The follow-up care each patient received would likely depend on theCHAPTER 8. HEALTH ECONOMICS OF THE IONA STUDY 168
reason for the hospitalisation and vary between individual patients. The precise
care that patients did receive was not known. Applying an arbitrary ﬁxed cost
for the follow-up care received after each hospitalisation patients experienced
seems the most appropriate method of reﬂecting the cost of follow-up care in the
CEA. As a result the ICER for the secondary analysis was more conservative
than for the primary analysis, implying it may be more useful in gauging the
true cost-eﬀectiveness of treatment with nicorandil. The costs associated with
the secondary analysis ICER will therefore be used as the basis for extending the
economic evaluation.
In the primary and secondary IONA ICERs calculated in Section 8.3.1 only
the ﬁrst primary endpoints patients suﬀered were included in the calculations.
In total patients in the nicorandil group suﬀered 467 primary endpoints and
in the placebo group patients suﬀered 604 primary endpoints, see Table 5.1.
Treatment with nicorandil prevented an additional 76 events when all the CHD
events patients suﬀered were considered. The resultant decrease in hospitalisation
costs were most likely already factored into the analysis as all the hospitalisations
cost for cardiovascular and cerebrovascular reasons were included in the costs used
in the calculations of the ICERs. If the risk of recurrent CHD events and not just
ﬁrst events were reduced by treatment with nicorandil, as shown in Section 5.3.1,
this would then have further implications on the cost-eﬀectiveness, with treatment
with nicorandil likely to be even more cost-eﬀective. If the recurrent CHD events
were included in the calculation of the Secondary IONA ICER then the net
cost of treatment with nicorandil became £252 per CHD prevented, as shown in
Equation 8.3. Compared to the Secondary IONA ICER, shown in Equation 8.2,CHAPTER 8. HEALTH ECONOMICS OF THE IONA STUDY 169
the cost of preventing a CHD event was more than halved.




It is still important to remember that the patients who were enrolled in the IONA
Study were at a higher risk of suﬀering CHD events than the general patient
population of CHD suﬀerers. This will have an aﬀect on the cost-eﬀectiveness of
nicorandil. The cost-eﬀectiveness will likely be reduced but as it was favourable
at a net cost of £252 per CHD event prevented that even with a decrease in
the cost-eﬀectiveness nicorandil would still remain cost-eﬀective to use in the
treatment of patients with CHD.
8.3.3 Estimation of 95% Conﬁdence Intervals for the ICERs
The ICERs calculated for both the primary and secondary CEA were informative
but they were only point-estimates and the uncertainty surrounding them was
unknown. To help ascertain the uncertainty 95% conﬁdence intervals will be
estimated. This was done by two diﬀerent methods, one parametric and one
non-parametric method. (Briggs et al., 2002a) Firstly, a parametric method was
used and this involved using Fieller’s Theorem (Fieller, 1954) to calculate the
limits for the CI. The assumption that the diﬀerence in eﬀects and costs between
treatment groups follows a joint Normal distribution was made. Fieller’s Theorem
was used as the CIs were being estimated for a ratio. The limits for the CI wereCHAPTER 8. HEALTH ECONOMICS OF THE IONA STUDY 170











where E represents the eﬀects of the treatments and C represents the costs of the











α/2var(∆C)] = 0 (8.5)
where R = ∆C/∆E.
Secondly, a non-parametric method was used and this was by means of boot-
strap sampling. (Efron and Tibshirani, 1993) The percentile bootstrap method
was used to estimate the limits of the CI. Patients were sampled with replacement
from the treatment groups, 2,565 patients from the nicorandil group and 2,561
patients from the placebo group in each sample, and the ICER for this sample of
patients was then calculated. The bootstrap sampling procedure was run 10,000
times and the samples were then ranked according to the calculated ICER value.
The lower limit of the 95% CI was taken as the 251st ICER value and the upper
limit as the 9,750th ICER value in the ranking. Both methods for estimating CIs
were used to produce 95% CIs for both the primary and secondary ICERs of the
IONA Study. The intervals along with the point estimates for the ICERs are
shown in Table 8.6.
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Table 8.6: The estimated 95% CIs for the primary and secondary ICERs of
the IONA Study
Economic ICER Point Method of Estimating the 95% Conﬁdence Intervals
Analysis Estimate (£) Fieller’s Theorem (£) Bootstrap Sampling (£)
Primary -5 -11,116 – 30,736 -11,822 – 25,210
Secondary 567 -10,507 – 34,491 -11,071 – 29,746
Adjusted Analyses to Included the Recurrent Events Patients Suﬀered
Primary -2 -4,419 – 6,747 -4,546 – 9,190
Secondary 252 -4,290 – 7,372 -4,288 – 10,891
method gave narrower intervals for both analyses. In the published NICE guide-
lines (NICE, 2004) it states that that above an ICER value of £30,000/QALY
there has to be very strong evidence to support recommendation of a treatment
for use. In the IONA Study QALYs were not used but instead the cost per CHD
prevented was considered. Using Fieller’s Theorem the estimated upper limit of
the 95% CI for the primary analysis was marginally above the £30,000 threshold
and for the secondary analysis the upper limit was £34,491. Even taking this
into consideration the cost-eﬀectiveness of treatment with nicorandil was still
favourable. For the bootstrap sampling intervals both the upper limits of the
CIs were below the £30,000 threshold. Both sets of intervals for the primary and
secondary analyses are illustrated in Figure 8.1.
Also shown in Table 8.6 are the ICERs and estimated 95% CIs for both the
adjusted primary and secondary economic analyses. In the adjusted analysis the
recurrent events that patients suﬀered were considered and not just the ﬁrst CHD
events. As when the recurrent events were considered treatment with nicorandil
prevented more CHD events than treatment with placebo the diﬀerence in theCHAPTER 8. HEALTH ECONOMICS OF THE IONA STUDY 172
Figure 8.1: Graphical representation of the estimated 95% CIs for the pri-
mary and secondary ICERs of the IONA Study
eﬀectiveness of the two treatments was greater. The estimated 95% CIs were nar-
rower as a result. The cost-eﬀectiveness of treatment with nicorandil was shown
to be favourable for both analyses and by both methods used to estimate the 95%
CIs. The problem of interpretation of negative ICERs discussed in Section 7.2
is illustrated by comparing the original primary analysis with the adjusted pri-
mary analysis. The ICER for the primary analysis showed that for every CHD
prevented there was a net cost saving of £5. In the adjusted primary analysis,
in which the treatment eﬀect was larger, the net cost saving per CHD prevented
was £2. If the actual values used in the calculation of the ICER are consideredCHAPTER 8. HEALTH ECONOMICS OF THE IONA STUDY 173
Figure 8.2: Graphical representation of the estimated 95% conﬁdence inter-
vals for the adjusted primary and secondary ICERs of the IONA
Study
the adjusted primary analysis should indicate treatment with nicorandil to be
more cost-eﬀective but due to the diﬀerence in costs being negative this is not
the case. The adjusted ICERs along with the estimated 95% CIs are illustrated
graphically in Figure 8.2.
In the IONA Study there was a signiﬁcant diﬀerence in the eﬀectiveness of
treatment with nicorandil over treatment with placebo implying that the denom-
inator used in the calculation of the primary and secondary ICERs in Equa-
tions 8.1 and 8.2 was strictly greater than zero. When this is not the situation
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to estimate a CI using Fieller’s Theorem a quadratic equation has to be solved,
Equation 8.5, and doing this gives the roots shown in Equation 8.4. For the roots
there are three situations that can occur and these are given in the paper by
O’Hagan et al. (2000):
1. The solution may be a proper ﬁnite interval, of the form [a,b].
2. The solution may be the complement of an interval, and so con-
sist of 2 distinct inﬁnite intervals of the form (-∞,a] ∪ [b,∞).
3. The solution may be the whole line (-∞,∞).
In certain situations the estimates of the CIs are inﬁnite or only exclude a small
interval of values. (Heitjan et al., 1999) Using such intervals for inference can
therefore be problematic. The beneﬁt of using a parametric method, which will
be more powerful if the assumption of a joint Normal distribution is valid, over
a non-parametric method like bootstrap sampling will be lost. When there is a
signiﬁcant diﬀerence in the eﬀects of the treatments the use of Fieller’s Theorem is
favoured over bootstrap sampling as it will give the same results each time unlike
the bootstrap where random sampling is used and the results generated will alter
each time. (Briggs et al., 2002a) The computation required to implement Fieller’s
Theorem is also signiﬁcantly less than that required to implement bootstrap
sampling. (Severens et al., 1999) In Sections 8.5 and 8.7 where the data set will
be split according to the risk of patients suﬀering CHD events and then the risk
of suﬀering GI and CHD events the sample sizes in each group will be reduced
and in most cases there will be a non-signiﬁcant diﬀerence in the eﬀectiveness of
treatment with nicorandil over treatment with placebo. Here the use of bootstrap
sampling to estimate the 95% CIs for the ICERs will be favoured.CHAPTER 8. HEALTH ECONOMICS OF THE IONA STUDY 175
8.4 Sensitivity Analysis of the IONA Study
In the paper of the economic evaluation of IONA Study by Walker et al. (2006)
sensitivity analysis was carried out on the result of the primary economic analysis.
The sensitivity analysis that was carried out was univariate sensitivity analysis
and this was done by ﬁrstly increasing the costs of angioplasty due to the increased
use of stents by three diﬀerent monetary values, £100, £200 and £500, and
secondly by increasing and decreasing the costs of hospital bed-days by 20%.
When the sensitivity to the costs of hospital bed-days was being investigated
the costs were inﬂated and deﬂated separately for three of the types of hospital
wards that patients were admitted to. The three types of ward that had their
cost altered were specialist cardiology, cardiac surgery and the intensive care unit
and coronary care unit combined group.
From the results of the sensitivity analysis undertaken by Walker et al. (2006),
shown in Table 8.7, it was seen that by increasing the cost of an angioplasty
procedure, due to the increased use of stents, only altered the cost-eﬀectiveness
of nicorandil marginally. The reported reason behind this was the fact that the
number of angioplasties that were carried out during the study were similar in the
two treatment groups with there only being a diﬀerence of eighteen between the
groups, 98 (3.8%) in the nicorandil group and 116 (4.5%) in the placebo group.
The changing of the costs of hospital bed-days had a larger eﬀect on the cost-
eﬀectiveness of nicorandil than the increasing costs of angioplasty procedures.
The results were least sensitive to changes in the cost of bed-days on specialist
cardiology wards followed by the combined intensive care unit and coronary care
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surgery wards. Even with the changes in the costs of goods and services within
the sensitivity analyses the overall cost-eﬀectiveness of treatment with nicorandil
remained favourable.
Table 8.7: Results of the sensitivity analysis performed on the primary cost-
eﬀective analysis of the IONA Study
ICER Value (£)
Primary Analysis -5
Increase angioplasty cost by £100 -35
Increase angioplasty cost by £200 -64
Increase angioplasty cost by £500 -153
Reduce specialist cardiology bed day cost by 20% 342
Increase specialist cardiology bed day cost by 20% -353
Reduce cardiac surgery bed day cost by 20% 1,051
Increase cardiac surgery bed day cost by 20% -1,061
Reduce intensive/coronary care unit bed day cost by 20% 606
Increase intensive/coronary care unit bed day cost by 20% -617
If the sensitivity analysis that was performed on the results of the economic
evaluation of the IONA Study was to be further expanded from the simple uni-
variate sensitivity analyses that were carried out then a multi-way sensitivity
analysis could have been performed. If a multi-way sensitivity analysis was to be
performed, using the univariate sensitivity analysis that was carried by Walker
et al. (2006) as an example, then the costs of angioplasty procedures and hospital
bed-days would be altered simultaneously in one analysis as opposed to individu-
ally in separate analyses, as was the case when the univariate sensitivity analysis
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8.5 Coronary Heart Disease Risk Levels
The net cost of nicorandil per primary endpoint prevented, as shown by Equa-
tions 8.1 and 8.2, indicates that nicorandil was cost-eﬀective when treating the
patient population of the IONA Study as a whole. Even taking into consid-
eration the likely smaller reduction in risk of suﬀering a CHD event that the
general population would experience treatment with nicorandil would still ap-
pear to be cost-eﬀective. In other circumstances and with other treatments the
cost-eﬀectiveness will not be so clear cut. If the risk of patients suﬀering events
could be calculated the patient population could then be split into diﬀerent levels
of risk. Treating only those patients in the higher risk sub-groups of the popula-
tion may improve the cost-eﬀectiveness of a treatment. The key factor to consider
is how the risk of suﬀering events should be calculated and then using this risk
how the population should be split into sub-groups. Using the IONA Study data
it was investigated whether treating only the higher risk patients would improve
the cost-eﬀectiveness of treatment with nicorandil. (Henderson et al., 2005)
Firstly, any such potential sub-groups of the population had to be identiﬁed.
In order to do this the risk of a patient suﬀering a CHD event had to be calculated
and this was done using the multivariable predictive model found for the primary
endpoint in Section 3.4.1. It should be noted that the multivariable predictive
model consisted of variables recorded on patients at baseline. Let RCHD equal the
risk of a patient suﬀering a CHD event. Then RCHD was calculated as follows:
RCHD = exp(xiˆ β) (8.6)
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number of variables included in the multivariable predictive model, and ˆ β is the
p × 1 vector of parameter estimates found from the Cox model for the primary
endpoint.
It was of interest to identify sub-groups of the patient population in which the
cost-eﬀectiveness of treatment with nicorandil would be improved. As a result
when the risk of patients suﬀering CHD events was calculated all patients were
treated as if they were in the placebo group of the study. In addition 67 patients,
41 (1.6%) in the nicorandil group and 26 (1.0%) in the placebo group, could not
have their risk of suﬀering a CHD event calculated due to these patients having
missing values for one or more of the baseline variables used to calculate RCHD.
For the remaining 5,059, using Equation 8.6, the risk of them suﬀering a CHD
event was then calculated. The patients were ranked according to their calculated
risk. According to this ranking the patients were then split into three groups of
approximately equal size: low, medium and high risk of suﬀering a CHD event.
It should be noted that patients who were recruited to the IONA Study were at
a high risk of suﬀering CHD events. Therefore, all three risk groups, including
the group deﬁned as the low risk group, would have a higher underlying risk of
suﬀering a CHD event than the general population. As a result when the risk
groups are being referred to it is in the context of the IONA Study and not the
general population. The grouping of patients into these three groups was based
solely on the ranking of their risk and did not take into account which treatment
group the patients were in. As a result the balance in numbers of patients between
the treatment groups due to randomisation was lost. This resulted in imbalances
of patient numbers between the treatment groups for the three levels of CHD
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risk groups using the total number of events suﬀered and the total costs for the
groups would likely have be misleading due to the random imbalances in patient
numbers between the treatment groups. This would have resulted in an inequality
between the number of patients who were at risk of suﬀering a CHD event and
more particularly in the total costs for the nicorandil and placebo groups within
the three risk groups. Shown in Table 8.8 are the proportion of patients who
suﬀered a ﬁrst CHD event and the mean cost per patients for the nicorandil and
placebo groups separately for the three levels of risk. As indicated in Section 8.3.2
the total costs used were the ones used in the secondary analysis.
Table 8.8: The proportion of patients who suﬀered a primary endpoint and
the mean cost per patient in the nicorandil and placebo groups
for the three levels of CHD risk
Low CHD Risk Group Nicorandil (n = 821) Placebo (n = 866)
Proportion of patients
who suﬀered a CHD event
0.07186 0.09238
Mean cost per patient (£) 1,161 1,094
Medium CHD Risk Group Nicorandil (n = 852) Placebo (n = 834)
Proportion of patients
who suﬀered a CHD event
0.1069 0.1389
Mean cost per patient (£) 1,367 1,415
High CHD Risk Group Nicorandil (n = 852) Placebo (n = 834)
Proportion of patients
who suﬀered a CHD event
0.2136 0.2386
Mean cost per patient (£) 2,186 2,233
As expected, starting from the low risk group and moving through the medium
risk group to ﬁnally the high risk group the proportion of patients who suﬀered
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CHD risk the following modiﬁed version of Equation 7.1 was used:
ICER =
Diﬀerence in Proportion of Patients who Suﬀered a CHD Event
Diﬀerence in Mean Cost per Patient Between the Treatment Groups
(8.7)
The ICERs for three levels of CHD risk as well as for the overall IONA Study,
the secondary analysis, with accompanying estimated 95% CIs can be seen in
Table 8.9.
Table 8.9: The cost per CHD event prevented for the three levels of CHD
risk as well as for the overall IONA Study with accompanying
estimated 95% CIs
Level of ICER Point Method of Estimating the 95% Conﬁdence Intervals
CHD Risk Estimate (£) Fieller’s Theorem (£) Bootstrap Sampling (£)
Overall 567 -10,507 – 34,491 -11,071 – 29,746
Low 3,255 -∞ – ∞ -73,622 – 81,960
Medium -1,497 -20,056 – 219,461 -22,111 – 34,488
High -1,885 -∞ – ∞ -88,195 – 77,403
The ICER for the low CHD risk patients was £3,255, higher than the ICER
for the overall data set. Treatment with nicorandil would still reduce the risk of
patients in the low risk group from suﬀering CHD events but not as cost-eﬀectively
as treating only those higher risk patients. Both the ICERs for the medium and
high risk groups had negative values at -£1,497 and -£1,885 indicating for these
two groups treatment with nicorandil resulted in a net cost saving per CHD event
prevented. The cost of nicorandil was more than oﬀ-set by the reduction in the
number of CHD events and resultant hospitalisation costs that these events would
have caused. The ICER for the high risk CHD group was numerically lower than
for the medium risk CHD group but only marginally.CHAPTER 8. HEALTH ECONOMICS OF THE IONA STUDY 181
Looking at the 95% CIs it can be seen that using Fieller’s Theorem the in-
tervals for the low and high CHD risk groups were the entire real line. This
means that there were no real roots to the solution of Equation 8.5 and that
there was no signiﬁcant diﬀerence in the eﬀectiveness of treatment with nico-
randil over treatment with placebo. For the medium CHD risk group there were
real roots for Equation 8.5 and there was a signiﬁcant diﬀerence in the eﬀective-
ness of treatment with nicorandil over treatment with placebo. This diﬀerence
in eﬀectiveness was only marginal and that resulted in the 95% CI estimated by
Fieller’s Theorem being so wide. The data set was split up and as a result was not
powered to show a signiﬁcant diﬀerence between the treatments in the three lev-
els of CHD risk so these results were not unexpected hence why in this situation
the use of bootstrap sampling over Fieller’s Theorem is recommend. The ICERs
with estimated 95% CIs, found by bootstrap sampling, are illustrated graphically
in Figure 8.3. The bootstrap sampling intervals for the low and high CHD risk
groups were wide so no meaningful inference can be made. The signiﬁcance dif-
ference in the eﬀectiveness of the treatment for the medium CHD risk group was
reﬂected in that the estimated 95% CI was much narrower than for either the low
or high CHD risk group. Comparing the medium CHD risk interval to that for
the overall data set indicated that treating only patients who were at a medium
risk of suﬀering a CHD event would improve the cost-eﬀectiveness of nicorandil.
Implying the same would be true for only treating those patients who were at a
high risk of suﬀering a CHD. It is likely that treating the medium and high CHD
risk groups with nicorandil would result in a net cost saving to the NHS.
In the case of nicorandil and the IONA Study the level of CHD risk for patients
was calculated using the model for the primary endpoint found in Section 3.4.1CHAPTER 8. HEALTH ECONOMICS OF THE IONA STUDY 182
Figure 8.3: The cost per CHD event prevented for the three levels of CHD
risk as well as for the overall IONA Study with accompanying
95% CIs estimated by bootstrap sampling
and Equation 8.6. If this model was to be used on the general population of
cardiovascular patients it may need to be revised as at present it is only based
on a sub-set of the population, namely the patients who took part in the IONA
Study, and it may not accurately model the general population. In order to make
the risk model more generalisable instead of using Equation 8.6 to calculate the
risk of patients suﬀering CHD events an externally validated CHD risk model
could have been used. One such example would have been to use Framingham
risk equations (Anderson et al., 1991; D’Agostino et al., 2000) to calculate the
risk of patients suﬀering CHD events. However, there is some evidence that CHDCHAPTER 8. HEALTH ECONOMICS OF THE IONA STUDY 183
risk estimation methods derived from the Framingham Study overestimate the
risk for patients from the UK. (Brindle et al., 2003) Therefore, using a CHD
risk equation derived from European data may be more appropriate, such as the
Systematic Coronary Risk Evaluation (SCORE) risk model. (Conroy et al., 2003)
If the procedure of ranking patients by their risk of suﬀering events was to
be used with other treatments, for diﬀerent health conditions, then risk models
would have to be produced for each diﬀerent condition. In all cases over time
the validity of the models would need to be checked and possibly updated and
modiﬁed. This could be due, for example, to changes in the patient population
or modiﬁed prescribing recommendations. Using nicorandil as an example if the
prescribing recommendations for antianginal drugs for patients with stable angina
were altered, since whether not a patient was being treated with a long acting
nitrate or a loop diuretic were both variables used in the calculation of RCHD,
the risk model would need to be checked to see if it was still valid.
This type of procedure identifying high risk groups of patients would be most
applicable where a treatment was known to be eﬀective but the cost-eﬀectiveness
of using it to treat the entire patient population was above the £30,000/QALY
threshold. If those patients who are at a higher risk of suﬀering events could be
identiﬁed using a risk model, then treatment could be targeted at those patients
who would most beneﬁt from it due to their high risk of suﬀering an event. In
this sub-group of the patient population the cost-eﬀectiveness of the treatment
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8.6 The Most Cost-Eﬀective Patients to Treat
Other methods for targeting treatments to the most cost-eﬀective sub-group of
patients have been developed and implemented on data from clinical trials. One
of these methods was demonstrated in the paper by J¨ onsson et al. (1999), which
is based on the Scandinavian Simvastatin Survival Study (4S). (Scandinavian
Simvastatin Survival Study Group, 1994) The patients who were randomised in
4S were all pre-existing suﬀerers of CHD disease. The method entailed investi-
gating the cost-eﬀectiveness of a sub-group of patients based on one particular
clinical characteristic, in the paper by J¨ onsson et al. (1999) this characteristic
was whether patients were diabetic. The cost-eﬀectiveness of simvastatin, the
cholesterol lowering drug investigated in 4S, was then investigated for patients
who were diabetic and then compared against the non-diabetic patients. The
cost-eﬀectiveness of simvastatin for diabetic patients was improved compared to
non-diabetic patients but as was the case in the IONA Study with nicorandil it
was cost-eﬀective to prescribe simvastatin to the whole patient population. In
other circumstances this may not be the case and the idea behind treating or not
treating patients based on one clinical or demographic variable, to improve the
cost-eﬀectiveness of the treatment, has merit. In the case of CHD the variable
used could be, for example, the age of patients, their diabetic status, as was used
in the paper by J¨ onsson et al. (1999) or the smoking status of patients. This
method would also be simpler to implement as only information regarding one
variable on patients is required unlike in the calculation of RCHD in Section 8.5,
where information regarding several variables was required.
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Johannesson et al. (1997) and in this analysis unlike in the one undertaken in
the paper by J¨ onsson et al. (1999) more than one recorded baseline variable was
considered when the population of patients were split into sub-groups to look
at cost-eﬀectiveness. Unlike the paper by J¨ onsson et al., 1999 whether patients
were diabetic was not considered but the age, sex and cholesterol levels of patients
before treatment with simvastatin or placebo were. The cost-eﬀectiveness of the
use of simvastatin was then calculated separately for men and women of diﬀerent
ages and baseline levels of cholesterol. As for when diabetic and non-diabetic
patients were investigated all the sub-groups of patients were cost-eﬀective to
treat with simvastatin. Treating younger males with higher levels cholesterol was
the most cost-eﬀective sub-group of patients to treat. This type of procedure
could be extended to include additional or diﬀerent variables depending on the
circumstances and the type of treatment being considered. This could lead to a
treatment that was not cost-eﬀective to prescribe to all patients being targeted
at sub-groups of the potential patient population in which the cost-eﬀectiveness
of the treatment would be acceptable.
In the paper by the Heart Protection Study Collaborative Group (2005) the
cost-eﬀectiveness of simvastatin was again investigated this time based on the
MRC/BHF Heart Protection Study (HPS). (Heart Protection Study Collabora-
tive Group, 2002) As with 4S those patients who were randomised in the HPS had
a history of CHD. A ﬁve year multivariate risk score similar to RCHD, described
in Section 8.5, was calculated using the parameter estimates found from a Cox
model. Patients were then ranked according to their ﬁve year risk score and split
into ﬁfths. The cost-eﬀectiveness of each ﬁfth was then assessed. Prescribing sim-
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calculated to be at the highest risk were the most cost-eﬀectiveness sub-group of
patients to treat. Similar results were seen in Section 8.5 for the IONA Study.
An additional factor that can aﬀect the long term cost-eﬀectiveness and the
actual cost of a treatment itself, in the case of both 4S and the HPS the cost-
eﬀectiveness of simvastatin, is when a drug goes oﬀ patent. Generic copies of
the drug can then be manufactured resulting in the price of the drug decreasing.
This factor was taken into consideration in a follow up analysis of the HPS,
looking at the lifetime cost-eﬀectiveness of simvastatin. (Heart Protection Study
Collaborative Group, 2006) As has already been stated simvastatin was cost-
eﬀective when treating the whole patient population. For treatments which are
on the cusp of being cost-eﬀective to use they could become cost-eﬀective if when
the drug goes oﬀ patent a generic equivalent can be produced at a fraction of the
cost of the original. This could also allow treatments, where cost-eﬀective sub-
groups had previously been identiﬁed, to be prescribed to an enlarged sub-group
of patients as a result of the cost of the treatment having been reduced. Implying
that once an economic evaluation of a treatment has been undertaken and the
ﬁndings implemented the ﬁndings should be revisited if and when circumstances
change to see if they are still valid.
The discussed procedures of identifying patients who are at a higher risk of suf-
fering events as well as the method introduced in Section 8.5 can all be used to aid
the cost-eﬀectiveness evaluations that treatments undergo. In the studies men-
tioned the treatments being investigated turned out to be within the bounds of
cost-eﬀectiveness to treat the whole patient population. Therefore, the full bene-
ﬁt of identifying sub-groups of the patient population where the cost-eﬀectiveness
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makes it too expensive to be recommended for widespread use these techniques
could be implemented to identify sub-groups where the cost-eﬀectiveness was be-
low the cost-eﬀectiveness acceptability threshold. The treatment could then be
recommended for use within these sub-groups of patients.
8.7 The Relationship between Beneﬁcial and Ad-
verse Events
Using the IONA Study data it will be explored whether there could be a relation-
ship between the beneﬁts that treatments give to patients and the adverse events
that they cause, due to side-eﬀects, and what if any the economic implications of
this relationship would be. Patients suﬀered GI events during the IONA Study
and models for the risk of patients suﬀering GI events were found in Section 3.6.
From these models and the analysis contained in Section 2.4.3 it was shown that
treatment with nicorandil was associated with an increased risk of suﬀering a GI
event. The nature of the GI events and the increase in the number of events
that patients suﬀered were not serious compared to the beneﬁts treatment with
nicorandil provided by preventing CHD events. In other situations and with
other treatments this may not be the case, such as chemotherapy treatment for
patients suﬀering from cancer. If a relationship did exist between the beneﬁcial
and adverse events a treatment caused this could be taken into consideration on
both clinical and economic grounds when the treatment is being prescribed.
In Section 8.5 the risk of patients suﬀering CHD events was calculated from
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and high risk patients. Kaplan-Meier estimates (Kaplan and Meier, 1958) and
the resulting curves for the GI events patients suﬀered can be plotted for the
three levels of CHD risk and these are shown in Figure 8.4.
Figure 8.4: Kaplan-Meier curves for suﬀering a GI event for the three levels
of CHD risk
From Figure 8.4 it can be seen that as time progresses there is an apparent
separation in the curves for the three levels of CHD risk. There does appear to
have been a relationship between the risk of suﬀering a CHD and GI event: if a
patient was at high risk of suﬀering a CHD event they were also at a higher risk
of suﬀering a GI event. This was true for the IONA Study but it may well not
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to be carried out for each separate case and set of circumstances.
To see if the relationship was as strong in the other direction, using Model B2
found in Section 3.6.1, the risk of a patient suﬀering a GI event was calculated
in a similar way to how the risk of suﬀering CHD events was calculated using
Equation 8.6. Let the risk of a patient suﬀering a GI event equal RGI, then the





i is the 1 × p vector of prognostic variables for patient i, where p is the
number of variables included in the model, and ˆ β is the p×1 vector of parameter
estimates found from the Cox model for the GI events.
Using Equation 8.8 the risk of patients suﬀering a GI event was then cal-
culated. As was the case when the risk of patients suﬀering CHD events was
calculated using Equation 8.6 when the risk of patients suﬀering GI was calcu-
lated all patients were treated as if they were in the placebo group of the study.
The risk of 16 (0.6%) patients in the nicorandil group and 13 (0.5%) patients in
the placebo group could not be calculated as there were missing values for one
or more of the baseline variables included in the GI event model. The patients
were split according to their risk of suﬀering GI events into three risk groups:
low, medium and high. Kaplan-Meier estimates and the resulting curves were
produced for the CHD events patients suﬀered and plotted for the three levels of
GI risk and are shown in Figure 8.5.
There is a similar pattern in Figure 8.5 to the one seen in Figure 8.4 in that
those patients who were calculated to be at high risk of GI events were alsoCHAPTER 8. HEALTH ECONOMICS OF THE IONA STUDY 190
Figure 8.5: Kaplan-Meier curves for suﬀering a CHD event for the three levels
of GI risk
at high risk of suﬀering CHD events. Given that the multivariable predictive
models for the CHD events and GI events share common prognostic variables
some relationship between the two types of events would be expected. The model
for the CHD events, found in Section 3.4.1, and Model B2 for the GI events, found
in Section 3.6.1, contained the following common variables: the angina status of
patients as assessed by the CCSF classiﬁcation, whether patients were being
treated with a long acting nitrate and whether patients were being treated with
a loop diuretic. In addition as the BMI of a patient was included in the model
for the CHD events and the weight of a patient, which is used in the calculationCHAPTER 8. HEALTH ECONOMICS OF THE IONA STUDY 191
of BMI, was included in the model for the GI events there was a further link
between the models for the two types of event.
Having seen that there was a relationship between the risk of suﬀering a CHD
and GI event how this aﬀects the cost-eﬀectiveness of treatment with nicorandil
will be explored. This was done in a similar way to how the cost-eﬀectiveness
of the diﬀerent levels of CHD risk were investigated in Section 8.5. However,
before the patients were ranked according to their risk of CHD they were ranked
by their risk of suﬀering a GI event using Equation 8.8. In order that each risk
group would contain suﬃcient numbers of patients from both treatment groups
the data set was split in half to give a low and a high GI risk group. Using
Equation 8.6 these two groups were further divided into low and high CHD risk
groups, giving four risk groups in total. Shown in Table 8.10 are the proportion
of patients who suﬀered a ﬁrst CHD event and the mean cost per patients for the
nicorandil and placebo groups separately for the four levels of combined GI and
CHD risk. Using the information contained in Table 8.10 and the modiﬁed ICER
formula, Equation 8.7, ICERs for the four risk levels were calculated as well as
estimated 95% CIs using both Fieller’s Theorem and bootstrap sampling. The
results are shown in Table 8.11.
From the point estimates for the ICERs for the combined GI and CHD risk
groups it was seen that for the low GI risk group it was cost-eﬀective to treat
both the low and high CHD risk groups. Although compared to the previously
calculated ICERs for the IONA Study the low GI risk group were the least cost-
eﬀective group of patients to treat. The ICER for the high CHD risk group was
higher than for the low CHD risk group. This may have been as result of the
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Table 8.10: The proportion of patients who suﬀered a primary endpoint and
the mean cost per patient in the nicorandil and placebo groups
for the combined levels of GI and CHD risk
Low GI Risk Group
Low CHD Risk Group Nicorandil (n = 652) Placebo (n = 742)
Proportion of patients
who suﬀered a CHD event
0.06992 0.09356
Mean cost per patient (£) 1,159 1,057
High CHD Risk Group Nicorandil (n = 622) Placebo (n = 645)
Proportion of patients
who suﬀered a CHD event
0.1206 0.1442
Mean cost per patient (£) 1,543 1,396
High GI Risk Group
Low CHD Risk Group Nicorandil (n = 670) Placebo (n = 592)
Proportion of patients
who suﬀered a CHD event
0.1134 0.1233
Mean cost per patient (£) 1,382 1,373
High CHD Risk Group Nicorandil (n = 617) Placebo (n = 646)
Proportion of patients
who suﬀered a CHD event
0.2236 0.2601
Mean cost per patient (£) 2,237 2,459
therefore accruing hospitalisation costs than in the low CHD risk group. However,
the point where the cost of nicorandil was more than oﬀ-set by the reduction in
the number of CHD events and resultant hospitalisation costs that these events
would have caused had not yet been reached. As a result the cost-eﬀectiveness
of treatment with nicorandil was reduced. In addition, although this group of
patients was the low GI risk group, patients in the high CHD risk group may have
suﬀered more GI events that in the low CHD risk group due to the relationship
seen between the two types of event, see Figures 8.4 and 8.5.
Any increase in the number of GI events and resultant hospitalisations suﬀered
by patients would impact on the cost-eﬀectiveness of treatment with nicorandil.CHAPTER 8. HEALTH ECONOMICS OF THE IONA STUDY 193
Table 8.11: The cost per CHD event prevented for the combined levels of GI
and CHD risk with accompanying estimated 95% CIs
Level of ICER Point Method of Estimating the 95% Conﬁdence Intervals
CHD Risk Estimate (£) Fieller’s Theorem (£) Bootstrap Sampling (£)
Low GI Risk Group
Low 4,324 -∞ – -32,391 ∪ -16,071 – ∞ -74,170 – 96,798
High 6,217 -∞ – ∞ -98,599 – 104, 671
High GI Risk Group
Low 872 -∞ – ∞ -138,063 – 120,148
High -6,099 -∞ – ∞ -60,373 - 52,290
For the high GI risk group treating both the low and high CHD risk groups was
also cost-eﬀective. In the high CHD risk group every CHD prevented resulted
in a net cost saving of £6,099, this net cost saving was the largest seen when
analysing the IONA Study data. For the low CHD risk group the net cost of ever
CHD event prevented was £872 which was again favourable and lower than for
either of the low or high CHD risk groups in the low GI risk group.
By ranking patients by their risk of suﬀering a GI event and then by there risk
of suﬀering a CHD event the cost-eﬀectiveness of nicorandil was improved. There
were no signiﬁcant diﬀerences in the eﬀectiveness of treatment with nicorandil
over treatment with placebo in the four risk groups and as a result the 95% CIs as
estimated by Fieller’s Theorem were not very informative. For three of the groups
the intervals were the entire real line and for the low risk CHD group in the low
risk GI group the interval only excluded the interval (-£32,391, -£16,071). For
this group real roots to the solution of Equation 8.5 did exist but as there was no
signiﬁcant diﬀerence in the eﬀectiveness of the treatments the interval was of the
form (-∞,a] ∪ [b,∞). The bootstrap sampling estimates were more informative
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the eﬀectives of the treatments for any of the risk groups. The bootstrap sampling
interval was especially wide for the low CHD risk group in the high GI risk group.
As all of the 95% CIs were so wide no deﬁnitive conclusions can be made about
the cost-eﬀectiveness of treatment with nicorandil. Although the general pattern
was that treating the group of patients who were at a higher risk of suﬀering GI
Figure 8.6: The cost per CHD event prevented for the levels of combined GI
and CHD risk with accompanying 95% CIs estimated by boot-
strap sampling
events was more cost-eﬀective. A graphical representation of the ICERs for the
combined levels of GI and CHD risk, along with the 95% CIs found by bootstrap
sampling, are shown in Figure 8.6.
It has been shown that treatment with nicorandil reduced the incidence ofCHAPTER 8. HEALTH ECONOMICS OF THE IONA STUDY 195
CHD events but increased the incidence of GI events and that there was a rela-
tionship between the risks of patients suﬀering both these types of events. If only
those patients who were calculated to be at high risk of suﬀering CHD events
were treated with nicorandil this would lead to a higher rate of patients suﬀering
GI events. As the rate of patients suﬀering GI events was small compared to the
rate patients suﬀered CHD events and the cost of these events were small com-
pared to CHD events the economic impact of treating only patients at high risk
of CHD and GI events would be minor. As the cost of the GI events had minimal
impact on the cost-eﬀectiveness calculations in this instance the cost-eﬀectiveness
of nicorandil was actually improved as the sub-group of patients identiﬁed were
at the greatest risk of suﬀering CHD events so therefore would beneﬁt most from
treatment with nicorandil. However, if this idea was to be applied in other sit-
uations with diﬀerent treatments where the adverse events they cause are more
serious and result in higher costs required to treat them then only treating high
risk patients could adversely aﬀect the cost-eﬀectiveness of a treatment. If this
process, or a similar one, was to be implemented with other treatments and not
just with nicorandil investigation would be needed to see if analogous ﬁndings to
the ones for the IONA Study could be found. This process would be most appli-
cable to treatments that have high rates of serious side-eﬀects that are costly to
treat and therefore have a large impact of the cost-eﬀectiveness of a treatment.Chapter 9
Conclusions and Further Work
The original clinical and economic evaluations for the IONA Study (The IONA
Study Group, 2002; Walker et al., 2006), the details of which are given in Sec-
tions 2.4.1, 2.4.2 and 8.3.1, indicated that nicorandil did have cardioprotective
eﬀects and that to achieve these clinical beneﬁts treatment with nicorandil was
cost-eﬀective. By extending both the clinical and economic evaluations it was
seen that the clinical beneﬁts of treatment with nicorandil extended past the
ﬁrst CHD events patients were at risk from and that the cost-eﬀectiveness of
treatment with nicorandil could be further improved.
It was found that adjustment for baseline explanatory variables did not sub-
stantially aﬀect the estimated risk reduction for CHD events. Nicorandil treat-
ment was also found to be associated with an increased risk of GI events. This
increased risk was still present in the multivariable model for the GI events. The
beneﬁts of nicorandil treatment would appear to out weigh the potential draw-
back of increased risk of suﬀering GI events.
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The area where the clinical evaluation could really be extended was by includ-
ing not just the ﬁrst event suﬀered but also the multiple recurrent events that
patients suﬀered. Considering only the primary endpoint where the number of
recurrent events was suﬃcient to make best use of the recurrent event models,
when the recurrent event analyses were compared to the time-to-ﬁrst event anal-
ysis the statistical signiﬁcance of the reduction in risk of patients suﬀering CHD
associated with treatment with nicorandil was improved for all of the methods of
analyses investigated. Here the underlying risk reduction associated with treat-
ment with nicorandil is not known. However, as was seen in Chapter 6 for the
second set of simulation conditions for the treatment eﬀect group of simulations
where the event rate was similar to the event rate for the primary endpoint in
IONA, the AG and WLW models estimated the treatment eﬀect to be larger com-
pared to the PWPa and PWPb models. For the simulations the reduction in risk
that the treatment should cause was known and the results for the PWPa and
PWPb models more accurately reﬂected this. For the IONA Study the AG and
WLW models estimated the reduction in risk caused by treatment with nicorandil
to be marginally higher then the PWPa and PWPb models did. It appeared that
for the IONA Study data the PWPb model most closely modelled the underlying
data.
Having introduced the random subject eﬀect into the data generation process
it was seen the PWPb model did not perform well under these conditions. The
positive stable variable used to generate the random subject eﬀect had the aﬀect
of reducing the parameter estimate for the treatment eﬀect by half. The event
rate was also greatly increased. As discussed in Chapter 5 the heterogeneity
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would have such a dramatic eﬀect on the parameter estimate. The advantage
of using the positive stable distribution in this case was that the assumption of
proportional hazards was preserved. If further simulations were to be performed
other data generation processes than used in Chapter 6 should be used to make
any ﬁndings more generalisable and to possibly reﬂect more accurately the degree
of frailty that might exist in a real population. (Metalfe and Thompson, 2006)
For example, a Poisson process, an Autoregressive model or a Gamma frailty
could be used to generate the data.
The inclusion of the random subject eﬀect did highlight that the recurrent
event models do not always give the same results and in some circumstances the
diﬀerences between the results for the models can be signiﬁcant. It is therefore
important that the most appropriate recurrent event model is used to analyse
data. The particular conditions for the data set such as the event rate and
whether the risk of events was constant need to be taken into consideration. The
model used to analyse the data should not be based on preconceived ideas but on
the actual observed pattern of the data. If a clinical evaluation is extended past
a time-to-ﬁrst event analysis to a recurrent event analysis the ﬁndings may gain
greater weight. However, if the model that is used to incorporate the recurrent
events into the analysis is not appropriate some of the beneﬁts of extending the
analysis past a simple time-to-ﬁrst event analysis may be lost as well as making
the results harder to interpret. The same is true if there are insuﬃcient numbers
of recurrent events available to include in the analysis.
One obvious approach to remove underlying frailty is to adjust for baseline
risk factors. Particularly for cardiovascular disease, many of the risk factors are
well understood. It is recommended that all recurrent event analyses should beCHAPTER 9. CONCLUSIONS AND FURTHER WORK 199
adjusted for important baseline predictors of outcome. The incorporation of an
explicit frailty parameter in the model is another approach worthy of consider-
ation. However, it is noted that this will not adjust for frailty that develops
with the occurrence of recurrent events. In some situations it may be best to use
only the traditional time-to-ﬁrst event analysis, and such analyses should perhaps
always be considered as the primary outcome of a study.
An alternative approach that could be used to model recurrent event data
that would potentially adjust for frailty that develops with the occurrence of
recurrent events would be to use a multi-state model. (Andersen and Keiding,
2002) When using a multi-state model all patients start in the same state at the
start of the trial. Patients then transition to other states when they suﬀer events.
The states that patients transition to depend on the type of event they suﬀer. If
the event patients suﬀer is death or another type of event that means they can no
longer participate in the trial they transition to an absorbing state. For patients
who transition to non-absorbing states they remain in that state until they suﬀer
a further event. Patients then transition to another state. Again the states that
patients transition to depend on the type of event they suﬀer. This modelling
process then continues for as long as patients are at risk of suﬀering events. The
use of multi-state models could be further extended by using competing risks
multi-state models. (Andersen et al., 2002; Putter et al., 2007)
It was seen that the cost-eﬀectiveness of treatment with nicorandil could be
improved. This was achieved by targeting it at sub-groups of the patient popula-
tion. The sub-groups being patients who had a higher underlying risk of suﬀering
CHD events. By targeting the prescribing of nicorandil to those patients calcu-
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for the NHS. The rationale for ongoing treatment was strengthened by the fact
that the cardioprotective eﬀects of treatment with nicorandil extended past the
ﬁrst CHD events patients suﬀered. Patients who had suﬀered previous CHD
events as well as patients newly diagnosed with CHD could beneﬁt from treat-
ment with nicorandil. Once patients have suﬀered a CHD event treatment with
nicorandil could be continued as it would still be clinically eﬀective as well as still
being cost-eﬀective. If the long term cost-eﬀectiveness of treatment with nico-
randil was to be investigated this could be achieved by using a Markov model.
(Briggs and Sculpher, 1997; Lang et al., 2003) Using a Markov model the num-
ber of CHD events that patients who took part in the IONA Study would suﬀer
after the end of the study and how frequently they would suﬀer such events could
be modelled. Thus, allowing the long term cost-eﬀectiveness of treatment with
nicorandil to be assessed.
A potential drawback of nicorandil is the GI side-eﬀects that nicorandil could
cause in patients. The side-eﬀects, if serious and requiring treatment and even
hospitalisation, could have implications on the cost-eﬀectiveness of a treatment.
These implications were not fully considered when the ICERs for the IONA Study
were calculated. Both the primary and secondary IONA ICERs included the
cost of the GI hospitalisations but no consideration was given to the extra actual
numbers of GI events patients suﬀered as in some way counteracting the numbers
of CHD events prevented. The number of GI events patients suﬀered could be
factored into the calculation of the ICERs as well as the costs that accompanied
these events. If the GI events were to be factored into the ICER calculation a
weighting factor would need to be applied to the GI events, as the GI events were
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also not a predeﬁned outcome of the study. Therefore, if a weighting factor of
one was applied to the CHD events then it would be likely that the GI events
would be assigned a weighting factor of less than one. If the GI events were
included in the denominator of the ICER and given an arbitrary weight of a half
the calculation of the secondary IONA ICER would become:




The adjusted secondary IONA ICER, with the inclusion of the recurrent GI events
in addition to the recurrent CHD events, would become:




For the secondary IONA ICER the net cost per ‘Event’ prevented rises to £947
and for the adjusted secondary IONA ICER it rises to £319. These ﬁgures still
indicate treatment with nicorandil to be cost-eﬀective. The advantage with these
formulations of the ICERs is that the numbers of adverse clinical events as well
as the cost associated with them are now factored into the ICER calculation.
This does raise an issue which could be further explored. The primary end-
point was a composite endpoint of three types of CHD event, which greatly
diﬀered in their severity. In the CEA the component parts of the primary end-
point were treated as the same and no consideration was given to the diﬀerence
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component parts of the primary endpoint could have diﬀerent weighting factors
applied to them. Consideration could also be given to whether there should only
be three weighting factors applied to the three component parts of the primary
endpoint or whether the non-fatal MIs and unplanned hospitalisations should be
further sub-divided based on the severity of the event. Having decided how many
weighting factors to apply to the component parts of the primary endpoint, as
well as whether there should be multiple weighting factor for the GI events, the
values of these weighting factors would have to be estimated. This could be done
by looking at QALY values that have been previously assigned to diﬀerent types
and severity of CHD and GI events. The assigned QALY values could then be
converted into weighting factors. How introducing these weighting factors would
impact the cost-eﬀectiveness of treatment with nicorandil could then be explored.
Following on from this, if monetary values could be assigned to the QALY val-
ues allocated to the diﬀerent types of event a net health beneﬁt analysis could
be performed. (Stinnett and Mullahy, 1998; Willan, 2001) In performing a net
health beneﬁt analysis the diﬃculties of calculating and interpreting ICERs can
be avoided. However, monetary values have to be assigned to QALYs which also
has its diﬃculties.
In Chapter 8 it was seen that there was a positive relationship between the risk
of suﬀering CHD and GI events. By treating those patients who were at a high risk
of suﬀering GI events as well as CHD events the cost-eﬀectiveness of treatment
with nicorandil could be improved. This was as a result of the fact that the cost
impact of the GI events were small compared to the CHD events. However, if side-
eﬀects have a larger impact on the net cost of prescribing treatments these cost-
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most likely to experience clinical beneﬁt from treatments as well as side-eﬀects
could be an important association and the potential links between the two types
of event could be investigated for other treatments. If patients will beneﬁt from
a treatment but are known to be at a heightened risk of suﬀering side-eﬀects
this could be taken into consideration when treatments are prescribed. Over
and above the cost-eﬀectiveness of treatments there always has to be a balance
between the beneﬁts and the harm that treatments can cause to patients.
Sensitivity analysis was carried out on the results of the economic evaluation of
the IONA Study but this is an area where the analysis could be further extended.
To gain a greater understanding of the uncertainty around the cost-eﬀectiveness of
treatment with nicorandil instead of performing a univariate sensitivity analysis
or extending that to a multi-way sensitivity analysis Probabilistic Sensitivity
Analysis could be used. If distributions for the hospitalisation costs and numbers
of primary endpoints suﬀered in both treatment groups could be speciﬁed for
the IONA Study then PSA could be performed. The fact that high risk patients
were enrolled in IONA could then be factored into the analysis. The eﬀectiveness
of treatment with nicorandil could be altered so that the cost-eﬀectiveness of
nicorandil could be investigated for the general patient population and not just
those at an elevated risk of suﬀering CHD events. Thus, allowing the result of
the CEA to be more general.
9.1 Summary
Both the original clinical and economic evaluations have been extended. The
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eﬀects of nicorandil were not just conﬁned to the ﬁrst CHD events that patients
were at risk of suﬀering. In the original economic evaluation the cost-eﬀectiveness
of treatment with nicorandil was found to be favourable and by extending the
analysis this ﬁnding has been reinforced and in some cases the cost-eﬀectiveness
was further improved. The original clinical and economic ﬁndings of the IONA
Study have been improved and made more robust as a result of utilising more of
the information that was recorded on patients during the study.
In modern society pharmaceutical companies are under great ﬁnancial pres-
sure to bring their products to market and as a result are trying to shorten the
length of clinical trials. For example, by using composite endpoints, as was the
case in the IONA Study. If the follow-up of clinical trials are shortened it is
likely that modelling of the trial data will become ever more important. In order
that this can be best achieved it is important that not only are data recorded
on patients during clinical trials but that the data are actually utilised in the
clinical and economic evaluations that are undertaken. By incorporating more
of the information recorded on patients during a clinical trial and by making the
best use of this information both the clinical and economic evaluations of clinical
trials can be expanded upon and lead to improved and more robust conclusions
being drawn.
A summary of the main ﬁndings are as follows:
1. The cardioprotective eﬀects of nicorandil were shown to extend past the
ﬁrst CHD events patients suﬀered.
2. The recurrent event models all have diﬀerent underlying assumptions and
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3. When analysing recurrent event data the choice of which model to use is
important and should be based on the particular conditions for the given
data set.
4. Not using the most appropriate recurrent event model for the given data
set can result in signiﬁcant levels of bias in the results.
5. The cost-eﬀectiveness of treatment with nicorandil could be further im-
proved by targeting it to those patients who were at the highest risk of
CHD events.
6. There has to be a balance between the beneﬁts and the harm that treat-
ments can cause to patients and as a result all such factors should be in-
cluded in the calculation of cost-eﬀectiveness.Appendix A
The IONA Study Endpoint
Deﬁnitions
This Appendix contains the deﬁnitions of the components parts of the primary
and secondary endpoints of the IONA Study that were used by the critical events
committee. (The IONA Study Group, 2001)
A.1 Hospitalisations
Before deﬁnitions of the component parts of the primary and secondary endpoints
are given a hospital admission will be deﬁned as well as what constituted an
unplanned hospital admission.
1. Hospital Admission
An admission to hospital is deﬁned as any attendance at hospital requiring
completion of the hospital admission procedures and usually at least an
overnight stay.
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2. Unplanned Hospital Admission
Unplanned admission is deﬁned as an emergency or other urgent, non-
elective admission precipitated by general practitioner (GP) referral or self
referral to an accident and emergency department, urgent GP referral to
hospital in some other way, emergency call to the ambulance service, or
urgent admission from a hospital outclinic. The admission must be pre-
cipitated by a need for urgent investigation or treatment which cannot be
provided on an outpatient basis and which cannot be deferred on an inpa-
tient basis.
A.2 Coronary Heart Disease Death
This consisted of all events satisfying the following deﬁnition:
All deaths shall be considered coronary heart disease unless an unequivocal
non-coronary heart disease cause can be established. Coronary heart disease
deaths will include sudden deaths, death due to myocardial infarction, death
due to heart failure, death due to a cardiac investigation/procedure/operation
(procedure related death).
1. Sudden death
Deaths fulﬁlling any one of the following criteria:
(a) witnessed and instantaneous, without new or worsening symptoms;
(b) witnessed and preceded or accompanied by symptoms attributable to
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(c) witnessed and preceded by symptoms attributable to a cardiac ar-
rhythmia for example, syncope or near syncope;
(d) patients resuscitated from cardiac arrest in the absence of worsening
heart failure or other causes of death, including acute myocardial in-
farction, and who die within 24 hours or without regaining conscious-
ness; similar patients who die despite attempted resuscitation;
(e) unwitnessed death in the absence of worsening heart failure or other
causes of death.
2. Death from heart failure
Death occurring when at least one of the following is present in the 48 hours
before death:
(a) new or increasing symptoms and/or signs (including worsening renal
function) of heart failure requiring the initiation of, or an increase in,
treatment directed at heart failure or occurring in a patient already
receiving maximum treatment for heart failure;
(b) heart failure symptoms or signs requiring continuous intravenous treat-
ment or oxygen administration;
(c) conﬁnement to bed but only if conﬁnement is for heart failure symp-
toms;
(d) pulmonary oedema suﬃcient to cause tachypnoea and distress not oc-
curring in the context of an acute myocardial infarct or as the conse-
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3. Death from myocardial infarction
Death occurring up to 28 days after a documented myocardial infarct.
Deaths from a myocardial infarct occurring as a direct result of an in-
vestigation, procedure, or operation will be classiﬁed as a death caused by
myocardial infarction and a procedure related death.
4. Coronary heart disease procedure related
Deaths deemed to be directly related to that investigation/procedure/operation.
5. Presumed coronary heart disease death
Death not fulﬁlling any of the above coronary heart disease categories and
any deﬁnite cardiovascular or non-cardiovascular deﬁnition below.
(a) Death from stroke
Death occurring up to 28 days after a documented stroke. Deaths from
stroke occurring as a direct consequence of an investigation/procedure/operation
will be classiﬁed as a death caused by a stroke and a procedure related
death.
(b) Cardiovascular procedure related deaths
Death occurring within seven days of a cardiovascular investigation,
procedure or operation and deemed to be directly related to that in-
vestigation/procedure/operation.
(c) Death from other cardiovascular causes
Death must be caused by a fully documented cardiovascular cause not
included above - for example, pulmonary embolism, ruptured aortic
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A.3 Non-Fatal Myocardial Infarction
This consisted of all events satisfying the following deﬁnition:
1. Silent myocardial infarction
An ECG, at an annual or at an unscheduled visit, that is diagnostic of
myocardial infarction (new Q waves ≥ 0.04 ms in duration in at least two
consecutive leads) and which was not evident on the previous ECG.
2. Acute myocardial infarction
All deﬁnite myocardial infarcts will be counted as events whether they
occurred spontaneously or as the direct consequence of an investigational
procedure or operation. A diagnosis of myocardial infarction will be made
if two of the following three criteria are met:
(a) At least one of the following:
i. cardiac ischaemic type pain lasting at least 30 minutes;
ii. pulmonary oedema;
iii. cardiogenic shock not otherwise explained.
(b) Development of new abnormal Q waves (≥ 0.04 ms in duration) in at
least two consecutive ECG leads not present on an ECG recorded be-
fore the current event, or transient elevation of ST segment followed by
T wave inversion in at least two consecutive leads, or new left bundle
branch block, or transient elevation of ST segment, new bundle branch
block, or other typical ECG changes leading to emergency angiogra-
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artery is demonstrated and following which successful emergency per-
cutaneous revascularisation (recannulation) is performed.
(c) An elevation of cardiac enzymes deﬁned as a transient increase in at
least one set of enzymes. (Elevation to at least twice the upper limit of
the local normal reference range, or creatine kinase (CK) MB fraction
greater equal here 10% of total CK)
A.4 Unplanned Hospital Admission for Cardiac
Chest Pain
This consisted of all events satisfying the following deﬁnition:
Cardiovascular, involving chest pain.
1. Acute myocardial infarction
All deﬁnite myocardial infarcts will be counted as events whether they
occurred spontaneously or as the direct consequence of an investigational
procedure or operation. A diagnosis of myocardial infarction will be made
if two of the following three criteria are met:
(a) At least one of the following:
i. cardiac ischaemic type pain lasting at least 30 minutes;
ii. pulmonary oedema;
iii. cardiogenic shock not otherwise explained.
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least two consecutive ECG leads not present on an ECG recorded be-
fore the current event, or transient elevation of ST segment followed by
T wave inversion in at least two consecutive leads, or new left bundle
branch block, or transient elevation of ST segment, new bundle branch
block, or other typical ECG changes leading to emergency angiogra-
phy during which a complete acute occlusion of at least one coronary
artery is demonstrated and following which successful emergency per-
cutaneous revascularisation (recannulation) is performed.
(c) An elevation of cardiac enzymes deﬁned as a transient increase in at
least one set of enzymes. (Elevation to at least twice the upper limit of
the local normal reference range, or creatine kinase (CK) MB fraction
greater equal here 10% of total CK)
2. Chest pain which is not associated with a myocardial infarct but requires
unplanned admission to hospital:
(a) Unstable angina
Typical cardiac ischaemic type chest pain requiring hospital admission
for treatment but not meeting the deﬁnition of myocardial infarction.
The patient must also:
i. develop new or evolving ST segment/T wave changes on the ECG
and
ii. have treatment with parenteral (buccal other than with short act-
ing preparations, intravenous, transcutaneous or subcutaneous)
heparin and/or glyceryl trinitrate, isosorbide dinitrate, or other
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(b) Deﬁnite angina
Typical cardiac ischaemic type chest pain requiring hospital admission
for treatment but not meeting the deﬁnition of myocardial infarction
or deﬁnite unstable angina and requiring additional antianginal treat-
ment (new antianginal drugs and/or increased dose of current treat-
ment and/or referral for “revascularisation”).
(c) Presumed angina
Admission with chest pain not fulﬁlling any of the above criteria and
where there is no other recorded cause for the pain. That is, any
admission with chest pain that is not caused by myocardial infarction,
unstable angina, or deﬁnite angina is “presumed angina” unless a ﬁrm
diagnosis to the contrary is recorded by the treating physician.Appendix B
SAS Simulation Code
This Appendix contains the SAS code used to simulate and then analyse the
recurrent event data. Shown is the SAS code used to generate the gap times
for the diﬀerent groups of simulations. Additionally, then shown is the SAS code
used to incorporate censoring into the gap time data and then analyse it using the
diﬀerent recurrent event models for the no treatment eﬀect group of simulations
with γ = 1.
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B.1 Gap Time Generation Code
No Treatment Eﬀect Group of Simulations with γ = 1
data null_exp (drop = seed seed2);
do k=1 to 10000;
seed = -1; seed2 = -1;
null = 0;









































No Treatment Eﬀect Group of Simulations with γ = 0.75
data null_weibull (drop = seed seed2);
do k=1 to 10000;
seed = -1; seed2 = -1;
null = 0;
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Treatment Eﬀect Group of Simulations with γ = 1
data treatment_exp (drop = seed seed2);
do k=1 to 10000;
seed = -1; seed2 = -1;
treatment = 0;









































Treatment Eﬀect Group of Simulations with γ = 0.75
data treatment_weibull (drop = seed seed2);
do k=1 to 10000;
seed = -1; seed2 = -1;
treatment = 0;
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Treatment Eﬀect for First Event
Group of Simulations with γ = 1
data first_exp (drop = seed seed2);
do k=1 to 10000;
seed = -1; seed2 = -1;
first = 0;









































Treatment Eﬀect for First Event
Group of Simulations with γ = 0.75
data first_weibull (drop = seed seed2);
do k=1 to 10000;
seed = -1; seed2 = -1;
first = 0;
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B.2 Incorporating Censoring and Analysing the
Recurrent Event Data
data censoring_null_hr1e (drop = d1 d2 d3 d4);
set null_exp (drop = t1 t2 t3 t4 a1 a2 a3 a4 s1 s2 s3 s4);
by k;
total_time = 2;
if d1 >= 2 then do;
event1 = 0; event2 = .; event3 = .; event4 = .;
tt1 = 2; tt2 = .; tt3 = .; tt4 = .;
end;
else if . < d1 < 2 then do;
event1 = 1; tt1 = d1; time1 = tt1;
if sum(d1 , d2) >= 2 then do;
event2 = 0; event3 = .; event4 = .;
tt2 = (2 - d1); tt3 = .; tt4 = .;
end;
else if . < sum(d1 , d2) < 2 then do;
event2 = 1; tt2 = d2; time2 = sum(tt1 , tt2);
if sum(d1 , d2 , d3) >= 2 then do;
event3 = 0; event4 = .;
tt3 = (2 - sum(d1 , d2)); tt4 = .;
end;
else if . < sum(d1 , d2 , d3) < 2 then do;
event3 = 1; tt3 = d3; time3 = sum(tt1 , tt2 , tt3);
if sum(d1 , d2 , d3 , d4) >= 2 then do;
event4 = 0;
tt4 = (2 - sum(d1 , d2 , d3));
end;
else if . < sum(d1 , d2 , d3 , d4) < 2 then do;
event4 = 1;
tt4 = d4; time4 = sum(tt1 , tt2 , tt3 , tt4);






data censoring_null_hr2e (drop = t1 t2 t3 t4);
set null_exp (drop = a1 a2 a3 a4 d1 d2 d3 d4 s1 s2 s3 s4);
by k;
total_time = 2;
if t1 >= 2 then do;
event1 = 0; event2 = .; event3 = .; event4 = .;
tt1 = 2; tt2 = .; tt3 = .; tt4 = .;
end;
else if . < t1 < 2 then do;
event1 = 1; tt1 = t1; time1 = tt1;
if sum(t1 , t2) >= 2 then do;
event2 = 0; event3 = .; event4 = .;
tt2 = (2 - t1); tt3 = .; tt4 = .;
end;
else if . < sum(t1 , t2) < 2 then do;
event2 = 1; tt2 = t2; time2 = sum(tt1 , tt2);
if sum(t1 , t2 , t3) >= 2 then do;
event3 = 0; event4 = .;
tt3 = (2 - sum(t1 , t2)); tt4 = .;
end;
else if . < sum(t1 , t2 , t3) < 2 then do;
event3 = 1; tt3 = t3; time3 = sum(tt1 , tt2 , tt3);
if sum(t1 , t2 , t3 , t4) >= 2 then do;
event4 = 0;
tt4 = (2 - sum(t1 , t2 , t3));
end;
else if . < sum(t1 , t2 , t3 , t4) < 2 then do;
event4 = 1;
tt4 = t4; time4 = sum(tt1 , tt2 , tt3 , tt4);






data censoring_null_hr3e (drop = s1 s2 s3 s4);
set null_exp (drop = t1 t2 t3 t4 a1 a2 a3 a4 d1 d2 d3 d4);
by k;
atotal_time = 2;
if s1 >= 2 then do;
aevent1 = 0; aevent2 = .; aevent3 = .; aevent4 = .;
aa1 = 2; aa2 = .; aa3 = .; aa4 = .;
end;
else if . < s1 < 2 then do;
aevent1 = 1; aa1 = s1; atime1 = aa1;
if sum(s1 , s2) >= 2 then do;
aevent2 = 0; aevent3 = .; aevent4 = .;
aa2 = (2 - s1); aa3 = .; aa4 = .;
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else if . < sum(s1 , s2) < 2 then do;
aevent2 = 1; aa2 = s2; atime2 = sum(aa1 , aa2);
if sum(s1 , s2 , s3) >= 2 then do;
aevent3 = 0; aevent4 = .;
aa3 = (2 - sum(s1 , s2)); aa4 = .;
end;
else if . < sum(s1 , s2 , s3) < 2 then do;
aevent3 = 1; aa3 = s3; atime3 = sum(aa1 , aa2 , aa3);
if sum(s1 , s2 , s3 , s4) >= 2 then do;
aevent4 = 0;
aa4 = (2 - sum(s1 , s2 , s3));
end;
else if . < sum(s1 , s2 , s3 , s4) < 2 then do;
aevent4 = 1;
aa4 = s4; atime4 = sum(aa1 , aa2 , aa3 , aa4);






data censoring_null_hr4e (drop = a1 a2 a3 a4);
set null_exp (drop = t1 t2 t3 t4 d1 d2 d3 d4 s1 s2 s3 s4);
by k;
atotal_time = 2;
if a1 >= 2 then do;
aevent1 = 0; aevent2 = .; aevent3 = .; aevent4 = .;
aa1 = 2; aa2 = .; aa3 = .; aa4 = .;
end;
else if . < a1 < 2 then do;
aevent1 = 1; aa1 = a1; atime1 = aa1;
if sum(a1 , a2) >= 2 then do;
aevent2 = 0; aevent3 = .; aevent4 = .;
aa2 = (2 - a1); aa3 = .; aa4 = .;
end;
else if . < sum(a1 , a2) < 2 then do;
aevent2 = 1; aa2 = a2; atime2 = sum(aa1 , aa2);
if sum(a1 , a2 , a3) >= 2 then do;
aevent3 = 0; aevent4 = .;
aa3 = (2 - sum(a1 , a2)); aa4 = .;
end;
else if . < sum(a1 , a2 , a3) < 2 then do;
aevent3 = 1; aa3 = a3; atime3 = sum(aa1 , aa2 , aa3);
if sum(a1 , a2 , a3 , a4) >= 2 then do;
aevent4 = 0;
aa4 = (2 - sum(a1 , a2 , a3));
end;
else if . < sum(a1 , a2 , a3 , a4) < 2 then do;
aevent4 = 1;
aa4 = a4; atime4 = sum(aa1 , aa2 , aa3 , aa4);






proc freq data = censoring_null_hr1e noprint;
by k null;
tables event1 / out = event1_null_hr1e;
tables event2 / out = event2_null_hr1e;
tables event3 / out = event3_null_hr1e;
tables event4 / out = event4_null_hr1e;
run;
proc freq data = censoring_null_hr2e noprint;
by k null;
tables event1 / out = event1_null_hr2e;
tables event2 / out = event2_null_hr2e;
tables event3 / out = event3_null_hr2e;
tables event4 / out = event4_null_hr2e;
run;
proc freq data = censoring_null_hr3e noprint;
by k null;
tables event1 / out = event1_null_hr3e;
tables event2 / out = event2_null_hr3e;
tables event3 / out = event3_null_hr3e;
tables event4 / out = event4_null_hr3e;
run;
proc freq data = censoring_null_hr4e noprint;
by k null;
tables event1 / out = event1_null_hr4e;
tables event2 / out = event2_null_hr4e;
tables event3 / out = event3_null_hr4e;
tables event4 / out = event4_null_hr4e;
run;
proc printto
print = ‘C:\Documents and Settings\nhenderso\Desktop\IE_hr1e.txt’
log = ‘C:\Documents and Settings\nhenderso\Desktop\IE_hr1e.txt’
new;
run;
ods output parameterestimates = first_events_null_hr1e;
proc phreg data = censoring_null_hr1e;




ods output parameterestimates = second_events_null_hr1e;
proc phreg data = censoring_null_hr1e;
model tt2*event3(0) = null / rl ties=exact;
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run;
ods noresults;
ods output parameterestimates = third_events_null_hr1e;
proc phreg data = censoring_null_hr1e;




ods output parameterestimates = fourth_events_null_hr1e;
proc phreg data = censoring_null_hr1e;




proc printto print = print log = log;
run;
proc printto
print = ‘C:\Documents and Settings\nhenderso\Desktop\IE_hr2e.txt’
log = ‘C:\Documents and Settings\nhenderso\Desktop\IE_hr2e.txt’
new;
run;
ods output parameterestimates = first_events_null_hr2e;
proc phreg data = censoring_null_hr2e;




ods output parameterestimates = second_events_null_hr2e;
proc phreg data = censoring_null_hr2e;




ods output parameterestimates = third_events_null_hr2e;
proc phreg data = censoring_null_hr2e;




ods output parameterestimates = fourth_events_null_hr2e;
proc phreg data = censoring_null_hr2e;




proc printto print = print log = log;
run;
proc printto
print = ‘C:\Documents and Settings\nhenderso\Desktop\IE_hr3e.txt’
log = ‘C:\Documents and Settings\nhenderso\Desktop\IE_hr3e.txt’
new;
run;
ods output parameterestimates = first_events_null_hr3e;
proc phreg data = censoring_null_hr3e;




ods output parameterestimates = second_events_null_hr3e;
proc phreg data = censoring_null_hr3e;




ods output parameterestimates = third_events_null_hr3e;
proc phreg data = censoring_null_hr3e;




ods output parameterestimates = fourth_events_null_hr3e;
proc phreg data = censoring_null_hr3e;




proc printto print = print log = log;
run;
proc printto
print = ‘C:\Documents and Settings\nhenderso\Desktop\IE_hr4e.txt’
log = ‘C:\Documents and Settings\nhenderso\Desktop\IE_hr4e.txt’
new;
run;
ods output parameterestimates = first_events_null_hr4e;
proc phreg data = censoring_null_hr4e;




ods output parameterestimates = second_events_null_hr4e;
proc phreg data = censoring_null_hr4e;




ods output parameterestimates = third_events_null_hr4e;
proc phreg data = censoring_null_hr4e;
model aa3*aevent3(0) = null / rl ties=exact;
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run;
ods noresults;
ods output parameterestimates = fourth_events_null_hr4e;
proc phreg data = censoring_null_hr4e;




proc printto print = print log = log;
run;
/*--------------------*/
/*-- No Increase No Subject --*/
/*--------------------*/
data model_null_hr1ea





























print = ‘C:\Documents and Settings\nhenderso\Desktop\AG_hr1e.txt’
log = ‘C:\Documents and Settings\nhenderso\Desktop\AG_hr1e.txt’
new;
run;
ods output parameterestimates = AG_null_hr1e;
proc phreg data = model_null_hr1ea covs(aggregate) covm;




proc printto print = print log = log;
run;
proc printto
print = ‘C:\Documents and Settings\nhenderso\Desktop\WLW_hr1e.txt’
log = ‘C:\Documents and Settings\nhenderso\Desktop\WLW_hr1e.txt’
new;
run;
ods output parameterestimates = WLW_null_hr1e;
proc phreg data = model_null_hr1ea covs(aggregate) covm;
strata ev;
by k; model tstop*status(0) = null / rl ties=exact;
id i;
run;
proc printto print=print log=log;
run;




if first.i then lstatus = 1;
if (status = 0 and lstatus = 0) then delete;
lstatus = status;
gaptime = tstop - tstart;
run;
proc printto
print = ‘C:\Documents and Settings\nhenderso\Desktop\PWPa_hr1e.txt’
log = ‘C:\Documents and Settings\nhenderso\Desktop\PWPa_hr1e.txt’
new;
run;
ods output parameterestimates = PWPa_null_hr1e;
proc phreg data = model_null_hr1eb covs(aggregate) covm;





proc printto print = print log = log;
run;
proc printto
print = ‘C:\Documents and Settings\nhenderso\Desktop\PWPb_hr1e.txt’
log = ‘C:\Documents and Settings\nhenderso\Desktop\PWPb_hr1e.txt’
new;
run;
ods output parameterestimates = PWPb_null_hr1e;
proc phreg data=model_null_hr1eb covs(aggregate) covm;
model gaptime*status(0) = null / rl ties=exact;
by k;




proc printto print = print log = log;
run;
/*--------------------*/
/*-- Increasing Risk No Subject --*/
/*--------------------*/
data model_null_hr2ea





























print = ‘C:\Documents and Settings\nhenderso\Desktop\AG_hr2e.txt’
log = ‘C:\Documents and Settings\nhenderso\Desktop\AG_hr2e.txt’
new;
run;
ods output parameterestimates = AG_null_hr2e;
proc phreg data=model_null_hr2ea covs(aggregate) covm;




proc printto print=print log=log;
run;
proc printto
print = ‘C:\Documents and Settings\nhenderso\Desktop\WLW_hr2e.txt’
log = ‘C:\Documents and Settings\nhenderso\Desktop\WLW_hr2e.txt’
new;
run;
ods output parameterestimates = WLW_null_hr2e;
proc phreg data=model_null_hr2ea covs(aggregate) covm;
strata ev;
by k; model tstop*status(0) = null / rl ties=exact;
id i;
run;
proc printto print=print log=log;
run;




if first.i then lstatus = 1;
if (status = 0 and lstatus = 0) then delete;
lstatus = status;
gaptime = tstop - tstart;
run;
proc printto
print = ‘C:\Documents and Settings\nhenderso\Desktop\PWPa_hr2e.txt’
log = ‘C:\Documents and Settings\nhenderso\Desktop\PWPa_hr2e.txt’
new;
run;
ods output parameterestimates = PWPa_null_hr2e;
proc phreg data=model_null_hr2eb covs(aggregate) covm;





proc printto print=print log=log;
run;
proc printto
print = ‘C:\Documents and Settings\nhenderso\Desktop\PWPb_hr2e.txt’
log = ‘C:\Documents and Settings\nhenderso\Desktop\PWPb_hr2e.txt’
new;
run;
ods output parameterestimates = PWPb_null_hr2e;
proc phreg data=model_null_hr2eb covs(aggregate) covm;






proc printto print=print log=log;
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/*--------------------*/
/*-- No Increase Subject --*/
/*--------------------*/
data model_null_hr3ea





























print = ‘C:\Documents and Settings\nhenderso\Desktop\AG_hr3e.txt’
log = ‘C:\Documents and Settings\nhenderso\Desktop\AG_hr3e.txt’
new;
run;
ods output parameterestimates = AG_null_hr3e;
proc phreg data=model_null_hr3ea covs(aggregate) covm;




proc printto print=print log=log;
run;
proc printto
print = ‘C:\Documents and Settings\nhenderso\Desktop\WLW_hr3e.txt’
log = ‘C:\Documents and Settings\nhenderso\Desktop\WLW_hr3e.txt’
new;
run;
ods output parameterestimates = WLW_null_hr3e;
proc phreg data=model_null_hr3ea covs(aggregate) covm;
strata ev;
by k; model tstop*status(0) = null / rl ties=exact;
id i;
run;
proc printto print=print log=log;
run;




if first.i then lstatus = 1;
if (status = 0 and lstatus = 0) then delete;
lstatus = status;
gaptime = tstop - tstart;
run;
proc printto
print = ‘C:\Documents and Settings\nhenderso\Desktop\PWPa_hr3e.txt’
log = ‘C:\Documents and Settings\nhenderso\Desktop\PWPa_hr3e.txt’
new;
run;
ods output parameterestimates = PWPa_null_hr3e;
proc phreg data=model_null_hr3eb covs(aggregate) covm;





proc printto print=print log=log;
run;
proc printto
print = ‘C:\Documents and Settings\nhenderso\Desktop\PWPb_hr3e.txt’
log = ‘C:\Documents and Settings\nhenderso\Desktop\PWPb_hr3e.txt’
new;
run;
ods output parameterestimates = PWPb_null_hr3e;
proc phreg data=model_null_hr3eb covs(aggregate) covm;






proc printto print=print log=log;
run;
/*--------------------*/
/*-- Increasing Risk Subject Effect --*/
/*--------------------*/
data model_null_hr4eaAPPENDIX B. SAS SIMULATION CODE 224





























print = ‘C:\Documents and Settings\nhenderso\Desktop\AG_hr4e.txt’
log = ‘C:\Documents and Settings\nhenderso\Desktop\AG_hr4e.txt’
new;
run;
ods output parameterestimates = AG_null_hr4e;
proc phreg data=model_null_hr4ea covs(aggregate) covm;




proc printto print=print log=log;
run;
proc printto
print = ‘C:\Documents and Settings\nhenderso\Desktop\WLW_hr4e.txt’
log = ‘C:\Documents and Settings\nhenderso\Desktop\WLW_hr4e.txt’
new;
run;
ods output parameterestimates = WLW_null_hr4e;
proc phreg data=model_null_hr4ea covs(aggregate) covm;
strata ev;
by k; model tstop*status(0) = null / rl ties=exact;
id i;
run;
proc printto print=print log=log;
run;




if first.i then lstatus = 1;
if (status = 0 and lstatus = 0) then delete;
lstatus = status;
gaptime = tstop - tstart;
run;
proc printto
print = ‘C:\Documents and Settings\nhenderso\Desktop\PWPa_hr4e.txt’
log = ‘C:\Documents and Settings\nhenderso\Desktop\PWPa_hr4e.txt’
new;
run;
ods output parameterestimates = PWPa_null_hr4e;
proc phreg data=model_null_hr4eb covs(aggregate) covm;





proc printto print=print log=log;
run;
proc printto
print = ‘C:\Documents and Settings\nhenderso\Desktop\PWPb_hr4e.txt’
log = ‘C:\Documents and Settings\nhenderso\Desktop\PWPb_hr4e.txt’
new;
run;
ods output parameterestimates = PWPb_null_hr4e;
proc phreg data=model_null_hr4eb covs(aggregate) covm;






proc printto print=print log=log;
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